var title_f23_22_23904="Palmoplantar pustulosis - heel";
var content_f23_22_23904=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palmoplantar pustulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pustules are present within an erythematous, scaly plaque.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_22_23904=[""].join("\n");
var outline_f23_22_23904=null;
var title_f23_22_23905="T3 rectal cancer EUS";
var content_f23_22_23905=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rectal cancer seen on endoscopic ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound image of a T3 rectal cancer with extension of the tumor into the perirectal space (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gavin C Harewood, MD and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_22_23905=[""].join("\n");
var outline_f23_22_23905=null;
var title_f23_22_23906="Normal thromboelastography and parameters";
var content_f23_22_23906=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58281%7ESURG%2F70388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58281%7ESURG%2F70388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Normal thromboelastography and parameters",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 273px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAERAlEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6P8T6+NBXTlXTr7UrnULr7JBb2ZiDs4iklJJldFACxP8AxelZ/wDwlGr/APQieJP+/wDp3/yVR4y/5GPwJ/2GpP8A03XldVQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVWk3ibRV8TR+Hv7Rt21t4mm+xo26RUABJYD7vDDG7Ge2apz+N/D8Gvf2PLfML0TpasRbymFZnAKxNMF8sOQRhC2eRxzQBD/wlGr/9CJ4k/wC/+nf/ACVR/wAJRq//AEIniT/v/p3/AMlV1VFAHK/8JRq//QieJP8Av/p3/wAlUf8ACUav/wBCJ4k/7/6d/wDJVS6l4ut9LvLW11HT7+3muVu3iBETZS3XczZVzgMCCo6+oWr/AIe1pdcsrW9t7G7hsrq0hu4ZpvLAcSLu24VywZRjOQBzwTzgAy/+Eo1f/oRPEn/f/Tv/AJKo/wCEo1f/AKETxJ/3/wBO/wDkquqooA5X/hKNX/6ETxJ/3/07/wCSqP8AhKNX/wChE8Sf9/8ATv8A5Krd0nVbPV4Z5dPm86OC4ltZDtZdssTlHXkDoykZ6HHGau0Acr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVVrw94kbV9Vv9NudG1LSb2zhhuGjvWgbfHK0qqVMMsg6wuCCQenrXQVyum/8AJU/EP/YF0z/0ff0AdVRRRQByvjL/AJGPwJ/2GpP/AE3XldVXK+Mv+Rj8Cf8AYak/9N15XVUAFFFFABRRRQAUUVUn1CGCVo3S6LDqUtpHH5hSDSbtuVGMpO0Vct0VyM3xH8KQ6wuk/wBrLLqxkMX2CCCWa4DBSxBiRSwwASSRwKsan4ujtCgttE8QahkkN9n0912YAPPmbM5z2z0OcUuZWuUqM3JRatfvp+Z01FcTq/ivxLFFayaJ4B1S/WVSzi4vrS1MY428GQnJycg4IxVyz1HxnOsMk3hvRLZHQM0cmtyGWMkZ2sFtiuQeDhiPQmhTT/4YqWHlG12tf7yf5PQ6qiufebxVI8Spp+iW6mRfMkN9LMQmfmwnkpk46fMKuyQ6wSPLv9PUd91k5/8AaooUr7CqUXT+Jr5NP8rmnRVDytU/5/LL/wABG/8AjlNkh1Yr+7vbEN6tZuR/6NFO/kJwSXxL8f8AI0aKzkh1YKN97Ylu5Fm4H/o2nGLVMcXlln/r0f8A+OUXfYFBWvzL8f8AIv0Vmxw6wM+bfWDem2ycf+1TT/K1T/n8sv8AwEb/AOOUX8hRgmruSX3/AORforIuYteWKZra80t5AreWklpIoLY4BYSHAzjJAP0rD3/EP/nh4T/7/XH/AMTSckty4UJVPha+bS/No7OiuUW68bxwxq2jeG7iXne41aeFevGF+zP2x3q79q8T/wDQI0X/AMGsv/yNRzpa/oxxw8pNxTWn95f56/I3qK52e78WLHmDRdCd89H1iVR+YtT/ACrNu9e8ZWd3ZxSeCYb2KVh582naxG4gXdg8TJEWOOcAe2aOdWv+gvq8ubkur/4lb772O0orAOu6gFJHhXWjjsJbPn/yPUVt4i1SXd5ng3X4MYx5k1ic/TbcmjnVr/oDw8lJRutf7y/O9l8zpKK5y68SXtrA00nhTXmRcZEX2WRuuOFWYk/gKH8VRLpn2oaPrrz4B+xiwfzeTjGT8nHX7368UKaf/DMcsPONrta/3k/yeh0dFchbeNnmuYon8K+KIVdwplksl2oCcbjhycDrwCa2rnXrS3AMkOpHJC/u9NuH6kD+FD69ew5PFCkmTUozp6v8Gn+VzVorm/8AhM9L/wCfXX//AAQ33/xmpLfxZp1xJsjttbDYz+80W8Qfm0QFPmXcTpTSu4v7joKK56fxdpsErRvba4WHUpol64/MREGsqX4qeCre8ltL7X7fT7yJgklvqCPaSoSoYZSVVYAhgc4xzRzLuCpTauov7jtqK426+KPgS12+b4w0Ft2ceVfRyfntJx+NQf8AC3Ph/wD9Ddo//gQKOZISpTkrpM7miuOb4oeBBbeefGGgbMZwL6Mv1x93O79K6L+1bf8A553v/gHN/wDE0cyBUpy2TL9FQWtzHcqxjWZQpwfMieM/+PAZqemnclpxdmFFFFAgooooAKKKKACiiigAooooAKKKKACiiigDzzxRqKx/Fbws32LV5YbSC7hnnh0u5lhRphD5eZFjKYO1snOFx82K5HWdN1J7LxF4VTSNRbUdR8URajb3a2rm3FuZ4ZjKZwuxSqoylS27IGAc17jRQBxPxR0Vdeg8N2c9g19Z/wBswvcxeWXURCOTJcD+HJAOeOcHrXCxeCIdMknvtL8Ptb31t4vtvskkNsQ0NkZYRIIuPlh2vLnbhcZz0r3CigDwi20PVhqgc6Xfhf7S8SyZNu+NsrHyj06P/Cf4u2apDw3qs3hvUrWfSNQIm8OeHrYx/Z3BZ45W81BxncoPzDqvfFfQlFAHhPi74fWVtD8QpdE8NCOa3sLebRhbWhxHchGLNbqBgSbkjyUG7pnrUeteHNRl8dalcXwmXUn1iGeyvIfD1zdTpbq0ZRY7xZRDFHgMrIwH8ZIORn3qigD5+m8LLb+H9f03TfD7WN+NflmvZF0SV1udNa6Z0UNHs89ArITEjltqldvapdD8ILe6voVvPp011oD67NcSWv8AYU2nWkC/2fIvywSuzLG0gXIbapZiACDz75RQB4l/wj8Nh8S4n0rQDcgalAEW50WWI2MCRhd1vfI3lCFQuRCRzkjFd78U4TN4btAtzfWzHVtOjL2d3LbOUkvIonUtGykgpI4xnuD1AIm8TeLF0DxVpFhcwXMtle2V3OxtLGe7mEkT26r8sKsQuJnySuMheR0PNfEHxppdzoNqkdr4gDDVtMkzJoF/GMLfwMeWhAzgHA6k4ABJAIB6NptlFp1jFaW73DxRDCtcXEk8h5zy8jMzde5NWa5X/hPNI/58/En/AITmo/8AxipfBfiQ+JJ/EDLDLFbWOoLaQCa1ltpSn2aCUl0lAYHdK+PlGVC9epAOlooooAK5XTf+Sp+If+wLpn/o+/rqq5XTf+Sp+If+wLpn/o+/oA6qiiigDlfGX/Ix+BP+w1J/6bryuqrlfGX/ACMfgT/sNSf+m68rqqACiivP/H3iOKyt4Ybizu9Qub64a00zQoP3Uuoypu3mQk8W/QsSNgT5m3BwtJu2xpTgpaydkjor3xZo1jb3FzeXiRWcSb1uCQVnOMlYQMtKRlfug5LBRlgQMWxHiLWLW6vIg8cVw832MX8sto1uodljY26IrkFdrEPIGIA/1ZYhb/hTwqmnX8uvatM994nvbaOG6u5cERKPmMMKjiOIMSdo5OAWLN8x6mly33H7Xlb9npf7/v8A8rHn9t4I1hb9blta0fT5txaS70fQkhu5SQchpZ5JwQScn5dxI+91zv3Pg/SL2z+y6ql1qduQnmRX13LPFKUIYF42bYfmAONuOBxwK6GimklsTOpOo7zd35lTS9NsdIsIrHSrO2sbKLPl29tEsUaZJJwqgAZJJ+pq3RRTICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAiu7aC8tZrW8hintpkaOWKVQ6SIwwVYHgggkEGua/4Vx4I/6E3w3/AOCuD/4muqooA5X/AIVx4I/6E3w3/wCCuD/4mj/hXHgf/oTfDf8A4K4P/ia6qigDlf8AhXHgf/oTfDf/AIK4P/ia6eGJIYkihRY4kUKiKMBQOAAOwp9FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUARtBE1wk7RIZ0VkSQqNyqxBYA9QCVXI77R6VzPxL/AORcs/8AsNaT/wCnG3rqqxfFugDxJpkVk2o32nrHdQ3YlsxEXLxOJEB8xHGA6o3TnaB0JBANqo4oIonmeKJEeZt8jKoBdtoXLepwqjJ7ADtUWm20tpYxQXF7cX0qAhri4EYkk56kRqq+3CjpVmgAooooAK5XTf8AkqfiH/sC6Z/6Pv66quV03/kqfiH/ALAumf8Ao+/oA6qiiigDlfGX/Ix+BP8AsNSf+m68rqq5Xxl/yMfgT/sNSf8ApuvK6qgDnvFWstpkTyJNHFb2ULahqEgIZ47ePLYCkYy+1lySOA5ByKxvhzpN7ePceLvFmlRWXifUcxpAxDtp9opIit1fJ68yMRtJaQggbQBh61ZReL/GFnon2iZYvOj1vV4ypVxBEwFnbHcMqruplKH5gVc/IXFerVMddWbVrRahHp+fX/JBRRRVGIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyum/8lT8Q/wDYF0z/ANH39dVXK6b/AMlT8Q/9gXTP/R9/QB1VFFFAHK+Mv+Rj8Cf9hqT/ANN15W3reoR6Vpsl7cSwwW8TIZZZmCpHGXAZmJIAABJyeBisTxl/yMfgT/sNSf8ApuvK5n45KdUsdK8OieW3XVbhbYyRE5JkdYSnp/qZbiQA9fIPoamTsjWhBTnrsrv7lf8AHY1PhTY213b6p4yEcwvvE8/2lnkyubWMsloAnRf3Oxj1JLtyRgDvKitLaCztYbW0higtoUWOKKJQiRoowFVRwAAAABUtUZBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyum/wDJU/EP/YF0z/0ff11Vcrpv/JU/EP8A2BdM/wDR9/QB1VFFFAHK+M/+Ri8Cf9hqT/03XlYOvWr+JPjLoVrBIn9n+GrdtSvwpRvMuJQ8dtGwyGVlXz5AcEYOMDcDW94y/wCRj8Cf9hqT/wBN15WX8L1l1HUvFviS4gjQanqRhtJYwB51pbqI42IyWB3ebkHHqAAeZb1SNoQTpym+ll83/wABM76iiiqMQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5XTf+Sp+If+wLpn/o+/rqq5XTf+Sp+If+wLpn/o+/oA6qiiigDz/4vav/AMI/B4d1nyPtH9nXt3eeTv2eZ5el3z7d2DjOMZwceldF4Bs/sHgfQLU4LxWECuwXbvfYNzEepOSevJryr9r5px8PdES1uJbaSfWo7cyRsQdklvcI44IyCrMCO4JB617Xp9v9ksLa23b/ACY1j3YxnAAzj8Km+tjTlap8z2b/AC3+66+8sUUUVRmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXK6b/yVPxD/ANgXTP8A0ff11Vcrpv8AyVPxD/2BdM/9H39AHVUUUUAeH/tasE8E+GmaNZAPEVsSjZwf3U3XBB/WvcK8T/ay0+61L4f6XHYSRRzwak16Gk6bYLK6mbsedsZAHTOM4HNev6LcNd6PYXEj73mgjkZsY3EqDmpt71zdzToqPVN/il/l+RdoooqjAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuV03/AJKn4h/7Aumf+j7+uqrldN/5Kn4h/wCwLpn/AKPv6AOqooooA434h2VvqOp+DbG+iWe0udVnhmibo6Npt6GU+xBIqb4WXxvfAekpKzG4s4/sE5dgWLwnyyxA6btofB5AYZp3jL/kYvAn/YZk/wDTdeVm+AbT+x/G3jvSkimEM15DrKSy4+c3MZVgpHYNAwAxkep7S200bQjGVOT6qz+Wz/Fo7yiiiqMQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5XTf8AkqfiH/sC6Z/6Pv66quV03/kqfiH/ALAumf8Ao+/oA6qiiigDlfGX/Ix+BP8AsNSf+m68rnPHe/Sfiv4K1y1Pl+b5mkah8gJmt5z+6O4/dVJ1jBIwd00a5+fB6Pxl/wAjH4E/7DUn/puvKyfjHo+qahoVvd+HUjfV7SVTCsjAKzCRJY154yZ4LcckDGckDJqZOyua0YqcuVvo/vtdfe9D0Cisrwprtn4n8OadremeaLO+hWeMSrtdQR0YcjIOQcEjjgkc1q1RkFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXK6b/AMlT8Q/9gXTP/R9/XVVyum/8lT8Q/wDYF0z/ANH39AHVUUUUAcr4y/5GPwJ/2GpP/TdeV0l1AtzEEkLAB0k+X1Vgw/UCub8Zf8jH4E/7DUn/AKbryuqoGm07o8/+H1/JpvizxL4OmhiS2s5DqemzxsD51vcSyNIhUZC+VMJIx0JUL8vGT6BXmfj2LVtGvE1/TPJLaELi/wDLfP8Aplg43Xdvxz5odY3QnC52A5wxr0mGRJoklhdZInUMrqchgehB7ikndFVIcjstv6/p+Y+iiimQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcrpv/JU/EP/AGBdM/8AR9/XVVyum/8AJU/EP/YF0z/0ff0AdVRRRQByvjL/AJGPwJ/2GpP/AE3XldVXK+Mv+Rj8Cf8AYak/9N15XVUAUNVsZbr7NLa3H2a6t5A6SFSysvRkZQRlSM8Z4IVuqiuJ8K2v/CudS/4R10jg8H3MyR6HLuybaaTe0ltK7NuO58mMkHJYoWyUB9Frk/FfhWHVI9SM8H9padqEIivtImIEdxtxiSNjjy5gAMHIBKpypAdZfu6pG0P3i5JStbb/ACv0+eifa7Z1lFea+G9bvfB1iNN8QXN1rGk2MYDav5KiaxQB2CXqBy2VRUxMq4YNlguN7d/pepWOr2EV7pV7bX1lLny7i2lWWN8Eg4ZSQcEEfUU077GcouLtJFuiiimSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyum/8lT8Q/8AYF0z/wBH39dVXK6b/wAlT8Q/9gXTP/R9/QB1VFFFAHK+Mv8AkY/An/Yak/8ATdeV1Vcr4y/5GPwJ/wBhqT/03XldVQAUUUUAFcZY+DTpl9fTWbRNDdzyXDRwTz2TF3Iy8hjcrI2Ao3FAxxkliST2dFJq5cKjimrJp/16r5HCQaJ4og1FksPEGqQIrPKi6hHbX1iVYn91kCK5JXdkEvxtGS3QznxTqtojR3mnWdxLbLtnKTSWbXDggEwJcRrGwPzH/XED5RuOQa7TFFKz7lc0G7uP3P8AzucFD8UNJS+a01fTtZ0qTajo8lst1E4YsP8AWWrSouNvIcrgEHpzXSDxT4f88wjXdK84Lv8AL+2R7tucZxnpnjNbNVdQ0+z1K2NvqNpb3duSGMU8ayLkdDgjFGol7Ny1ul9/+Q6xvrS/iMtjcwXMQbaXhkDgH0yO/IqxWD/whvhj/oXNF/8AAGL/AOJqtH4D8MwXf2rTtJi0u4KsryaW72JlBIJ3+SU38jjdnHOMZOROXVf19xco0brlk/uX/wAl/kdPRWD/AMIrp/8Az8a1/wCDm8/+O0+10FrNnFnrGrRws+/ypZ1uMHAGA0qu4HGcbsZJxihOXVCnGil7km35pL9X+Rt0VQ+w3H/QVvf++If/AI3TZNPuXXC6xfoc9VSD+sZp3fYlwSXxL8f8jRorPWwuQoB1a9OB1KQ8/wDkOhrC5IIGrXoyOoWHj/yHSu+wckbfEvx/yNCis2PT7lVw2sX7nPVkg/pGKoax4ZbVvJ8/Xdcg8rOPslyLfOcfe2KM9OM9OfWht9EOEIbzlZeSu/0X4nQ0Vzd34We6sYbSXxFr6xRbdrRXKRyHAwN0ioGb3yTk8nmiz8H2dvCEl1HX7ls58yXWLkN9PlcD9KG5dF/X3FQjRa96TXyT/wDbkdJRXNy+DNMkmSVrrXwy4wF16+VeD3UTYP4ipv8AhFdP/wCfjWv/AAc3n/x2huXRf19wRjRu+aT+5f8AyX+ZvUVyVx8OfCV5qQv9U0WDVbwReQJdUd70qmd20eczAcknj1PqavJ4L8LRoqJ4a0RUUYCrYRAAen3aLytt/X3Ao0eazk7ei/Lm/U36pXuradYSiK+1C0tpSu4JNMqEjpnBPTg/lWa/gvwtIjI/hrRGRhgqbCIgj0Py1Hb+BvCVshS38L6FEhOSqafCoz68LReVtv6+4HGjzaSdvRflzfqXv+Ek0P8A6DOm/wDgUn+NOj1/RpGxHq2nuRzhblD/AFqr/wAIb4Y/6FzRf/AGL/4mtm3hitoI4LeNIoYlCJGihVRQMAADgADtQubqKapK3I2/kl+rMy98TaDYRCW+1vS7aIttDzXcaAnrjJPXg1DD4w8MzQPPD4i0eSFM7pFvYiq4GTk7sDit2inqQ3Don9//AADm/wDhPPCH/Q16B/4MYf8A4qpbbxn4XupClr4k0WZwNxWO+iY49cBq36KNRtwton9//AOIl+KXhaOR0afVSVJBKaLespx6EQkEe44pYPid4ZuJVit21uWVuiJoN+xPfoIa7aijUG6dtE/v/wCAcVcfE3w3bSeXc/25DJjO2TQb9T+Rhqq3xS0ie6jt9H0zXNTkZGkci0+xJGAVHL3bQqSd3AUsflJwMV39FGoJ07ap/f8A8A4668Z31oqtdeDNfgVjgGS601Qfzu6z7r4lS2+zb4J8V3W7P/Hktndbf97yrhtvtnGcHHQ16DRSd+gQdNfGm/R2/RnG2PjPU721S4h8BeK1jfOBMbGF+DjlHuQw6dx71oWWta3fSlE8K3dgqrkvqd3boGPYL5DzEnr1Cj610VFUiJWu7bGV5+uf9A7Tf/A9/wD4zWom4opcANjkA5AP1paKBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcrpv/JU/EP/AGBdM/8AR9/XVVyum/8AJU/EP/YF0z/0ff0AdVRRRQByvjL/AJGPwJ/2GpP/AE3XldVXK+Mv+Rj8Cf8AYak/9N15XVUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyum/8lT8Q/8AYF0z/wBH39dVXK6b/wAlT8Q/9gXTP/R9/QB1VFFFAHK+Mv8AkY/An/Yak/8ATdeV1Vcr4y/5GPwJ/wBhqT/03XldVQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXK6b/yVPxD/wBgXTP/AEff11Vcrpv/ACVPxD/2BdM/9H39AHVUUUUAcr4y/wCRj8Cf9hqT/wBN15XVVyvjL/kY/An/AGGpP/TdeV1VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcrpv/JU/EP/AGBdM/8AR9/XVVyum/8AJU/EP/YF0z/0ff0AdVRRRQByvjL/AJGPwJ/2GpP/AE3XldVXP+LdEvtXfRrjSr+2sb3TL03kb3Nq1xG+YJoSpVZIz0mJzu6joaq/YfHH/Qw+G/8AwQz/APyZQB1VFcr9h8cf9DD4b/8ABDP/APJlH2Hxx/0MPhv/AMEM/wD8mUAdVRXK/YfHH/Qw+G//AAQz/wDyZR9h8cf9DD4b/wDBDP8A/JlAHVUVyv2Hxx/0MPhv/wAEM/8A8mUfYfHH/Qw+G/8AwQz/APyZQB1VFcr9h8cf9DD4b/8ABDP/APJlH2Hxx/0MPhv/AMEM/wD8mUAdVRXK/YfHH/Qw+G//AAQz/wDyZR9h8cf9DD4b/wDBDP8A/JlAHVUVyv2Hxx/0MPhv/wAEM/8A8mUfYfHH/Qw+G/8AwQz/APyZQB1VFcr9h8cf9DD4b/8ABDP/APJlH2Hxx/0MPhv/AMEM/wD8mUAdVRXK/YfHH/Qw+G//AAQz/wDyZR9h8cf9DD4b/wDBDP8A/JlAHVUVyv2Hxx/0MPhv/wAEM/8A8mUfYfHH/Qw+G/8AwQz/APyZQB1VFcr9h8cf9DD4b/8ABDP/APJlH2Hxx/0MPhv/AMEM/wD8mUAdVRXK/YfHH/Qw+G//AAQz/wDyZR9h8cf9DD4b/wDBDP8A/JlAHVUVyv2Hxx/0MPhv/wAEM/8A8mUfYfHH/Qw+G/8AwQz/APyZQB1VFcr9h8cf9DD4b/8ABDP/APJlH2Hxx/0MPhv/AMEM/wD8mUAdVRXK/YfHH/Qw+G//AAQz/wDyZR9h8cf9DD4b/wDBDP8A/JlAHVUVyv2Hxx/0MPhv/wAEM/8A8mUfYfHH/Qw+G/8AwQz/APyZQB1VFcr9h8cf9DD4b/8ABDP/APJlH2Hxx/0MPhv/AMEM/wD8mUAdVRXK/YfHH/Qw+G//AAQz/wDyZR9h8cf9DD4b/wDBDP8A/JlAHVUVyv2Hxx/0MPhv/wAEM/8A8mUfYfHH/Qw+G/8AwQz/APyZQB1VFcr9h8cf9DD4b/8ABDP/APJlH2Hxx/0MPhv/AMEM/wD8mUAdVRXK/YfHH/Qw+G//AAQz/wDyZR9h8cf9DD4b/wDBDP8A/JlAHVUVyv2Hxx/0MPhv/wAEM/8A8mUfYfHH/Qw+G/8AwQz/APyZQB1VFcr9h8cf9DD4b/8ABDP/APJlH2Hxx/0MPhv/AMEM/wD8mUAdVRXK/YfHH/Qw+G//AAQz/wDyZR9h8cf9DD4b/wDBDP8A/JlAHVUVyv2Hxx/0MPhv/wAEM/8A8mUfYfHH/Qw+G/8AwQz/APyZQB1VFcr9h8cf9DD4b/8ABDP/APJlH2Hxx/0MPhv/AMEM/wD8mUAdVRXK/YfHH/Qw+G//AAQz/wDyZR9h8cf9DD4b/wDBDP8A/JlAHVUVyv2Hxx/0MPhv/wAEM/8A8mUfYfHH/Qw+G/8AwQz/APyZQB1VFcr9h8cf9DD4b/8ABDP/APJlH2Hxx/0MPhv/AMEM/wD8mUAdVRXK/YfHH/Qw+G//AAQz/wDyZR9h8cf9DD4b/wDBDP8A/JlAHVUVyv2Hxx/0MPhv/wAEM/8A8mUfYfHH/Qw+G/8AwQz/APyZQB1VFcr9h8cf9DD4b/8ABDP/APJlH2Hxx/0MPhv/AMEM/wD8mUAdVRXK/YfHH/Qw+G//AAQz/wDyZR9h8cf9DD4b/wDBDP8A/JlAHVUVyv2Hxx/0MPhv/wAEM/8A8mUfYfHH/Qw+G/8AwQz/APyZQB1VFcr9h8cf9DD4b/8ABDP/APJlH2Hxx/0MPhv/AMEM/wD8mUAdVRXK/YfHH/Qw+G//AAQz/wDyZR9h8cf9DD4b/wDBDP8A/JlAHVVyum/8lT8Q/wDYF0z/ANH39H2Hxx/0MPhv/wAEM/8A8mVL4c0PVbPX9T1fXNTsb65vLW2tFWzsXtkjSF52BIaWQsSZz3H3RQB0tFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal citrated rapid TEG tracing with normal ACT, R time, K time, alpha angle, MA, G, and LY30.",
"    <div class=\"footnotes\">",
"     R (reaction time): time from sample placement or activation until the tracing amplitude reaches 2 mm; K (clot formation time): time elapsed between the R-time and the point where the tracing amplitude reaches 20 mm; alpha angle: angle between the middle line of the tracing and a tangential line to the developing \"body\" of the tracing; MA (maximal amplitude): the maximal amplitude reached after clot initiation; G: a calculated measure of total clot strength based on amplitude; LY30: the amount of clot lysis detected 30 minutes after the maximal amplitute (MA) is reached; SP (split point): time from sample placement (or activation with an exogenous procoagulant) until the earliest detectable resistance.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Secondary hyperfibrinolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Citrated rapid-TEG showing secondary hyperfibrinolysis. The red tracing indicates a normal study.",
"    <br>",
"     This study shows a normal ACT, R time, K time, and alpha angle; high LY30 reflecting hyperfibrinolysis; normal MA and G, reflecting onset of fibrinolysis after achieving maximal clot strength.",
"     <div class=\"footnotes\">",
"      R (reaction time): time from sample placement or activation until the tracing amplitude reaches 2 mm; K (clot formation time): time elapsed between the R-time and the point where the tracing amplitude reaches 20 mm; alpha angle: angle between the middle line of the tracing and a tangential line to the developing \"body\" of the tracing; MA (maximal amplitude): the maximal amplitude reached after clot initiation; G: a calculated measure of total clot strength based on amplitude; LY30: the amount of clot lysis detected 30 minutes after the maximal amplitute (MA) is reached; SP (split point): time from sample placement (or activation with an exogenous procoagulant) until the earliest detectable resistance.",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_22_23906=[""].join("\n");
var outline_f23_22_23906=null;
var title_f23_22_23907="Double football hold";
var content_f23_22_23907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Double football hold",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Dr. Nancy Hurst.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_22_23907=[""].join("\n");
var outline_f23_22_23907=null;
var title_f23_22_23908="Cleavage view";
var content_f23_22_23908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cleavage view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 422px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cleavage views of both breasts may be obtained to image the medial tissues adequately. A small nodule in the medial aspect of the right breast is not seen on the original CC view (Panel A) but well seen on the cleavage view (Panel B).",
"    <div class=\"footnotes\">",
"     CC: craniocaudal.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_22_23908=[""].join("\n");
var outline_f23_22_23908=null;
var title_f23_22_23909="Clomiphene: Drug information";
var content_f23_22_23909=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clomiphene: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/14/17636?source=see_link\">",
"    see \"Clomiphene: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F153216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Clomid&reg;;",
"     </li>",
"     <li>",
"      Serophene&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F153217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Clomid&reg;;",
"     </li>",
"     <li>",
"      Serophene&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F153232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ovulation Stimulator;",
"     </li>",
"     <li>",
"      Selective Estrogen Receptor Modulator (SERM)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F153219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Ovulation induction:",
"     </b>",
"     Oral: Females:",
"     <b>",
"      Note:",
"     </b>",
"     Intercourse should be timed to coincide with the expected time of ovulation (usually 5-10 days after a clomiphene course).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Initial course:",
"     </i>",
"     50 mg once daily for 5 days. Begin on or about the fifth day of cycle if progestin-induced bleeding is scheduled or spontaneous uterine bleeding occurs prior to therapy. Therapy may be initiated at anytime in patients with no recent uterine bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Dose adjustment:",
"     </i>",
"     Subsequent doses may be increased to 100 mg once daily for 5 days only if ovulation does not occur at the initial dose. Lower doses (12.5-25 mg daily) may be used in women sensitive to clomiphene or who consistently develop large ovarian cysts (ASRM, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Repeat courses:",
"     </i>",
"     If needed, the 5-day cycle may be repeated as early as 30 days after the previous one. Exclude the presence of pregnancy. The lowest effective dose should be used (ASRM, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Maximum dose:",
"     </i>",
"     100 mg once daily for 5 days for up to 6 cycles. Discontinue if ovulation does not occur after 3 courses of treatment; or if 3 ovulatory responses occur but pregnancy is not achieved. Long-term therapy (&gt;6 cycles) is not recommended. Re-evaluate if menses does not occur following ovulatory response. Doses have ranged from 50-250 mg daily, although doses &gt;100 mg daily are not as successful (ASRM, 2006). The maximum recommended dose in women with PCOS is 150 mg daily (ASRM, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F153220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15795865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15795866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in patients with a history of liver disease or dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F153200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as citrate: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clomid&reg;: 50 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serophene&reg;: 50 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F153186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5183724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The total daily dose should be taken at one time to maximize effectiveness.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F153202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of ovulatory dysfunction in patients desiring pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F153238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ClomiPHENE may be confused with clomiPRAMINE, clonidine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Clomid&reg; may be confused with clonidine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Serophene&reg; may be confused with Sarafem&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F153230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Endocrine &amp; metabolic: Ovarian enlargement (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes (10%), breast discomfort (2%), abnormal uterine bleeding (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Distention/bloating/discomfort (6%), nausea (2%), vomiting (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual symptoms (2%, includes blurred vision, diplopia, floaters, lights, phosphenes, photophobia, scotomata, waves)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal accommodation, acne, allergic reaction, arrhythmia, chest pain, depression, dizziness, dyspnea, edema, endometriosis, erythema multiforme, erythema nodosum, eye pain, fatigue, fever, hepatitis, hypertension, hypertrichosis, leukocytosis, macular edema, migraine, mood changes, neoplasms, optic neuritis, ovarian cyst, ovarian hemorrhage, palpitation, PE, phlebitis, posterior vitreous detachment, pruritus, psychosis, retinal hemorrhage, retinal thrombosis, retinal vascular spasm, seizure, stroke, syncope, tachycardia, thrombophlebitis, thyroid disorder, tinnitus, transaminase increased, tubal pregnancy, uterine hemorrhage, vision loss (temporary/prolonged)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F153205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clomiphene citrate or any of its components; liver disease; abnormal uterine bleeding; enlargement or development of ovarian cyst (not due to polycystic ovarian syndrome); uncontrolled thyroid or adrenal dysfunction; presence of an organic intracranial lesion such as pituitary tumor; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F153190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian enlargement: May be accompanied by abdominal distention or abdominal pain and generally regresses without treatment within 2-3 weeks. If ovaries are abnormally enlarged, withhold hCG to reduce the risk of ovarian hyperstimulation syndrome (OHSS).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian hyperstimulation syndrome (OHSS): OHSS is characterized by severe ovarian enlargement, abdominal pain/distention, nausea, vomiting, diarrhea, dyspnea, and oliguria, and may be accompanied by ascites, pleural effusion, hypovolemia, electrolyte imbalance, hemoperitoneum, and thromboembolic events. If severe hyperstimulation occurs, stop treatment and hospitalize patient. This syndrome develops rapidly within 24 hours to several days and generally occurs during the 7-10 days immediately following treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Visual disturbances: Blurring or other visual symptoms can occur; symptoms may increase with higher doses or duration of therapy. Patients with visual disturbances should discontinue therapy and have an eye exam.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian cancer:  Prolonged use may increase the risk of borderline or invasive ovarian cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polycystic ovarian syndrome (PCOS): Use with caution in patients unusually sensitive to pituitary gonadotropins (eg, PCOS); a lower dose may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Uterine fibroids: Use caution in patients with uterine fibroids, may cause further enlargement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: To minimize risks, use only at the lowest effective dose for the shortest duration of therapy (especially for the first course of therapy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician: Use should be supervised by physicians who are thoroughly familiar with infertility problems and their management.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multiple births: May result from the use of these medications; advise patient of the potential risk of multiple births before starting the treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Selective Estrogen Receptor Modulators may enhance the adverse/toxic effect of Ospemifene. Ospemifene may also enhance adverse/toxic effects of other Selective Estrogen Receptor Modulators. Selective Estrogen Receptor Modulators may diminish the therapeutic effect of Ospemifene. Ospemifene may also diminish the therapeutic effects of other Selective Estrogen Receptor Modulators.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F153197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5183299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryofetal and structural malformations were observed in animal reproduction studies. The incidence of adverse fetal effects following maternal use of clomiphene for ovulation induction is similar to those seen in the general population. Clomiphene is not indicated for use in women who are already pregnant.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F153223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5183301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clomiphene may decrease lactation.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F153207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Clomid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $489.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (ClomiPHENE Citrate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $207.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Serophene Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (10): $122.65",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5183726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pelvic exam prior to each course of therapy; basal body temperature, serum progesterone, urinary luteinizing hormone; follicular growth and endometrial thickness may be useful in some cases; pregnancy test prior to repeat courses",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F153201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum progesterone: Ovulation generally occurs with levels &ge;3 ng/mL; best results with levels &gt;10 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F153208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anexin (PY);",
"     </li>",
"     <li>",
"      Biogen (PE);",
"     </li>",
"     <li>",
"      Blesifen (ID);",
"     </li>",
"     <li>",
"      Clomene (PH);",
"     </li>",
"     <li>",
"      Clomhexal (AU);",
"     </li>",
"     <li>",
"      Clomid (AE, AR, AU, BE, BH, CH, CY, EG, FR, GB, IE, IQ, IR, IT, JO, KW, LB, LY, MY, NL, OM, PK, QA, SA, SG, SY, TH, TW, YE);",
"     </li>",
"     <li>",
"      Clomifen (FI);",
"     </li>",
"     <li>",
"      Clomihexal (ZA);",
"     </li>",
"     <li>",
"      Clomoval (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Clonin (TW);",
"     </li>",
"     <li>",
"      Clostil (PH);",
"     </li>",
"     <li>",
"      Clostilbegyt (AE, BB, BG, BH, BM, BS, BZ, CY, EG, GY, HN, IQ, IR, JM, JO, KW, LB, LY, OM, PL, PR, QA, RU, SA, SR, SY, TT, YE);",
"     </li>",
"     <li>",
"      Dufine (PT);",
"     </li>",
"     <li>",
"      Duinum (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, SC, SD, SG, SL, SN, TH, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Dyneric (DE);",
"     </li>",
"     <li>",
"      Fermil (AU);",
"     </li>",
"     <li>",
"      Fertec (CO);",
"     </li>",
"     <li>",
"      Ferticlo (PH);",
"     </li>",
"     <li>",
"      Fertilan (CL, HK);",
"     </li>",
"     <li>",
"      Fertilin (TR);",
"     </li>",
"     <li>",
"      Fertilphen (ID);",
"     </li>",
"     <li>",
"      Fertin (ID);",
"     </li>",
"     <li>",
"      Fertomid (IN);",
"     </li>",
"     <li>",
"      Genoclam (ID);",
"     </li>",
"     <li>",
"      I-Clom (PH);",
"     </li>",
"     <li>",
"      Ikaclomin (IL);",
"     </li>",
"     <li>",
"      Ofertil (ID);",
"     </li>",
"     <li>",
"      Omifin (CO, MX);",
"     </li>",
"     <li>",
"      Ova-Mit (BB, BM, BS, BZ, GY, JM, PR, SR, TT);",
"     </li>",
"     <li>",
"      Ovamit (EC, MY, TH);",
"     </li>",
"     <li>",
"      Ovipreg (IN);",
"     </li>",
"     <li>",
"      Ovulet (PH);",
"     </li>",
"     <li>",
"      Pergotime (BE, DK, FR, NO, SE);",
"     </li>",
"     <li>",
"      Pinfetil (ID);",
"     </li>",
"     <li>",
"      Profertil (ID);",
"     </li>",
"     <li>",
"      Provula (ID);",
"     </li>",
"     <li>",
"      Serofene (AR, MX, VE);",
"     </li>",
"     <li>",
"      Serophene (AE, AT, AU, BH, CH, CY, CZ, EG, HK, IQ, IR, JO, KP, KW, LB, LY, NL, NZ, OM, QA, SA, SG, SY, TH, TW, UY, YE);",
"     </li>",
"     <li>",
"      Serpafar (GR);",
"     </li>",
"     <li>",
"      Zimaquin (CN, PE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F153189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clomiphene is a racemic mixture consisting of zuclomiphene (~38%) and enclomiphene (~62%), each with distinct pharmacologic properties. Enclomiphene is much less potent in inducing ovulation; however, it is more rapidly absorbed and metabolized, allowing the more potent activity of zuclomiphene to predominate. Zuclomiphene acts at the level of the hypothalamus, occupying cell surface and intracellular estrogen receptors (ERs) for longer durations than estrogen. This interferes with receptor recycling, effectively depleting hypothalamic ERs and inhibiting normal estrogenic negative feedback. Impairment of the feedback signal results in increased pulsatile GnRH secretion from the hypothalamus and subsequent pituitary gonadotropin (FSH, LH) release, causing growth of the ovarian follicle, followed by follicular rupture.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F153204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Ovulation: 5-10 days following course of treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Effects are cumulative; ovulation may occur in the cycle following the last treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Readily absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; undergoes enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: ~6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily feces; urine (small amounts)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Practice Bulletins--Gynecology, \"ACOG Practice Bulletin No. 108: Polycystic Ovary Syndrome,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      2009, 114(4):936-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/22/23909/abstract-text/19888063/pubmed\" id=\"19888063\" target=\"_blank\">",
"        19888063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dickey RP and Holtkamp DE, &ldquo;Development, Pharmacology, and Clinical Experience With Clomiphene Citrate,&rdquo;",
"      <i>",
"       Hum Reprod Update",
"      </i>",
"      , 1996, 2(6):483-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/22/23909/abstract-text/9111183/pubmed\" id=\"9111183\" target=\"_blank\">",
"        9111183",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldstein SR, Siddhanti S, Ciaccia AV, et al. &ldquo;A Pharmacological Review of Selective Oestrogen Receptor Modulators,&rdquo;",
"      <i>",
"       Hum Reprod Update",
"      </i>",
"      , 2000, 6(3):212-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/22/23909/abstract-text/10874566/pubmed\" id=\"10874566\" target=\"_blank\">",
"        10874566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Practice Committee of the American Society for Reproductive Medicine, &ldquo;Use of Clomiphene Citrate in Women,&rdquo;",
"      <i>",
"       Fertil Steril",
"      </i>",
"      , 2006, 86(5 Suppl):187-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/22/23909/abstract-text/17055820/pubmed\" id=\"17055820\" target=\"_blank\">",
"        17055820",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Purvin VA, &ldquo;Visual Disturbance Secondary to Clomiphene Citrate,&rdquo;",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 1995, 113(4):482-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/22/23909/abstract-text/7710399/pubmed\" id=\"7710399\" target=\"_blank\">",
"        7710399",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sokol RZ, &ldquo;Prevention and Management of Complications Occurring During Treatment With Clomiphene,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1990, 5(5):313-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/22/23909/abstract-text/2222865/pubmed\" id=\"2222865\" target=\"_blank\">",
"        2222865",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, &ldquo;Consensus on Infertility Treatment Related to Polycystic Ovary Syndrome,&rdquo;",
"      <i>",
"       Fertil Steril",
"      </i>",
"      , 2008, 89(3):505-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/22/23909/abstract-text/18243179/pubmed\" id=\"18243179\" target=\"_blank\">",
"        18243179",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vause TDR, Cheung AP, Sierra S, et al, \"Ovulation Induction in Polycystic Ovary Syndrome,\"",
"      <i>",
"       J Obstet Gynaecol Can",
"      </i>",
"      ,  2010, 32(5):495-502.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/22/23909/abstract-text/20500959/pubmed\" id=\"20500959\" target=\"_blank\">",
"        20500959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walker AB, Eldridge PR, and MacFarlane IA, &ldquo;Clomiphene-Induced Pituitary Apoplexy in a Patient With Acromegaly,&rdquo;",
"      <i>",
"       J Endocrinol",
"      </i>",
"      , 1995, 144:29.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9281 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-3AAB480B33-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_22_23909=[""].join("\n");
var outline_f23_22_23909=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153216\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153217\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153232\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153219\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153220\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795865\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795866\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153200\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153186\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5183724\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153202\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153238\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153230\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153205\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153190\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299066\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219406\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153197\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5183299\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153223\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5183301\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153207\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5183726\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153201\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153208\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153189\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153204\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9281\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9281|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/14/17636?source=related_link\">",
"      Clomiphene: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_22_23910="Hydrocodone and pseudoephedrine: Drug information";
var content_f23_22_23910=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydrocodone and pseudoephedrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/20/4421?source=see_link\">",
"    see \"Hydrocodone and pseudoephedrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F180237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rezira&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F180247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antitussive/Decongestant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F180240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Antitussive/nasal decongestant:",
"     </b>",
"     Oral: 5 mL every 4-6 hours as needed (maximum: 20 mL/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F180241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F180224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rezira&trade;: Hydrocodone bitartrate 5 mg and pseudoephedrine hydrochloride 60 mg per 5 mL (480 mL) [contains propylene glycol; grape flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F180214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F180249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13163287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use calibrated oral syringes; household teaspoons and tablespoons are not recommended for measurement.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F180225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of cough and nasal congestion associated with common cold",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14199154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F180245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F180228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to hydrocodone, pseudoephedrine or any component of the formulation; severe hypertension or coronary artery disease; narrow-angle glaucoma; urinary retention; concurrent use during or within 14 days of MAO inhibitor therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F180218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (codeine, hydromorphone, levorphanol, morphine, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory  depression: May cause dose-related respiratory depression, risk increased in children, elderly, patients with pulmonary disease, and when used postoperatively.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease); contraindicated with severe disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure: Use with caution in patients with increased intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pulmonary disease (eg, asthma) or decreased ventilatory function; dose-related respiratory depression occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergics: Concurrent use may result in paralytic ileus; use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2D6 &ldquo;poor metabolizers&rdquo;: Due to the role of CYP2D6 in the metabolism of hydrocodone to hydromorphone (an active metabolite with higher binding affinity to mu-opioid receptors compared to hydrocodone), patients with genetic variations of CYP2D6, including &ldquo;poor metabolizers&rdquo; or &ldquo;extensive metabolizers,&rdquo; may have decreased or increased hydromorphone formation, respectively. Variable effects in positive and negative opioid effects have been reported in these patients; however, limited data exists to determine if clinically significant differences of analgesia and toxicity can be predicted based on CYP2D6 phenotype (Hutchinson, 2004; Otton, 1993; Zhou, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: Appropriate use: Underlying cause of cough should be determined prior to prescribing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Measuring device : Appropriate use: Accurate measuring devices should be used to measure solution doses. Calibrated oral syringes are most accurate. Household teaspoons and tablespoons are not recommended for measurement.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F180244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F180220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease serum concentrations of the active metabolite(s) of Hydrocodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F180234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Ethanol: Hydrocodone may enhance the CNS depressant effect of alcohol (ethyl).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5586944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5586945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. In humans, birth defects, including some heart defects, have been associated with maternal use of opioid analgesics, including hydrocodone, during the first trimester of pregnancy (Broussard, 2011). Use of opioids during pregnancy may produce physical dependence in the neonate. Symptoms of opioid withdrawal may include excessive crying, diarrhea, fever, hyper-reflexia, irritability, respiratory rate increased, sneezing, tremors, vomiting, or yawning; respiratory depression may occur in the newborn if opioids are used prior to delivery. Also refer to pseudoephedrine monograph.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5586946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5586947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hydrocodone and pseudoephedrine are excreted in breast milk. In one study, the calculated dose of hydrocodone to a nursing infant was 0.2% to 9% (mean: 2.4%) of the weight-adjusted maternal dose. Hydromorphone was also measurable in 12 cases; the total opioid dose to a nursing infant was calculated to be 0.1% to 9.9% (mean: 1.5%) of the weight-adjusted maternal dose. Concentrations may be increased in women who are extensive metabolizers of CYP2D6. Caution should be used since most persons are not aware of their CYP2D6 genotype status. When hydrocodone is used in breast-feeding women, it is recommended to use the lowest dose for the shortest duration of time and observe the infant for adverse events. Some clinicians recommend limiting the dose to hydrocodone bitartrate 30 mg/day (Sauberan, 2011). The manufacturer recommends discontinuing the medication or to discontinue nursing during therapy. Also refer to pseudoephedrine monograph.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Rezira Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60-5 mg/5 mL (480 mL): $370.80",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F180217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hydrocodone binds to opiate receptors in the CNS, altering the perception of and response to pain; suppresses cough in medullary center; produces generalized CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pseudoephedrine directly stimulates alpha-adrenergic receptors of respiratory mucosa causing vasoconstriction; directly stimulates beta-adrenergic receptors causing bronchial relaxation, increased heart rate and contractility.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F180227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pseudoephedrine:",
"     </b>",
"     See Pseudoephedrine (Systemic) monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hydrocodone:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onset of action: Narcotic analgesic: 10-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolism: Hepatic; O-demethylation via primarily CYP2D6 to hydromorphone (major, active metabolite with ~10- to 33-fold higher or as much as a &gt;100-fold higher binding affinity for the mu-opioid receptor than hydrocodone); N-demethylation via CYP3A4 to norhydrocodone (major metabolite); and ~40% of metabolism/clearance occurs via other non-CYP pathways, including 6-ketosteroid reduction to 6-alpha-hydrocol and 6-beta-hydrocol, and other elimination pathways (eg, fecal, biliary, intestinal, renal) (Hutchinson, 2004; Volpe, 2011; Zhou, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life elimination: 3.3-4.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excretion: Urine (26% of single dose in 72 hours, with ~12% as unchanged drug, 5% as norhydrocodone, 4% as conjugated hydrocodone, 3% as 6-hydrocodol, and 0.21% as conjugated 6-hydromorphol (Zhou, 2009)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics Committee on Drugs. The Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/22/23910/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson PO, Sauberan JB, Lane JR, et al, &ldquo;Hydrocodone Excretion Into Breast Milk: The First Two Reported Cases,&rdquo;",
"      <i>",
"       Breastfeed Med",
"      </i>",
"      , 2007, 2(1):10-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/22/23910/abstract-text/17661614/pubmed\" id=\"17661614\" target=\"_blank\">",
"        17661614",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broussard CS, Rasmussen SA, Reefhuis J, et al, \"National Birth Defects Prevention Study: Maternal Treatment With Opioid Analgesics and Risk for Birth Defects,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2011, 204(4):314.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/22/23910/abstract-text/21345403/pubmed\" id=\"21345403\" target=\"_blank\">",
"        21345403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hutchinson MR, Menelaou A, Foster DJ, et al, &ldquo;CYP2D6 and CYP3A4 Involvement in the Primary Oxidative Metabolism of Hydrocodone by Human Liver Microsomes,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2004, 57(3):287-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/22/23910/abstract-text/14998425/pubmed\" id=\"14998425\" target=\"_blank\">",
"        14998425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molina DK and Hargrove VM, &ldquo;What Is the Lethal Concentration of Hydrocodone?,&rdquo;",
"      <i>",
"       Am J Forensic Med Pathol",
"      </i>",
"      , 32(2):108-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/22/23910/abstract-text/20407360/pubmed\" id=\"20407360\" target=\"_blank\">",
"        20407360",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Otton SV, Schadel M, Cheung SW, et al, &ldquo;CYP2D6 Phenotype Determines the Metabolic Conversion of Hydrocodone to Hydromorphone,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1993, 54(5):463-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/22/23910/abstract-text/7693389/pubmed\" id=\"7693389\" target=\"_blank\">",
"        7693389",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rathmell JP, Viscomi CM, and Ashburn MA, &ldquo;Management of Nonobstetric Pain During Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1997, 85(5):1074-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/22/23910/abstract-text/9356103/pubmed\" id=\"9356103\" target=\"_blank\">",
"        9356103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sauberan JB, Anderson PO, Lane JR, et al, \"Breast Milk Hydrocodone and Hydromorphone Levels in Mothers Using Hydrocodone for Postpartum Pain,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2011, 117(3):611-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/22/23910/abstract-text/21343764/pubmed\" id=\"21343764\" target=\"_blank\">",
"        21343764",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Volpe DA, McMahon Tobin GA, Mellon RD, et al, &ldquo;Uniform Assessment and Ranking of Opioid Mu Receptor Binding Constants for Selected Opioid Drugs,&rdquo;",
"      <i>",
"       Regul Toxicol Pharmacol",
"      </i>",
"      , 2011, 59(3):385-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/22/23910/abstract-text/21215785 /pubmed\" id=\"21215785 \" target=\"_blank\">",
"        21215785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhou SF, &ldquo;Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part II,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2009, 48(12):761-804.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/22/23910/abstract-text/19902987/pubmed\" id=\"19902987\" target=\"_blank\">",
"        19902987",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8761 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_22_23910=[""].join("\n");
var outline_f23_22_23910=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180237\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180247\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180240\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180241\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180224\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180214\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180249\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13163287\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180225\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14199154\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180245\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180228\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180218\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180244\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180220\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180234\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5586944\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5586945\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5586946\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5586947\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323185\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180217\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180227\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8761\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8761|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/20/4421?source=related_link\">",
"      Hydrocodone and pseudoephedrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_22_23911="Etiology of carpal tunnel syndrome";
var content_f23_22_23911=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology of carpal tunnel syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/22/23911/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/22/23911/contributors\">",
"     Milind J Kothari, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/22/23911/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/22/23911/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/22/23911/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/22/23911/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/22/23911/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carpal tunnel syndrome (CTS) refers to the complex of symptoms and signs brought on by compression of the median nerve as it travels through the carpal tunnel. Patients commonly experience pain, paresthesia, and less commonly, weakness in the median nerve distribution. CTS is the most frequent compressive focal mononeuropathy seen in clinical practice.",
"   </p>",
"   <p>",
"    This topic will review the etiology of CTS. Other clinical aspects of CTS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=see_link\">",
"     \"Clinical manifestations and diagnosis of carpal tunnel syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44008?source=see_link\">",
"     \"Treatment of carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The carpal tunnel is formed by the transverse carpal ligament (flexor retinaculum) superiorly with the carpal bones inferiorly (",
"    <a class=\"graphic graphic_figure graphicRef59856 \" href=\"UTD.htm?1/28/1477\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/1\">",
"     1",
"    </a>",
"    ]. The median nerve, accompanied by the nine flexor tendons of the forearm musculature, must pass through this anatomic tunnel (",
"    <a class=\"graphic graphic_figure graphicRef53265 \" href=\"UTD.htm?18/45/19158\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. When compression of the median nerve occurs, ischemia and mechanical disruption of the nerve follow.",
"   </p>",
"   <p>",
"    The median nerve emerges from the brachial plexus in the upper arm with contributions from the C6, C7, C8, and T1 nerve roots (",
"    <a class=\"graphic graphic_figure graphicRef50576 \" href=\"UTD.htm?34/25/35222\">",
"     figure 3",
"    </a>",
"    ). Roots C6 and C7 supply the median sensory fibers that provide sensation to the thenar eminence and the first three and a half digits of the hand. Roots C8 and T1 supply the median motor fibers that innervate the distal median muscles of the forearm and hand. Thus, nerve fibers that are destined to comprise the median nerve exit the spine at these nerve roots to travel in the upper, middle, and lower trunks of the brachial plexus. These fibers will then pass through the lateral and medial cords of the brachial plexus and combine to form the median nerve.",
"   </p>",
"   <p>",
"    The median nerve has no branches in the upper arm. As the median nerve passes through the antecubital fossa region, it lies adjacent to the brachial artery on the medial side before passing more deeply within the forearm.",
"   </p>",
"   <p>",
"    In the upper portion of the forearm, the median nerve innervates four muscles (the pronator teres, flexor carpi radialis, palmaris longus, and the flexor digitorum superficialis). The median nerve then gives off a peripheral nerve branch that forms the anterior interosseous nerve, which innervates the pronator quadratus muscle just proximal to the wrist. The anterior interosseous nerve also innervates the flexor pollicis longus muscle and medial head of the flexor digitorum profundus I and II muscles.",
"   </p>",
"   <p>",
"    The median nerve proper runs parallel to the anterior interosseous nerve in the forearm. In the region proximal to the wrist, the palmar cutaneous sensory branch of the median nerve comes off to provide sensation to the lateral half of the palm. Because the palmer branch of the median nerve passes over, rather than through, the carpal tunnel, sensation change (pain or numbness) involving the thenar eminence is typically not observed in CTS. The pattern of sensory innervation of the median nerve is demonstrated in the figure (",
"    <a class=\"graphic graphic_figure graphicRef70720 \" href=\"UTD.htm?37/44/38593\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As the median nerve crosses the wrist, it passes through the carpal tunnel along with nine flexor muscle tendons (",
"    <a class=\"graphic graphic_figure graphicRef59856 \" href=\"UTD.htm?1/28/1477\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53265 \" href=\"UTD.htm?18/45/19158\">",
"     figure 2",
"    </a>",
"    ). Inflammation and compression of the median nerve most commonly occurs within the carpal tunnel. Rarely, median entrapment can also occur more proximally in the region of the elbow or just distal to the elbow.",
"   </p>",
"   <p>",
"    Upon exiting the carpal tunnel, the median nerve provides motor and sensory innervation to the hand. The muscles of the hand that are innervated by the median nerve are the abductor pollicis brevis, the flexor pollicis brevis (superficial head), the opponens pollicis, and the first and second lumbricals. Although these muscles can be affected in patients with severe or long-standing CTS, the lumbrical is sometimes spared.",
"   </p>",
"   <p>",
"    There are occasionally anomalous innervations in the hand that can make the diagnosis more challenging; however, the above described anatomy is the most common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of CTS is multifactorial. Increased pressure in the intracarpal canal plays a key role in the development of clinical CTS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the precise etiology of increased carpal tunnel pressure in CTS is uncertain, experimental evidence suggests that anatomic compression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inflammation are possible mechanisms. Increased pressure in the carpal tunnel can injure the nerve directly, impair axonal transport, or compress vessels in the perineurium and cause median nerve ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nine flexor tendons, any of which can become inflamed or thickened, pass through the carpal tunnel alongside the median nerve. Anatomic compression may result from a noninflammatory fibrosis affecting the subsynovial connective tissue that surrounds the flexor tendons [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/4\">",
"     4",
"    </a>",
"    ]. Other possible causes of compression include congenitally small anatomic space, mass lesions (such as a cyst, neoplasm, or persistent median artery) and edema or inflammatory conditions that result from systemic illness such as rheumatoid arthritis.",
"   </p>",
"   <p>",
"    Upper extremity posture also influences carpal tunnel pressure. The lowest carpal tunnel pressure is seen when the wrist is in a neutral or slightly flexed position, and it increases proportionately with deviation from this posture [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/2,6-9\">",
"     2,6-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathologic analysis of human nerve compression has revealed edema and thickening of vessel walls within the endoneurium and perineurium, noninflammatory synovial fibrosis and vascular proliferation, fibrosis, myelin thinning, and nerve fiber degeneration and regeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/2,10,11\">",
"     2,10,11",
"    </a>",
"    ]. These factors may account for surgical reports of an \"hour glass\" shaped deformity of the median nerve in the region of the carpal tunnel [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/4\">",
"     4",
"    </a>",
"    ]. This deformity may reflect relative thinning of the nerve beneath the transverse carpal tunnel ligament and swelling of the nerve in more distal and proximal segments [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is some evidence that vascular proliferation and fibrosis are associated with increased expression of prostaglandin E2 and vascular endothelial growth factor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the precise role of these factors in CTS is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carpal tunnel syndrome is a common disorder. The estimated annual incidence of CTS per 100,000 population ranges from 324 to 542 for women, and 125 to 303 for men [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Depending on its definition, the estimated prevalence of CTS in the general population is 1 to 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. CTS is more frequent in women (0.7 to 9.2 percent) than in men (0.4 to 2.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/14,16-18\">",
"     14,16-18",
"    </a>",
"    ]. The prevalence of CTS appears to be highest in obese women, and lowest in thin and normal-sized men [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/19\">",
"     19",
"    </a>",
"    ]. In two of the larger studies, the female to male ratio for CTS prevalence was approximately 3 to 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/14,17\">",
"     14,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of CTS may be higher in the industrial setting than in the general population, as illustrated by prevalence estimates of 5 to 15 percent in the workplace [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. However, these estimates may not be directly comparable to general population studies due to differences in case ascertainment. Most of the occupational studies have not employed neurophysiologic testing. Furthermore, factors relating to secondary gain typically were not well controlled. In a report that followed 432 workers for an average of five years, the incidence of CTS was 12.4 cases per 1000 workers per year, with an average annual incidence rate of 1.2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some data suggest that CTS accounts for a significant proportion of workplace absences among work-related disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], and for 14 percent or more of work-related upper extremity disorders in industry [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/25\">",
"     25",
"    </a>",
"    ]. However, the reliability of these reports is uncertain; industrial health studies use varied and sometimes subjective criteria to establish the diagnosis of CTS. The role of repetitive",
"    <span class=\"nowrap\">",
"     hand/wrist",
"    </span>",
"    use and workplace factors in the development of CTS remains controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of conditions have been associated with CTS, include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Female gender",
"     </li>",
"     <li>",
"      Pregnancy",
"     </li>",
"     <li>",
"      Diabetes",
"     </li>",
"     <li>",
"      Rheumatoid arthritis",
"     </li>",
"     <li>",
"      Hypothyroidism",
"     </li>",
"     <li>",
"      Connective tissue diseases",
"     </li>",
"     <li>",
"      Preexisting median mononeuropathy",
"     </li>",
"     <li>",
"      Genetic predisposition",
"     </li>",
"     <li>",
"      Aromatase inhibitor use",
"     </li>",
"     <li>",
"      Workplace factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity, usually defined as increased body mass index, is a probable risk factor for median neuropathy at the wrist and for symptomatic CTS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/15,19,20,26-29\">",
"     15,19,20,26-29",
"    </a>",
"    ]. However, not all studies support the relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Female gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have reported a female predominance in the frequency of CTS. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    One possible explanation for the female predominance is anatomic. The cross sectional area of the proximal carpal tunnel is smaller in women than in men. Furthermore, women with CTS may have smaller cross sectional areas than control women without CTS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Coexisting conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of CTS is increased relative to the general population in patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], rheumatoid arthritis and other connective tissue diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/33,34\">",
"     33,34",
"    </a>",
"    ], pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], and thyroid disease. A 2003 systematic review of CTS found evidence supporting an association for three disorders: diabetes (odds ratio [OR] 2.2, 95% CI 1.5-3.1), hypothyroidism (OR 1.4, 95% CI 1-2), and rheumatoid arthritis (OR 2.2, 95% CI 1.4-3.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accumulation of fluid is the likely etiology of CTS in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study reported that up to one-third of patients with acromegaly have median nerve compression that is frequently bilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/38\">",
"     38",
"    </a>",
"    ]. These findings are due to soft tissue enlargement (synovial edema and tendon hyperplasia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7015?source=see_link\">",
"     \"Rheumatic and bone disorders associated with acromegaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individuals with a preexisting median mononeuropathy, defined using commonly accepted electrodiagnostic parameters (eg, a prolonged median sensory latency), are more likely to develop CTS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/20,39,40\">",
"     20,39,40",
"    </a>",
"    ]. In addition, CTS can occur in rare patients who have hereditary neuropathy with liability to pressure palsy. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Genetic predisposition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Genetic predisposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that some patients have a genetic predisposition to CTS. A twin study found that up to one-half of the liability for CTS in women was genetic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition, patients with bilateral CTS are more likely to a have a family history of CTS than patients with unilateral or no disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/41\">",
"     41",
"    </a>",
"    ]. However, this may be a reflection of inherited anatomic variability in the size of the carpal tunnel, familial predisposition to other medical conditions (ie, diabetes), or some undefined predisposing factor.",
"   </p>",
"   <p>",
"    Hereditary neuropathy with liability to pressure palsy (HNPP) is a recurrent, episodic demyelinating neuropathy. Affected patients typically present with isolated nerve palsies. The most frequently affected nerves are those at common sites of trauma or entrapment and include the axillary, median, radial, ulnar, peroneal, or brachial plexus nerves. Single nerve palsies typically appear sequentially, resolving in days to months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21895?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of hereditary neuropathies\", section on 'Hereditary neuropathy with liability to pressure palsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of aromatase inhibitors appears to be associated with an increased risk of arthralgias and CTS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. As an example, a trial that evaluated over 6000 women with breast cancer found that CTS developed significantly more frequently in patients assigned to the aromatase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    than in those assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    (2.6 versus 0.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/43\">",
"     43",
"    </a>",
"    ]. Most of the CTS cases were mild to moderate in severity and did not require treatment.",
"   </p>",
"   <p>",
"    In addition, a prospective case-control study found that the use of aromatase inhibitors compared with nonuse was associated with significantly increased tendon thickness on sonograms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/44\">",
"     44",
"    </a>",
"    ]. These results suggest that the mechanism of aromatase inhibitor-associated CTS is tendon thickening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Workplace factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, there is controversy regarding the role of workplace factors in the development of carpal tunnel syndrome. Conditions that have been proposed to cause or aggravate CTS include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sustained wrist or palm pressure",
"     </li>",
"     <li>",
"      Prolonged wrist extension and flexion",
"     </li>",
"     <li>",
"      Repetitive hand and wrist use",
"     </li>",
"     <li>",
"      Work with vibrating tools",
"     </li>",
"     <li>",
"      Use of hands in cold temperatures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there is no definitive evidence that these factors play a role in the development of CTS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective analysis of 256 industrial workers found that obesity and female gender were significant risk factors for CTS [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/29\">",
"       29",
"      </a>",
"      ]. Other variables (use of vibrating tools, hand force, repetitive hand use, amount of keyboard time, heavy lifting) were",
"      <strong>",
"       not",
"      </strong>",
"      significantly associated with CTS.",
"     </li>",
"     <li>",
"      In a longitudinal study of 432 industrial and clerical workers, predictors for CTS included higher body mass index; a history of tendonitis in the wrist, hand, or fingers; the presence of numbness, tingling, and pain; and higher peak",
"      <span class=\"nowrap\">",
"       force/hand",
"      </span>",
"      activity levels [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/20\">",
"       20",
"      </a>",
"      ]. However, there was no association with repetitive low force hand use.",
"     </li>",
"     <li>",
"      A prospective report compared 52 asymptomatic subjects who had electrodiagnostic findings of median mononeuropathy with 54 control subjects who had normal electrodiagnostic studies and similar job requirements [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/40\">",
"       40",
"      </a>",
"      ]. After 70 months, more subjects with abnormal electrophysiological studies reported CTS symptoms than those with normal studies. However, there was no clear demonstration that the CTS symptoms were related to occupational exposure. An equally viable explanation is that symptomatic CTS developed in some patients as part of the natural history of initially asymptomatic median nerve compression [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A cross-sectional study assessed the risk of CTS in over 1100 workers, evaluating personal and work related factors [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/45\">",
"       45",
"      </a>",
"      ]. CTS was ascertained using both clinical and electrophysiologic criteria. Analysis by logistic regression modeling suggested that lifting, using vibrating hand tools, frequent wrist bending activities, and working on an assembly line all were associated with increased risk of CTS [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the variable and often conflicting data, the role of workplace factors in the development of CTS is not clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Computer use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is commonly believed that computer use",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clerical duties increase the risk of developing CTS, this association is",
"    <strong>",
"     not",
"    </strong>",
"    supported by most studies. A 2008 systematic review of eight epidemiologic studies found insufficient evidence to link computer use with the development of CTS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/46\">",
"     46",
"    </a>",
"    ]. However, most of the included studies were of suboptimal quality and suffered from important limitations such as referral bias, lack of consistency, and low statistical power. The range of findings among individual studies analyzed in the systematic review is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A report of 2465 workers from Sweden found that intensive keyboard use was associated with a significantly",
"      <strong>",
"       decreased",
"      </strong>",
"      risk of CTS compared with low keyboard use [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In a study that compared medical employees with (n = 22) and without (n = 216) CTS, there was no difference in the two groups with regard to computer use [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A questionnaire study of over 5000 workers in Denmark found that the use of a mouse device for &gt;30 hours a week was associated with symptoms of possible CTS at night [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/48\">",
"       48",
"      </a>",
"      ]. However, there was no statistically significant association with keyboard use [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12949063\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median nerve may be injured at the wrist in a variety of situations, including crush injury of the hand, and Colles or carpal bone fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited and conflicting data with regard to the potential association of age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/29,40\">",
"     29,40",
"    </a>",
"    ], estrogen-progestin oral contraceptive use [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/15,28,49-51\">",
"     15,28,49-51",
"    </a>",
"    ], and smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/51-53\">",
"     51-53",
"    </a>",
"    ] with CTS. For unclear reasons, studies of American workers consistently report higher risk estimates of CTS than studies published elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23911/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/49/18194?source=see_link\">",
"       \"Patient information: Carpal tunnel syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The carpal tunnel is formed by the transverse carpal ligament (flexor retinaculum) superiorly and the carpal bones inferiorly (",
"      <a class=\"graphic graphic_figure graphicRef59856 \" href=\"UTD.htm?1/28/1477\">",
"       figure 1",
"      </a>",
"      ). The median nerve, accompanied by the nine flexor tendons of the forearm musculature, must pass through this anatomic tunnel (",
"      <a class=\"graphic graphic_figure graphicRef53265 \" href=\"UTD.htm?18/45/19158\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathophysiology of CTS is multifactorial. Increased pressure in the intracarpal canal is thought to play a key role in the development of clinical CTS. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CTS is a common disorder. The estimated prevalence of CTS in the general population is 1 to 5 percent. CTS is more frequent in women, with a female to male ratio of approximately 3 to 1. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for CTS include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Female gender",
"     </li>",
"     <li>",
"      Coexisting conditions (diabetes, pregnancy, rheumatoid arthritis, hypothyroidism, connective tissue diseases, preexisting median mononeuropathy)",
"     </li>",
"     <li>",
"      Genetic predisposition",
"     </li>",
"     <li>",
"      Aromatase inhibitor use",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of repetitive",
"    <span class=\"nowrap\">",
"     hand/wrist",
"    </span>",
"    use and workplace factors in the development of CTS is controversial. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to acknowledge Dr. Robert P. Sheon and Dr. Kevin Scott, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/1\">",
"      Jillapalli D, Shefner JM. Electrodiagnosis in common mononeuropathies and plexopathies. Semin Neurol 2005; 25:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/2\">",
"      Keir PJ, Rempel DM. Pathomechanics of peripheral nerve loading. Evidence in carpal tunnel syndrome. J Hand Ther 2005; 18:259.",
"     </a>",
"    </li>",
"    <li>",
"     Preston, DC, Shapiro, BE. Median neuropathy. In: Electromyography and neuromuscular disorders: Clinical-electrophysiologic correlations, Butterworth-Heinemann, Boston 1998. p.231.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/4\">",
"      Bland JD. Carpal tunnel syndrome. Curr Opin Neurol 2005; 18:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/5\">",
"      Amirfeyz R, Gozzard C, Leslie IJ. Hand elevation test for assessment of carpal tunnel syndrome. J Hand Surg Br 2005; 30:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/6\">",
"      Seradge H, Jia YC, Owens W. In vivo measurement of carpal tunnel pressure in the functioning hand. J Hand Surg Am 1995; 20:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/7\">",
"      Szabo RM, Chidgey LK. Stress carpal tunnel pressures in patients with carpal tunnel syndrome and normal patients. J Hand Surg Am 1989; 14:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/8\">",
"      Weiss ND, Gordon L, Bloom T, et al. Position of the wrist associated with the lowest carpal-tunnel pressure: implications for splint design. J Bone Joint Surg Am 1995; 77:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/9\">",
"      Keir PJ, Wells RP, Ranney DA, Lavery W. The effects of tendon load and posture on carpal tunnel pressure. J Hand Surg Am 1997; 22:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/10\">",
"      Mackinnon SE, Dellon AL, Hudson AR, Hunter DA. Chronic human nerve compression--a histological assessment. Neuropathol Appl Neurobiol 1986; 12:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/11\">",
"      Donato G, Galasso O, Valentino P, et al. Pathological findings in subsynovial connective tissue in idiopathic carpal tunnel syndrome. Clin Neuropathol 2009; 28:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/12\">",
"      Atroshi I, Englund M, Turkiewicz A, et al. Incidence of physician-diagnosed carpal tunnel syndrome in the general population. Arch Intern Med 2011; 171:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/13\">",
"      Gelfman R, Melton LJ 3rd, Yawn BP, et al. Long-term trends in carpal tunnel syndrome. Neurology 2009; 72:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/14\">",
"      Atroshi I, Gummesson C, Johnsson R, et al. Prevalence of carpal tunnel syndrome in a general population. JAMA 1999; 282:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/15\">",
"      de Krom MC, Kester AD, Knipschild PG, Spaans F. Risk factors for carpal tunnel syndrome. Am J Epidemiol 1990; 132:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/16\">",
"      Stevens JC, Witt JC, Smith BE, Weaver AL. The frequency of carpal tunnel syndrome in computer users at a medical facility. Neurology 2001; 56:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/17\">",
"      Stevens JC, Sun S, Beard CM, et al. Carpal tunnel syndrome in Rochester, Minnesota, 1961 to 1980. Neurology 1988; 38:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/18\">",
"      de Krom MC, Knipschild PG, Kester AD, et al. Carpal tunnel syndrome: prevalence in the general population. J Clin Epidemiol 1992; 45:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/19\">",
"      Werner RA, Albers JW, Franzblau A, Armstrong TJ. The relationship between body mass index and the diagnosis of carpal tunnel syndrome. Muscle Nerve 1994; 17:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/20\">",
"      Gell N, Werner RA, Franzblau A, et al. A longitudinal study of industrial and clerical workers: incidence of carpal tunnel syndrome and assessment of risk factors. J Occup Rehabil 2005; 15:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/21\">",
"      Franklin GM, Haug J, Heyer N, et al. Occupational carpal tunnel syndrome in Washington State, 1984-1988. Am J Public Health 1991; 81:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/22\">",
"      Silverstein BA, Fine LJ, Armstrong TJ. Occupational factors and carpal tunnel syndrome. Am J Ind Med 1987; 11:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/23\">",
"      Cheadle A, Franklin G, Wolfhagen C, et al. Factors influencing the duration of work-related disability: a population-based study of Washington State workers' compensation. Am J Public Health 1994; 84:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/24\">",
"      De Kesel R, Donceel P, De Smet L. Factors influencing return to work after surgical treatment for carpal tunnel syndrome. Occup Med (Lond) 2008; 58:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/25\">",
"      Silverstein BA, Fine LJ, Armstrong TJ. Hand wrist cumulative trauma disorders in industry. Br J Ind Med 1986; 43:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/26\">",
"      Bland JD. The relationship of obesity, age, and carpal tunnel syndrome: more complex than was thought? Muscle Nerve 2005; 32:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/27\">",
"      Kouyoumdjian JA, Zanetta DM, Morita MP. Evaluation of age, body mass index, and wrist index as risk factors for carpal tunnel syndrome severity. Muscle Nerve 2002; 25:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/28\">",
"      Vessey MP, Villard-Mackintosh L, Yeates D. Epidemiology of carpal tunnel syndrome in women of childbearing age. Findings in a large cohort study. Int J Epidemiol 1990; 19:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/29\">",
"      Nathan PA, Istvan JA, Meadows KD. A longitudinal study of predictors of research-defined carpal tunnel syndrome in industrial workers: findings at 17 years. J Hand Surg Br 2005; 30:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/30\">",
"      Hakim AJ, Cherkas L, El Zayat S, et al. The genetic contribution to carpal tunnel syndrome in women: a twin study. Arthritis Rheum 2002; 47:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/31\">",
"      Albers JW, Brown MB, Sima AA, Greene DA. Frequency of median mononeuropathy in patients with mild diabetic neuropathy in the early diabetes intervention trial (EDIT). Tolrestat Study Group For Edit (Early Diabetes Intervention Trial). Muscle Nerve 1996; 19:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/32\">",
"      Leach RE, Odom JA Jr. Systemic causes of carpal tunnel syndrome. Postgrad Med 1968; 44:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/33\">",
"      Barnes CG, Currey HL. Carpal tunnel syndrome in rheumatoid arthritis. A clinical and electrodiagnostic survey. Ann Rheum Dis 1967; 26:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/34\">",
"      Herbison GJ, Teng C, Martin JH, Ditunno JF Jr. Carpal tunnel syndrome in rheumatoid arthritis. Am J Phys Med 1973; 52:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/35\">",
"      Padua L, Aprile I, Caliandro P, et al. Symptoms and neurophysiological picture of carpal tunnel syndrome in pregnancy. Clin Neurophysiol 2001; 112:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/36\">",
"      Padua L, Di Pasquale A, Pazzaglia C, et al. Systematic review of pregnancy-related carpal tunnel syndrome. Muscle Nerve 2010; 42:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/37\">",
"      van Dijk MA, Reitsma JB, Fischer JC, Sanders GT. Indications for requesting laboratory tests for concurrent diseases in patients with carpal tunnel syndrome: a systematic review. Clin Chem 2003; 49:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/38\">",
"      Ezzat S, Forster MJ, Berchtold P, et al. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994; 73:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/39\">",
"      Nathan PA, Keniston RC, Myers LD, et al. Natural history of median nerve sensory conduction in industry: relationship to symptoms and carpal tunnel syndrome in 558 hands over 11 years. Muscle Nerve 1998; 21:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/40\">",
"      Werner RA, Gell N, Franzblau A, Armstrong TJ. Prolonged median sensory latency as a predictor of future carpal tunnel syndrome. Muscle Nerve 2001; 24:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/41\">",
"      Alford JW, Weiss AP, Akelman E. The familial incidence of carpal tunnel syndrome in patients with unilateral and bilateral disease. Am J Orthop (Belle Mead NJ) 2004; 33:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/42\">",
"      Nishihori T, Choi J, DiGiovanna MP, et al. Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer. Clin Breast Cancer 2008; 8:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/43\">",
"      Sestak I, Sapunar F, Cuzick J. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol 2009; 27:4961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/44\">",
"      Dizdar O, Oz&ccedil;akar L, Malas FU, et al. Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol 2009; 27:4955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/45\">",
"      Armstrong T, Dale AM, Franzblau A, Evanoff BA. Risk factors for carpal tunnel syndrome and median neuropathy in a working population. J Occup Environ Med 2008; 50:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/46\">",
"      Thomsen JF, Gerr F, Atroshi I. Carpal tunnel syndrome and the use of computer mouse and keyboard: a systematic review. BMC Musculoskelet Disord 2008; 9:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/47\">",
"      Atroshi I, Gummesson C, Ornstein E, et al. Carpal tunnel syndrome and keyboard use at work: a population-based study. Arthritis Rheum 2007; 56:3620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/48\">",
"      Andersen JH, Thomsen JF, Overgaard E, et al. Computer use and carpal tunnel syndrome: a 1-year follow-up study. JAMA 2003; 289:2963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/49\">",
"      Albani G, Priano L, Campanelli L, et al. Carpal tunnel syndrome and oral contraceptive drugs: risk or protective factor? J Peripher Nerv Syst 2003; 8:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/50\">",
"      Sabour MS, Fadel HE. The carpal tunnel syndrome--a new complication ascribed to the \"pill\". Am J Obstet Gynecol 1970; 107:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/51\">",
"      Geoghegan JM, Clark DI, Bainbridge LC, et al. Risk factors in carpal tunnel syndrome. J Hand Surg Br 2004; 29:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/52\">",
"      Nathan PA, Meadows KD, Istvan JA. Predictors of carpal tunnel syndrome: an 11-year study of industrial workers. J Hand Surg Am 2002; 27:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/53\">",
"      Nathan PA, Keniston RC, Lockwood RS, Meadows KD. Tobacco, caffeine, alcohol, and carpal tunnel syndrome in American industry. A cross-sectional study of 1464 workers. J Occup Environ Med 1996; 38:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23911/abstract/54\">",
"      Abbas MA, Afifi AA, Zhang ZW, Kraus JF. Meta-analysis of published studies of work-related carpal tunnel syndrome. Int J Occup Environ Health 1998; 4:160.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5258 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-BE0BA8F269-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_22_23911=[""].join("\n");
var outline_f23_22_23911=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Female gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Coexisting conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Genetic predisposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Workplace factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Computer use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12949063\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5258\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5258|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/28/1477\" title=\"figure 1\">",
"      Carpal tunnel syndrome structures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/45/19158\" title=\"figure 2\">",
"      Cross section of wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/25/35222\" title=\"figure 3\">",
"      Trunks and cords of the brachial plexus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/44/38593\" title=\"figure 4\">",
"      Median sensory territory",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=related_link\">",
"      Clinical manifestations and diagnosis of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21895?source=related_link\">",
"      Overview of hereditary neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/49/18194?source=related_link\">",
"      Patient information: Carpal tunnel syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7015?source=related_link\">",
"      Rheumatic and bone disorders associated with acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44008?source=related_link\">",
"      Treatment of carpal tunnel syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_22_23912="Growth management in preterm infants";
var content_f23_22_23912=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Growth management in preterm infants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/22/23912/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/22/23912/contributors\">",
"     Ian J Griffin, MB ChB",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/22/23912/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/22/23912/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/22/23912/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/22/23912/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/22/23912/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/22/23912/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth impairment during early infancy, a period of substantial cellular hyperplasia and hypertrophy, can have permanent detrimental effects. Abnormalities in growth during this time period may persist into adulthood, especially in patients who were preterm infants. This was illustrated in a report of very low birth weight (VLBW, &lt;1500 g) infants who were twice as likely to have a height less than the third percentile at 20 years of age than that of normal birth weight controls (10 versus 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preterm infants are at risk for poor growth while in the neonatal intensive care unit (NICU) and after discharge from the NICU. They must be closely monitored and may require interventions to promote better growth.",
"   </p>",
"   <p>",
"    Growth in the preterm infant, including monitoring of growth and managing growth impairment while in the NICU and after discharge, will be discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NORMATIVE GROWTH DATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normative growth data are available for healthy term infants. However, data are limited for preterm infants during both hospitalization and after discharge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42633?source=see_link&amp;anchor=H13#H13\">",
"     \"Normal growth patterns in infants and prepubertal children\", section on 'Evaluation of growth'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Term infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normative data are available for intrauterine growth in the last trimester and during infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight increases by 208",
"      <span class=\"nowrap\">",
"       g/week",
"      </span>",
"      from 28 weeks gestation to 6 months of age. After birth, infants typically gain 30",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      until 3 months of age and 20",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      between 3 and 12 months of age.",
"     </li>",
"     <li>",
"      Length increases by 1.1",
"      <span class=\"nowrap\">",
"       cm/week",
"      </span>",
"      from 28 to 40 weeks gestation; after birth, growth is 0.75 and 0.5",
"      <span class=\"nowrap\">",
"       cm/week",
"      </span>",
"      for the first three and the following two to three months, respectively.",
"     </li>",
"     <li>",
"      Head circumference increases by 0.75",
"      <span class=\"nowrap\">",
"       cm/week",
"      </span>",
"      during the last trimester, 0.5",
"      <span class=\"nowrap\">",
"       cm/week",
"      </span>",
"      from birth to three months of age, and then approximately 0.25",
"      <span class=\"nowrap\">",
"       cm/week.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Preterm infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Curves used to track growth of preterm infants are not ideal. Those for hospitalized infants have been based upon intrauterine standards or upon small numbers of preterm infants. Growth curves for VLBW infants that reflect NICU practices common during the 1990s have been reported by the NICHD Neonatal Research Network [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/4\">",
"     4",
"    </a>",
"    ]. However, these curves do not necessarily describe optimal growth.",
"   </p>",
"   <p>",
"    Once they regain their birth weight, the growth of preterm infants is targeted to the following goals based upon the estimated intrauterine growth from historical cohort studies of live births of infants of varying gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Weight &mdash; 15",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day",
"     </li>",
"     <li>",
"      Length &mdash; 1",
"      <span class=\"nowrap\">",
"       cm/week",
"      </span>",
"     </li>",
"     <li>",
"      Head circumference &mdash; 0.7",
"      <span class=\"nowrap\">",
"       cm/week",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, this practice has resulted in inadequate growth, as most low birth weight infants have weights that are below the 10th percentile at the time of discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. It also appears that the estimated \"normal\" in utero weight gain during the third trimester varies from 11.2 to 20",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, there are periods of slower growth that occur during episodes of infection or feeding intolerance that need to be compensated by accelerated growth during other time periods [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/7\">",
"     7",
"    </a>",
"    ]. Although most centers, including our own, use a minimum growth target of 15",
"    <span class=\"nowrap\">",
"     g/kg,",
"    </span>",
"    growth often remains inadequate, suggesting that higher goals are required to avoid malnutrition of preterm infants during hospitalization. Further studies are needed to establish appropriate growth targets in preterm infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Growth chart",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only one published growth chart from 1976 is currently available to track the growth of preterm infants during hospitalization and after discharge through one year of age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/8\">",
"     8",
"    </a>",
"    ]. This chart, however, reflects NICU practices and outcomes that differ from contemporary care [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/7\">",
"     7",
"    </a>",
"    ]. As a result, to follow growth after discharge, most clinicians use standard growth charts with an adjustment for prematurity (ie, corrected age for gestational age) until approximately three years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The growth curves published by the World Health Organization (WHO) should be used for children younger than 24 months of age, and the Center for Disease Control and Prevention (CDC) growth curves for children between 2 and 19 years of age. The CDC and WHO growth charts are available at the CDC web site (",
"    <a class=\"external\" href=\"file://www.cdc.gov/growthcharts/\">",
"     www.cdc.gov/growthcharts/",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Monitoring of growth'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42633?source=see_link&amp;anchor=H16#H16\">",
"     \"Normal growth patterns in infants and prepubertal children\", section on 'Growth charts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2007, an updated growth chart for use with preterm infants between 22 weeks gestational age and 50 weeks postmenstrual age (PMA), which is equivalent to an adjusted age of 10 weeks postterm, was constructed using data from several population studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/11\">",
"     11",
"    </a>",
"    ]. This chart (referred to as the Fenton preterm infant growth chart) can be used in conjunction with the WHO curves, especially in infants who are younger than 50 weeks PMA. Both applications can convert raw data into Z scores, values that represent the number of standard deviations from the median height and weight values for age, for comparison over a 10-week transition period between growth charts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7279167\">",
"    <span class=\"h1\">",
"     GROWTH IN THE NICU",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preterm infants do not achieve optimal growth in the NICU. Poor postnatal growth occurs in preterm infants of all birth weight and gestational age categories. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=see_link&amp;anchor=H2#H2\">",
"     \"Incidence and mortality of the premature infant\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This is illustrated by the following studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/4,12,13\">",
"     4,12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 4438 premature infants from the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network demonstrated that 99 percent of appropriate for gestational age (AGA) extremely low birth weight (ELBW, birth weight &le;1000 g) and 97 percent of AGA very low birth weight (VLBW, birth weight &lt;1500) had weights &le;10th percentile at 36 weeks postmenstrual age [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another multicenter report, most of the 1660 VLBW infants (birth weight between 501 to 1500 g) grew along a trajectory below that of a reference fetus of the same postmenstrual age [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A multicenter study of 382 larger preterm infants (30 to 35 week gestation, mean birth weight of 2024 g), demonstrated weight growth velocity that was less than in utero growth standards [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/13\">",
"       13",
"      </a>",
"      ]. In these patients, growth velocity from seven days to discharge averaged 13.3",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day, and only 2 percent of the group achieved intrauterine growth rates of 15",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both increased nutritional requirements due to stress (eg, episodes of sepsis) and inadequate nutritional intake contribute to the poor growth of hospitalized preterm infants. Inadequate intake can occur with either enteral or parenteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/14\">",
"     14",
"    </a>",
"    ]. Immature gastrointestinal function limits the advancement of enteral feedings, while poor tolerance of intravenous lipids and glucose limits the use of parenteral nutrition.",
"   </p>",
"   <p>",
"    As a result, in preterm infants, nutrient intakes often fail to meet the recommended dietary intakes, resulting in rapid accruement of protein and energy deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/15\">",
"     15",
"    </a>",
"    ]. Deficits increase with decreasing gestational age and are most severe in extremely low birth weight (ELBW) infants (birth weight &lt;1000 g).",
"   </p>",
"   <p>",
"    This was illustrated in a prospective study that measured protein and energy intakes in 105 preterm infants (birth weight &lt;1750 and gestational age &lt;34 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/15\">",
"     15",
"    </a>",
"    ]. By the end of the first week of life, deficits (the difference between recommended intakes and achieved intakes) in energy intake averaged between 300 and 400",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    and in protein intake averaged between 12 and 14",
"    <span class=\"nowrap\">",
"     g/kg.",
"    </span>",
"    Larger deficits were seen in infants born before 30 weeks gestation compared to those born after 30 weeks gestation. These deficits, especially in the most premature infants, are difficult to replace. The inability to recoup these losses contributes to impaired growth by the preterm infant.",
"   </p>",
"   <p>",
"    In another study, the mean energy expenditure of ELBW infants near the time of discharge at a postconceptional age of 34 to 38 weeks remained significantly greater than that of term infants (89 versus 58",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/16\">",
"     16",
"    </a>",
"    ]. These results demonstrated the need for greater energy intake in the ELBW infants at the time of discharge compared to term infants. Interventions to improve intake are required to ensure adequate growth for the preterm infant in the NICU. A more detailed discussion on enteral nutrition and feeding for the premature infant to maintain adequate growth is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/28/458?source=see_link\">",
"     \"Nutritional composition of human milk and preterm formula for the premature infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/8/19593?source=see_link\">",
"     \"Approach to enteral nutrition in the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An analysis of data from NICHD Neonatal Research Network registry and three NICUs in Cincinnati provided more information on growth in the NICU [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/17\">",
"     17",
"    </a>",
"    ]. In this study of preterm infants (gestational age 26 to 29 weeks) born between 1991 and 2003, growth was measured both by weight-for-age and weight-for-length. From birth to discharge, although the percentage of small-for-age infants (&lt;10th percentile) increased from 12 to 21 percent, the percentage of small-for-length infants (&lt;10th percentile) decreased from 10 to 4 percent, and the percentage of large-for-length infants increased from 5 to 17 percent. In this cohort of infants, although both weight and length gain in the NICU were poor, weight-for-length percentile increased during hospitalization, suggesting that weight gain was relatively preserved compared to length gain. In other words, in the NICU, weight gain was poor, but length gain was even poorer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DISCHARGE PLANNING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to NICU discharge, infants should have a nutritional evaluation, and a feeding plan should be developed. This should account for factors that may have interfered with growth in the NICU and provide a baseline for serial monitoring of weight, length, and head circumference after discharge. Additionally, an assessment should be made of the home environment, including eligibility for government nutrition or medical assistance programs, as lack of social support may be associated with growth failure.",
"   </p>",
"   <p>",
"    The nutritional goal for most preterm infants during hospitalization is for an energy intake of 120",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day (",
"    <a class=\"graphic graphic_table graphicRef59766 \" href=\"UTD.htm?26/32/27147\">",
"     table 1",
"    </a>",
"    ). This is equivalent to 150 to 160",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per day of premature formula (24",
"    <span class=\"nowrap\">",
"     kcal/oz",
"    </span>",
"    or 80",
"    <span class=\"nowrap\">",
"     kcal/100",
"    </span>",
"    mL) or 160 to 180",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per day of fortified human milk. Ad libitum fed preterm infants will often consume larger amounts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to discharge, the infant should be able to consume ad libitum quantities of human milk or formula. Appropriate growth should be demonstrated on the proposed discharge feeding regimen. The target volume generally is one that supports a weight gain of at least 15",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day or higher. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/28/458?source=see_link\">",
"     \"Nutritional composition of human milk and preterm formula for the premature infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11738?source=see_link\">",
"     \"Care of the neonatal intensive care unit graduate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     AFTER DISCHARGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little data regarding the specific nutrient intakes required in premature infants after discharge. The overall goal is to achieve the body composition and rate of growth of a normal",
"    <span class=\"nowrap\">",
"     fetus/infant",
"    </span>",
"    of the same postmenstrual age during the first entire year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/19\">",
"     19",
"    </a>",
"    ]. As a result, ongoing monitoring of growth is the essential first step in the management of growth in these infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Monitoring of growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth parameters include the infant's weight, length, and head circumference and should be monitored on a weekly to biweekly basis for the first four to six weeks after hospital discharge. After this initial period of close observation, infants who are growing normally can be followed on a monthly and then every two month schedule.",
"   </p>",
"   <p>",
"    Corrections for gestational age should be made for weight through 24 months of age, for stature through 40 months of age, and for head circumference through 18 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/20\">",
"     20",
"    </a>",
"    ]. We recommend using the Fenton preterm infant growth chart until the infant is 50 weeks PMA (",
"    <a class=\"graphic graphic_figure graphicRef70389 \" href=\"UTD.htm?25/54/26471\">",
"     figure 1",
"    </a>",
"    ), at which point the CDC growth curves for term infants (beginning at 40 weeks PMA) can be utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/11,21\">",
"     11,21",
"    </a>",
"    ]. There is a 10 week transition period when both charts can be used simultaneously and z score values can be compared. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Growth chart'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Biweekly or monthly follow-up visits should continue for infants with slow growth who remain below the third percentile on a standard growth curve when they have reached 40 postmenstrual weeks, or who have chronic health problems (eg, bronchopulmonary dysplasia). Close monitoring should continue until a steady adequate growth pattern is established [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants who fall off their growth curve are growing suboptimally (ie, failing to thrive) and should be evaluated and treated as soon as the poor growth is identified. Delays in instituting treatment simply worsen the degree of growth failure and increase the amount of catch-up growth that will subsequently be required to achieve normal growth. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Interventions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Infants who are extremely short may need further evaluation for growth retardation, including consultation by a pediatric endocrinologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=see_link\">",
"     \"Diagnostic approach to short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Head circumference",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slow head growth is associated with developmental delay. In one report, VLBW infants whose head circumferences were below normal by eight months corrected age had poor cognitive function, academic achievement, and behavior at eight years of age, compared to controls with normal head size [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/23\">",
"     23",
"    </a>",
"    ]. A rapid increase in head circumference may indicate post hemorrhagic hydrocephalus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31465?source=see_link\">",
"     \"Management and complications of intraventricular hemorrhage in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants with abnormal head growth should have neuroimaging studies to evaluate the cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biochemical monitoring (eg, serum calcium, phosphorus, and alkaline phosphatase) is usually not helpful in the evaluation of the poorly growing NICU graduate. An exception is an elevation of serum alkaline phosphatase, which is associated with reduced stature later in life [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/7\">",
"     7",
"    </a>",
"    ]. It remains uncertain whether targeted interventions (phosphorus, calcium, or vitamin D supplementation) in preterm infants with elevated serum alkaline phosphatase (&gt;600 IU) results in improved height in childhood or adulthood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40567?source=see_link&amp;anchor=H12#H12\">",
"     \"Calcium and phosphorus requirements of newborn infants\", section on 'Osteopenia of prematurity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102775492\">",
"    <span class=\"h1\">",
"     LONG-TERM OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited on the long-term growth in individuals who were born prematurely, especially those who were extremely premature (gestational age &lt;28 weeks). In a follow-up study from Australia, extremely premature survivors were consistently shorter than term controls at all ages through 18 years of age (at 18 years of age, mean height Z scores of -0.47&plusmn;1.14 versus 0.26&plusmn;0.98) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/24\">",
"     24",
"    </a>",
"    ]. The extremely premature survivors were also lighter than term controls, however, this difference decreased with age so that BMI z scores were similar for the two groups by 18 years of age. Further investigation is needed to better understand the factors that alter growth trajectories for children who are born extremely preterm and develop targeted interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INTERVENTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Routine nutrient supplementation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Formula-fed infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of nutrient-enriched formula after hospital discharge for formula-fed preterm infants is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/19,25,26\">",
"     19,25,26",
"    </a>",
"    ]. The commercially available enriched formulas compared to standard formulas are calorically denser (75",
"    <span class=\"nowrap\">",
"     kcal/100",
"    </span>",
"    mL versus 67",
"    <span class=\"nowrap\">",
"     kcal/100",
"    </span>",
"    mL) and have a higher content of protein, calcium, phosphorus, zinc, and vitamins A, E, and D.",
"   </p>",
"   <p>",
"    A systematic review of 15 trials evaluated growth and neurodevelopmental outcome in infants who received nutrient-rich formula versus those who received standard full-term formula [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/27\">",
"     27",
"    </a>",
"    ]. Because of differences in study design, data synthesis was limited. In addition, there were no data on long-term growth, and development beyond 18 months. This review concluded that there was little evidence supporting the benefit of enriched formulas on the growth and development of discharged preterm infants.",
"   </p>",
"   <p>",
"    In contrast, the European Society of Pediatric Gastroenterology Hepatology and Nutrition after reviewing the same data concluded that infants should received enriched formula after discharge because they are at risk for long-term growth failure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a subsequent trial, infants fed standard formula compared to those who received enriched formula had increased height, weight, and head circumference at one year of age and at all intermittent time points from birth [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/29\">",
"     29",
"    </a>",
"    ]. The authors hypothesized that the unexpected results were due to a greater formula intake of infants who received standard formula. However, since the infants were fed ad libitum and there were no records of daily intake, this theory could not be confirmed.",
"   </p>",
"   <p>",
"    In contrast, another trial of 49 preterm infants (gestational age &le; 33 weeks) reported that infants who received enriched formula for two months after discharge had higher body weight and bone mineral content than those who received standard term formula [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These results demonstrate the limited and conflicting data regarding the benefit of enriched formula versus standard term formula in preterm infants. It is the author's view that the balance of the current evidence favors a small, but significant, growth advantage to enriched formulas after discharge. However, whether these benefits are sustained and whether they improve or worsen long-term health is unclear. An alternate approach is to provide enriched formulas to preterm infants who do not maintain adequate growth or fail to \"catch up\" after hospital discharge, although this approach has not been systematically studied.",
"   </p>",
"   <p>",
"    The decision whether or not to use a nutritional enriched formula should be made as part of the discharge planning process of formula-fed preterm infants. In our institution, we recommend enriched formula for infants with weights below the 10th percentile for age and who were born with birth weights below 1500 g. We also recommend changing to enriched formula in those infants who initially received standard formula if they fail to maintain adequate growth or fail to \"catch up\" after hospital discharge.",
"   </p>",
"   <p>",
"    In infants who receive standard formulas, additional vitamin supplementation and iron may be required to meet the needs of premature NICU grads [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Human milk-fed infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;A group of particular concern is the human milk-fed preterm baby. Current evidence is clear that despite the many non-nutritional advantages of human milk feeding, growth of these babies is poorer than infants who received standard term formula [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/31\">",
"     31",
"    </a>",
"    ]. Limited data in studies with small numbers of patients suggest that infants after discharge who received nonfortified human milk compared to those who received formula showed calcium and phosphorus deficiency and lower bone mineral content [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/32\">",
"     32",
"    </a>",
"    ]. However, this difference disappeared by two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data are limited on the efficacy of nutrient enrichment with either \"complimentary\" feeds of an enriched formula or fortification of human milk after hospital discharge in human milk-fed infants [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/19,31,34\">",
"     19,31,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the only trial to date, infants were randomly assigned to unfortified human milk (n = 102) or fortified human milk (n = 105) until four months corrected age (CA). A third group of infants (n = 113) were fed preterm formula [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/35\">",
"     35",
"    </a>",
"    ]. There were no differences in weight, length, and head circumferences between the two groups who received human milk. Infants who were fed preterm formula had higher increase in weight Z scores at term and length Z scores at six months CA than the two groups fed human milk. Boys who received preterm formula were also longer and heavier than those fed human milk.",
"   </p>",
"   <p>",
"    In contrast, a small trial of 39 preterm infants (range of birth weight 750 to 1800 g) demonstrated that infants after discharge who received half of their intake as fortified human milk compared with controls fed unfortified human milk were longer (mean length, 46.3 versus 45 cm) and tended to be heavier (mean weight, 5535 versus 5042 g) at the end of the 12 week study [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/36\">",
"     36",
"    </a>",
"    ]. The enriched milk was estimated to contain 80 kcal and 2.2 g protein per 100 mL. Mean energy intake between the two groups did not differ, but mean protein, calcium, phosphorus, zinc, and vitamins A and D intakes were lower in the control group.",
"   </p>",
"   <p>",
"    Although it remains uncertain whether or not fortification of human milk improves growth, maintaining human milk feeding of the preterm infant after hospital discharge should remain the goal. As an alternative to fortified human milk, which requires collection of pumped breast milk and addition of nutrients, human milk-fed infants with poor growth can be given two or three feeds daily of a postdischarge enriched formula. This has a surprisingly small effect on absolute nutrient intake but does increase the intake of protein by 20 to 30 percent and calcium intake by about 50 percent compared to exclusive human milk feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/26\">",
"     26",
"    </a>",
"    ]. These changes are similar to those reported with the use of fortifiers for human milk in the previously discussed study and to the relative increases in protein and mineral intake that result from changing from a term infant formula to an enriched one [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human milk-fed premature infants should also receive iron and vitamin D supplementation, as these two nutrients are inadequately supplied by human milk alone. Exclusively human milk-fed infants appear to be at risk for osteopenia of prematurity, and biochemical evaluation will often detect an elevated serum alkaline phosphatase. Data, however, are lacking on what interventions to use in human milk-fed infants with evidence of poor bone health as well as those who exhibit poor growth. In these infants, we will use fortified human milk or enriched formula recognizing that these interventions have not been adequately studied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40567?source=see_link&amp;anchor=H12#H12\">",
"     \"Calcium and phosphorus requirements of newborn infants\", section on 'Osteopenia of prematurity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Poor oral feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some preterm infants will struggle to maintain adequate enteral caloric intake due to poor oral feeding from developmental problems, oral aversion, or chronic medical problems. In particular, infants who were intubated and mechanically ventilated for a long time period may have difficulty with oral feeding, in part because of abnormal development of suck and swallow rhythms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/37\">",
"     37",
"    </a>",
"    ]. Neurologic impairment may also interfere with oral feeding and growth [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/38\">",
"     38",
"    </a>",
"    ]. These patients may benefit from occupational or speech therapy to improve oral motor function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21576?source=see_link\">",
"     \"Sucking and swallowing disorders in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In rare cases, infants with oral motor dysfunction may benefit from nasogastric or orogastric tube feeding while awaiting developmental improvement in the coordination required for oral feeding. All or a proportion of feedings may be provided by this route. In some cases, a gastrostomy may be preferred [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/38\">",
"     38",
"    </a>",
"    ]. This approach may also decrease caloric expenditure in chronically ill infants, such as those with congenital heart disease or bronchopulmonary dysplasia.",
"   </p>",
"   <p>",
"    In one report, fewer respiratory infections were seen in preterm infants discharged home with nursing care while they still required tube feedings compared to those who remained in the hospital until they could take full oral feeds [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. There were no differences between the groups in infant health, surgical procedures, or medications. Despite these findings, the safety, efficacy, or cost-benefit ratio of gavage feedings at home is not clear, and this technique must be used with caution [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7279658\">",
"    <span class=\"h1\">",
"     NEURODEVELOPMENTAL OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Greater weight gain before reaching term appears to be associated with improved neurodevelopmental outcome. This was illustrated in a study of 613 infants (gestational age below 33 weeks) that demonstrated greater weight gain, body mass index (BMI), and head growth before 40 weeks PMA (ie, term) were associated with higher Bayley Mental and Psychomotor Developmental Indexes (MDI and PDI) scores at 18 months corrected age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/42\">",
"     42",
"    </a>",
"    ]. From term to four months corrected age, weight gain and linear growth were associated with higher PDI Bayley scores; however, there was not an associated improvement in either MDI or PDI Bayley scores with BMI. After four months corrected age, there was no association between any growth parameter and cognitive testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     BRONCHOPULMONARY DYSPLASIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth failure is common in infants with bronchopulmonary dysplasia (BPD), with reported rates of 30 to 67 percent in infants with BPD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/43\">",
"     43",
"    </a>",
"    ]. Possible factors that contribute to poor growth in these infants include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased energy expenditure [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduced fat absorption [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/46\">",
"       46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Chronic hypoxia or suboptimal tissue oxygenation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Poor feeding endurance and performance with lower sucking pressure and decreased sucking frequency and swallowing in infants with severe BPD (requiring home oxygen therapy) compared to infants without BPD or with milder BPD [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infants with BPD who received postnatal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    therapy appear to be especially susceptible to poor growth [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although it is established that poor growth is a common problem in infants with BPD, there has only been one randomized controlled trial to study the efficacy of nutrient-enriched formula in affected patients. In this study of 60 infants with BPD, patients were randomly assigned to one of two different 30",
"    <span class=\"nowrap\">",
"     kcal/oz",
"    </span>",
"    formulas until three months corrected age. Infants receiving protein and mineral enriched formula had better growth than control infants at three months corrected age. However, there was no difference in growth between the two groups at 12 months corrected age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/50\">",
"     50",
"    </a>",
"    ]. Whether this means that the benefits to the formula were transient, or whether the difference is dependent upon continued administration of nutrient-enriched formula beyond three months corrected age is not clear.",
"   </p>",
"   <p>",
"    In our institution, the nutritional management of these infants is highly individualized, especially in those with severe BPD. Fluid intake is largely determined by the baby's respiratory status. Enriched formulas or fortified human milk can be modified to meet the age-appropriate nutritional intakes of these infants with higher nutrient needs than premature infants without chronic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23912/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preterm infants are often significantly underweight at the time of hospital discharge. At discharge, they remain at increased nutritional risk and merit close growth monitoring after hospital discharge. (See",
"      <a class=\"local\" href=\"#H7279167\">",
"       'Growth in the NICU'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Preterm infants'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Monitoring of growth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enriched formula may improve the growth of preterm infants and is a reasonable option for formula-fed babies. We suggest using enriched formula for infants with weights below the 10th percentile for age at the time of hospital discharge and who were born with birth weights below 1500 g (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Formula-fed infants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After hospital discharge, exclusively human milk-fed preterm infants are at increased risk for suboptimal growth compared to formula-fed infants. In our practice, if there is suboptimal growth, we suggest that infants receive two or three supplemental feedings of enriched formula daily (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The long-term goal is to maintain human milk feeding in these infants. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Human milk-fed infants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants with BPD are at increased risk of growth failure after hospital discharge. Protein and mineral enriched feeds may provide short-term advantages in growth. In our practice, the feeding of these infants needs to be individualized before hospital discharge to ensure adequate growth within the fluid intake limits imposed by the chronic lung disease. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Bronchopulmonary dysplasia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/1\">",
"      Hack M, Flannery DJ, Schluchter M, et al. Outcomes in young adulthood for very-low-birth-weight infants. N Engl J Med 2002; 346:149.",
"     </a>",
"    </li>",
"    <li>",
"     Costarino AT Jr, Baumgart S. Water as Nutrition. In: Nutritional Needs of the Preterm Infant: Scientific Basis and Practical Guidelines, Tsang RC, et al (Eds), William and Wilkins, Baltimore 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/3\">",
"      Babson SG. Growth of low-birth-weight infants. J Pediatr 1970; 77:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/4\">",
"      Ehrenkranz RA, Younes N, Lemons JA, et al. Longitudinal growth of hospitalized very low birth weight infants. Pediatrics 1999; 104:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/5\">",
"      Lubchenco LO, Hansman C, Boyd E. Intrauterine growth in length and head circumference as estimated from live births at gestational ages from 26 to 42 weeks. Pediatrics 1966; 37:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/6\">",
"      Lucas A, Gore SM, Cole TJ, et al. Multicentre trial on feeding low birthweight infants: effects of diet on early growth. Arch Dis Child 1984; 59:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/7\">",
"      Griffin IJ. Nutritional assessment in preterm infants. Nestle Nutr Workshop Ser Pediatr Program 2007; 59:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/8\">",
"      Babson SG, Benda GI. Growth graphs for the clinical assessment of infants of varying gestational age. J Pediatr 1976; 89:814.",
"     </a>",
"    </li>",
"    <li>",
"     Hack M, Fanaroff AA. Growth patterns in the ICN graduate. In: Pediatric Care of the ICN Graduate, Ballard RA (Ed), Saunders, Philadelphia 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/10\">",
"      Hack M, Friedman H, Fanaroff AA. Outcomes of extremely low birth weight infants. Pediatrics 1996; 98:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/11\">",
"      Fenton TR, Sauve RS. Using the LMS method to calculate z-scores for the Fenton preterm infant growth chart. Eur J Clin Nutr 2007; 61:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/12\">",
"      Lemons JA, Bauer CR, Oh W, et al. Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics 2001; 107:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/13\">",
"      Blackwell MT, Eichenwald EC, McAlmon K, et al. Interneonatal intensive care unit variation in growth rates and feeding practices in healthy moderately premature infants. J Perinatol 2005; 25:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/14\">",
"      Cooke RJ, Embleton ND. Feeding issues in preterm infants. Arch Dis Child Fetal Neonatal Ed 2000; 83:F215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/15\">",
"      Embleton NE, Pang N, Cooke RJ. Postnatal malnutrition and growth retardation: an inevitable consequence of current recommendations in preterm infants? Pediatrics 2001; 107:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/16\">",
"      Guilfoy VM, Wright-Coltart S, Leitch CA, Denne SC. Energy expenditure in extremely low birth weight infants near time of hospital discharge. J Pediatr 2008; 153:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/17\">",
"      Olsen IE, Lawson ML, Meinzen-Derr J, et al. Use of a body proportionality index for growth assessment of preterm infants. J Pediatr 2009; 154:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/18\">",
"      Cooke RJ, Griffin IJ, McCormick K, et al. Feeding preterm infants after hospital discharge: effect of dietary manipulation on nutrient intake and growth. Pediatr Res 1998; 43:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/19\">",
"      Greer FR. Post-discharge nutrition: what does the evidence support? Semin Perinatol 2007; 31:89.",
"     </a>",
"    </li>",
"    <li>",
"     Low Birth Weight and Intrauterine Growth Charts. In: Pediatric Nutrition Handbook, 6th ed, Kleinman RE (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2008. p.1228.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/21\">",
"      Fenton TR. A new growth chart for preterm babies: Babson and Benda's chart updated with recent data and a new format. BMC Pediatr 2003; 3:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/22\">",
"      Manser JI. Growth in the high-risk infant. Clin Perinatol 1984; 11:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/23\">",
"      Hack M, Breslau N, Weissman B, et al. Effect of very low birth weight and subnormal head size on cognitive abilities at school age. N Engl J Med 1991; 325:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/24\">",
"      Roberts G, Cheong J, Opie G, et al. Growth of extremely preterm survivors from birth to 18 years of age compared with term controls. Pediatrics 2013; 131:e439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/25\">",
"      Carver JD. Nutrition for preterm infants after hospital discharge. Adv Pediatr 2005; 52:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/26\">",
"      Griffin IJ, Cooke RJ. Nutrition of preterm infants after hospital discharge. J Pediatr Gastroenterol Nutr 2007; 45 Suppl 3:S195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/27\">",
"      Young L, Morgan J, McCormick FM, McGuire W. Nutrient-enriched formula versus standard term formula for preterm infants following hospital discharge. Cochrane Database Syst Rev 2012; 3:CD004696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/28\">",
"      ESPGHAN Committee on Nutrition, Aggett PJ, Agostoni C, et al. Feeding preterm infants after hospital discharge: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2006; 42:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/29\">",
"      Koo WW, Hockman EM. Posthospital discharge feeding for preterm infants: effects of standard compared with enriched milk formula on growth, bone mass, and body composition. Am J Clin Nutr 2006; 84:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/30\">",
"      Picaud JC, Decullier E, Plan O, et al. Growth and bone mineralization in preterm infants fed preterm formula or standard term formula after discharge. J Pediatr 2008; 153:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/31\">",
"      Griffin IJ. Postdischarge nutrition for high risk neonates. Clin Perinatol 2002; 29:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/32\">",
"      Abrams SA, Schanler RJ, Garza C. Bone mineralization in former very low birth weight infants fed either human milk or commercial formula. J Pediatr 1988; 112:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/33\">",
"      Schanler RJ, Burns PA, Abrams SA, Garza C. Bone mineralization outcomes in human milk-fed preterm infants. Pediatr Res 1992; 31:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/34\">",
"      McCormick FM, Henderson G, Fahey T, McGuire W. Multinutrient fortification of human breast milk for preterm infants following hospital discharge. Cochrane Database Syst Rev 2010; :CD004866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/35\">",
"      Zachariassen G, Faerk J, Grytter C, et al. Nutrient enrichment of mother's milk and growth of very preterm infants after hospital discharge. Pediatrics 2011; 127:e995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/36\">",
"      O'Connor DL, Khan S, Weishuhn K, et al. Growth and nutrient intakes of human milk-fed preterm infants provided with extra energy and nutrients after hospital discharge. Pediatrics 2008; 121:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/37\">",
"      Gewolb IH, Bosma JF, Taciak VL, Vice FL. Abnormal developmental patterns of suck and swallow rhythms during feeding in preterm infants with bronchopulmonary dysplasia. Dev Med Child Neurol 2001; 43:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/38\">",
"      Motion S, Northstone K, Emond A, et al. Early feeding problems in children with cerebral palsy: weight and neurodevelopmental outcomes. Dev Med Child Neurol 2002; 44:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/39\">",
"      Collins CT, Makrides M, McPhee AJ. Early discharge with home support of gavage feeding for stable preterm infants who have not established full oral feeds. Cochrane Database Syst Rev 2003; :CD003743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/40\">",
"      Ortenstrand A, Waldenstr&ouml;m U, Winbladh B. Early discharge of preterm infants needing limited special care, followed by domiciliary nursing care. Acta Paediatr 1999; 88:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/41\">",
"      Raddish M, Merritt TA. Early discharge of premature infants. A critical analysis. Clin Perinatol 1998; 25:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/42\">",
"      Belfort MB, Rifas-Shiman SL, Sullivan T, et al. Infant growth before and after term: effects on neurodevelopment in preterm infants. Pediatrics 2011; 128:e899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/43\">",
"      Johnson DB, Cheney C, Monsen ER. Nutrition and feeding in infants with bronchopulmonary dysplasia after initial hospital discharge: risk factors for growth failure. J Am Diet Assoc 1998; 98:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/44\">",
"      Wilson DC, McClure G. Energy requirements in sick preterm babies. Acta Paediatr Suppl 1994; 405:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/45\">",
"      Denne SC. Energy expenditure in infants with pulmonary insufficiency: is there evidence for increased energy needs? J Nutr 2001; 131:935S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/46\">",
"      Boehm G, Bierbach U, Moro G, Minoli I. Limited fat digestion in infants with bronchopulmonary dysplasia. J Pediatr Gastroenterol Nutr 1996; 22:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/47\">",
"      Chye JK, Gray PH. Rehospitalization and growth of infants with bronchopulmonary dysplasia: a matched control study. J Paediatr Child Health 1995; 31:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/48\">",
"      Mizuno K, Nishida Y, Taki M, et al. Infants with bronchopulmonary dysplasia suckle with weak pressures to maintain breathing during feeding. Pediatrics 2007; 120:e1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/49\">",
"      Leitch CA, Ahlrichs J, Karn C, Denne SC. Energy expenditure and energy intake during dexamethasone therapy for chronic lung disease. Pediatr Res 1999; 46:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/50\">",
"      Brunton JA, Saigal S, Atkinson SA. Growth and body composition in infants with bronchopulmonary dysplasia up to 3 months corrected age: a randomized trial of a high-energy nutrient-enriched formula fed after hospital discharge. J Pediatr 1998; 133:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23912/abstract/51\">",
"      Atkinson SA. Special nutritional needs of infants for prevention of and recovery from bronchopulmonary dysplasia. J Nutr 2001; 131:942S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5003 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-F770B2E4D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_22_23912=[""].join("\n");
var outline_f23_22_23912=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NORMATIVE GROWTH DATA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Term infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Preterm infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Growth chart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7279167\">",
"      GROWTH IN THE NICU",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DISCHARGE PLANNING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      AFTER DISCHARGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Monitoring of growth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Head circumference",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102775492\">",
"      LONG-TERM OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Routine nutrient supplementation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Formula-fed infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Human milk-fed infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Poor oral feeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7279658\">",
"      NEURODEVELOPMENTAL OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      BRONCHOPULMONARY DYSPLASIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5003\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5003|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/54/26471\" title=\"figure 1\">",
"      Fenton growth chart premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5003|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/32/27147\" title=\"table 1\">",
"      Energy requirements premature",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/8/19593?source=related_link\">",
"      Approach to enteral nutrition in the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40567?source=related_link\">",
"      Calcium and phosphorus requirements of newborn infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11738?source=related_link\">",
"      Care of the neonatal intensive care unit graduate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=related_link\">",
"      Diagnostic approach to short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=related_link\">",
"      Incidence and mortality of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31465?source=related_link\">",
"      Management and complications of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42633?source=related_link\">",
"      Normal growth patterns in infants and prepubertal children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/28/458?source=related_link\">",
"      Nutritional composition of human milk and preterm formula for the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21576?source=related_link\">",
"      Sucking and swallowing disorders in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_22_23913="Subclinical hyperthyroidism";
var content_f23_22_23913=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Subclinical hyperthyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/22/23913/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/22/23913/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/22/23913/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/22/23913/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/22/23913/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/22/23913/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/22/23913/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of sensitive assays for thyrotropin (TSH) resulted in the identification of patients who have low serum TSH concentrations (&lt;0.5",
"    <span class=\"nowrap\">",
"     mU/mL)",
"    </span>",
"    but normal serum free thyroxine (T4) and triiodothyronine (T3) concentrations, a constellation of biochemical findings defined as subclinical hyperthyroidism. The term overt hyperthyroidism refers to patients with elevated levels of free T4, T3, or both, and a subnormal TSH concentration. Both subclinical and overt hyperthyroidism are biochemical definitions since hyperthyroid symptoms are non-specific and may be present in patients with subclinical disease, and absent in those with overt disease, especially the elderly.",
"   </p>",
"   <p>",
"    Subclinical hyperthyroidism will be discussed here. Overt hyperthyroidism is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=see_link\">",
"     \"Diagnosis of hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of subclinical hyperthyroidism are the same as the causes of overt hyperthyroidism and, like overt hyperthyroidism, subclinical hyperthyroidism can be persistent or transient (",
"    <a class=\"graphic graphic_table graphicRef76972 \" href=\"UTD.htm?31/45/32476\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=see_link\">",
"     \"Disorders that cause hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Exogenous subclinical hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 10 million people in the United States, and possibly as many as 200 million people worldwide, are taking thyroid hormone. All are at risk for subclinical hyperthyroidism, whether intentional or unintentional. Among patients taking T4, as many as 25 percent have low serum TSH values [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4165?source=see_link\">",
"     \"Exogenous hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many of these patients have hypothyroidism, and in them subclinical hyperthyroidism is not the goal of thyroid hormone therapy. However, subclinical hyperthyroidism is the goal of thyroid hormone therapy in patients with thyroid cancer and in some patients with solitary thyroid nodules, multinodular or diffuse goiters, or a history of head and neck irradiation. In these patients, the benefits of TSH suppression are thought to outweigh the risks of subclinical hyperthyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the management of differentiated thyroid cancer\", section on 'Thyroid hormone suppression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22535?source=see_link\">",
"     \"Thyroid hormone suppressive therapy for thyroid nodules and benign goiter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Endogenous subclinical hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autonomously functioning thyroid adenomas and multinodular goiters are the most common causes of endogenous subclinical hyperthyroidism. Among patients over age 55, hyperthyroidism due to multinodular goiters was subclinical in 57 percent of patients, while hyperthyroidism due to Graves' disease was subclinical in only 6 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/3\">",
"     3",
"    </a>",
"    ]. In another study, 22 percent of patients with multinodular goiter had subclinical hyperthyroidism, while 28 percent of those with subclinical hyperthyroidism had autonomous area(s) on thyroid imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subclinical hyperthyroidism also occurs in patients with thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/5\">",
"     5",
"    </a>",
"    ], and it has been reported in 63 percent of euthyroid patients with Graves' ophthalmopathy (euthyroid Graves' disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/6\">",
"     6",
"    </a>",
"    ] and 4 percent of those with Graves' disease in remission [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/7\">",
"     7",
"    </a>",
"    ]. It may also be seen in patients with early Graves' disease prior to the onset of more overt hyperthyroidism. In addition, pregnant women (especially in the first trimester) and those with hyperemesis gravidarum (or trophoblastic disease), who have high serum chorionic gonadotropin concentrations, may have subclinical hyperthyroidism. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several large studies have examined the prevalence of subclinical hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/8-14\">",
"     8-14",
"    </a>",
"    ]. The results of these studies, primarily in subjects over age 55 to 60 years, can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of subclinical hyperthyroidism in the community varies between 0.7 and 12.4 percent. This variability is in part due to differences in the definition of low serum TSH values and in the patient populations studied. In the United States, the National Health and Nutrition Examination Survey (NHANES III), which excluded subjects with known thyroid disease, 0.7 percent of 16,533 people had subclinical hyperthyroidism (TSH &lt;0.1",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Subclinical hyperthyroidism is more common in areas of the world with mild to moderate iodine deficiency. In addition, subclinical thyroid dysfunction is more common in females, smokers, and the elderly [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When studied weeks to a year later, 40 to 60 percent of subjects with subclinical hyperthyroidism have normal values [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/9,11\">",
"       9,11",
"      </a>",
"      ]. This is most likely to occur in subjects with only slightly subnormal serum TSH values (eg, between 0.1 and 0.5",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      when first studied. In an analysis of a primary care network that included 422,242 persons without known thyroid disease, 52 percent who had a serum TSH concentration &lt;0.35",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"      at baseline had a normal TSH subsequently in the absence of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are conflicting data regarding the frequency of progression from subclinical to overt hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/8,11,18-21\">",
"     8,11,18-21",
"    </a>",
"    ]. Progression to overt hyperthyroidism appears to be related to the degree of subclinical hyperthyroidism and the underlying disease. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based study from Scotland, 2024 adults with at least two suppressed (&lt;0.4",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      serum TSH levels measured four months apart with normal free or total T4 and total T3 were identified [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/21\">",
"       21",
"      </a>",
"      ]. In the first year of observation, the overall progression rate from subclinical to overt hyperthyroidism was 6.1 percent. For patients with stable subclinical hyperthyroidism who did not progress after one year, progression rates at two, five, and seven years were 0.6, 0.7, and 0.5 percent, respectively. Although the proportion of patients who progressed to overt hyperthyroidism was small, progression was approximately twice as common in patients with serum TSH &lt;0.1",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"      compared with those with TSH between 0.1 and 0.4",
"      <span class=\"nowrap\">",
"       mU/L.",
"      </span>",
"     </li>",
"     <li>",
"      In a New Zealand study of 96 patients with endogenous subclinical thyrotoxicosis (TSH &lt;0.25",
"      <span class=\"nowrap\">",
"       mU/L),",
"      </span>",
"      progression to overt hyperthyroidism occurred in 8 percent at one year, and increased to 26 percent at five years. At five years, overt hyperthyroidism was seen in 9, 21, and 61 percent of patients whose subclinical hyperthyroidism was due to Graves&rsquo; disease, nodular goiter, and autonomous nodules, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Brazilian study of 48 women &lt;65 years who had TSH &le;0.1",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"      (confirmed by repeat measurement six to eight weeks later), 20 percent with nodular disease and 40 percent with Graves&rsquo; disease progressed from subclinical to overt hyperthyroidism over a two-year period [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/19\">",
"       19",
"      </a>",
"      ]. In a separate study of women &ge;60 years with only minimal thyrotoxicosis (TSH 0.1 to 0.4",
"      <span class=\"nowrap\">",
"       mU/L),",
"      </span>",
"      progression to overt hyperthyroidism was uncommon (approximately 1 percent yearly) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study from the UK, 20.3 percent of patients with subclinical hyperthyroidism and TSH &lt;0.1",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"      progressed to overt hyperthyroidism over an average of 32 months, compared with 6.8 percent of those with TSH 0.1 to 0.39",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Framingham study of adults &gt;60 years with a TSH &lt;0.1",
"      <span class=\"nowrap\">",
"       mU/L,",
"      </span>",
"      only 4.3 percent of patients progressed to overt hyperthyroidism after four years [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skeleton and the cardiovascular system are the major target tissues adversely affected by subclinical hyperthyroidism, although abnormalities in other systems have been reported (",
"    <a class=\"graphic graphic_table graphicRef79602 \" href=\"UTD.htm?37/20/38219\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Bone and mineral metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid hormone directly stimulates bone resorption, and overt hyperthyroidism is associated with increased bone resorption (and to a lesser extent low bone formation), low bone density, and an increase in fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/23\">",
"     23",
"    </a>",
"    ]. The changes are greatest in cortical bone (wrist), least in trabecular bone (lumbar spine), and intermediate in mixed cortical-trabecular bone (hip).",
"   </p>",
"   <p>",
"    In some, but not all, studies, subclinical hyperthyroidism is associated with low bone density in postmenopausal women. Whether subclinical hyperthyroidism increases fracture rate is debated, but there is no reason to doubt that similar durations of subclinical hyperthyroidism would have similar effects on the skeleton, but to a less severe degree. Any adverse effect of T4 on bone density is likely dose-dependent. This topic is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17593?source=see_link\">",
"     \"Bone disease with hyperthyroidism and thyroid hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cardiovascular effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overt hyperthyroidism is associated with an increased risk of atrial fibrillation, heart failure, pulmonary hypertension, and angina. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=see_link\">",
"     \"Cardiovascular effects of hyperthyroidism\"",
"    </a>",
"    .) Patients with subclinical hyperthyroidism also have an increased risk of atrial fibrillation and, in addition, have more subtle cardiac findings, including increases in heart rate, cardiac contractility, and left ventricular mass [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis of patient level data from five prospective cohort studies (8711 participants, 810 with endogenous subclinical hyperthyroidism), subclinical hyperthyroidism was associated with an increased risk of atrial fibrillation (HR 1.68, 95% CI 1.16-2.43) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/26\">",
"     26",
"    </a>",
"    ]. The risk was higher for TSH levels &lt;0.1",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    compared with 0.1 to 0.44",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    (HRs 2.54 versus 1.63).",
"   </p>",
"   <p>",
"    The cumulative incidence of atrial fibrillation in patients with subclinical hyperthyroidism is illustrated by the findings of a prospective cohort study of approximately 2000 adults over age 60 years (without atrial fibrillation) followed for 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/14\">",
"     14",
"    </a>",
"    ]. For subjects with serum TSH values &lt;0.1",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    0.1 to 0.4",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    or within the normal range, the cumulative incidence of atrial fibrillation was 28, 16, and 11 percent, respectively (",
"    <a class=\"graphic graphic_figure graphicRef55024 \" href=\"UTD.htm?19/0/19469\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In biochemically euthyroid individuals, both serum TSH and free T4 concentrations may also be associated with atrial fibrillation risk. In a population-based study of 1426 subjects, euthyroid individuals with a TSH in the lowest quartile had a higher risk of atrial fibrillation than those in the highest quartile [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/27\">",
"     27",
"    </a>",
"    ]. Similar findings were noted in another population-based study of 5519 euthyroid (normal serum TSH and free T4) elderly subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/28\">",
"     28",
"    </a>",
"    ]. Higher serum free T4 concentrations (within the normal range) were independently associated with atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines for the management of atrial fibrillation in patients with hyperthyroidism are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H26#H26\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Patients with hyperthyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Coronary heart disease events, heart failure, and other cardiac parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the meta-analysis described above (22,437 participants, 718 with endogenous subclinical hyperthyroidism), the risk of coronary heart disease events was higher in patients with endogenous subclinical hyperthyroidism (HR 1.21, 95% CI 0.99-1.46) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/26\">",
"     26",
"    </a>",
"    ]. Similar findings were reported in a population based study from Scotland, which was not included in the meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/29\">",
"     29",
"    </a>",
"    ]. Endogenous subclinical hyperthyroidism was associated with an increased risk of nonfatal cardiovascular disease (HR 1.39, 95% CI 1.22-1.58) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/29\">",
"     29",
"    </a>",
"    ]. In another cohort of men and women aged 70 to 82 with a history of vascular disease (5316 participants, 71 with subclinical hyperthyroidism, five taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    ), the risk of heart failure over 3.2 years of follow-up was higher compared with euthyroid controls (HR 2.93, 95% CI 1.37-6.24) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/30\">",
"     30",
"    </a>",
"    ], and in a pooled analysis of individual data from six prospective cohort studies (25,390 participants, 648 with subclinical hyperthyroidism), patients with TSH levels &lt;0.10",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    had a higher risk of heart failure than euthyroid controls (16 events in 154 participants [10.4 percent] versus 1762 events in 22,674 [7.8 percent], HR 1.94, 95% CI 1.01-3.72) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/31\">",
"     31",
"    </a>",
"    ]. The risk persisted (HR 1.8, 95% CI 1.04-3.13) when those using thyroid hormone were excluded from the analysis.",
"   </p>",
"   <p>",
"    Subclinical hyperthyroidism has several other effects on cardiac function, all similar to but less severe and less frequent than those in overt hyperthyroidism. These include sinus tachycardia, atrial premature beats, increase in left ventricular mass index, increase in cardiac contractility, impaired endothelial function, reduced exercise tolerance, reduced heart rate variability, and an increase in markers of coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/24,25,32-35\">",
"     24,25,32-35",
"    </a>",
"    ]. The presence of cardiovascular findings is variable, likely due to the degree of TSH suppression, the underlying disease, and individual sensitivity to thyroid hormone excess.",
"   </p>",
"   <p>",
"    The degree of TSH suppression that predicts adverse cardiovascular effects is unknown. However, in one small study of exogenous subclinical hyperthyroidism, cardiovascular parameters that were abnormal at higher doses became normal when the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    was adjusted so that the TSH measured approximately 0.1",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although subclinical hyperthyroidism has been associated with several cardiovascular risk factors, it is unknown whether there is an increase in mortality. In a meta-analysis of five population-based studies examining the association between subclinical hyperthyroidism (TSH less than 0.3 to 0.5",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    and cardiovascular and all-cause mortality, the risk for all-cause and cardiovascular mortality was not significant (RRs 1.12, 95% CI 0.89-1.42 and 1.19, 95% CI 0.81-1.76, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/37\">",
"     37",
"    </a>",
"    ]. In contrast, another meta-analysis showed a significantly increased risk of all-cause mortality (HR 1.41, 95% CI 1.12-1.79) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/38\">",
"     38",
"    </a>",
"    ]. In a mathematical model designed a priori to explore mortality risk, the excess mortality after diagnosis of subclinical hyperthyroidism depended upon age, with an increase beyond the age of 60 years.",
"   </p>",
"   <p>",
"    The meta-analyses included patients with both exogenous and endogenous subclinical hyperthyroidism. Serum T3 levels are higher in patients with endogenous than exogenous subclinical hyperthyroidism, and this may confer a higher mortality risk [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/24\">",
"     24",
"    </a>",
"    ]. In the meta-analysis of 10 prospective cohort studies described above (52,674 participants, 2188 with endogenous subclinical hyperthyroidism) that included only patients with endogenous subclinical hyperthyroidism, there was an increased risk of both total (HR 1.24, 95% CI 1.06-1.46) and cardiovascular (HR 1.29, 95% CI 1.02-1.62) mortality in patients with endogenous subclinical hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/26\">",
"     26",
"    </a>",
"    ]. The risk of cardiovascular mortality was higher for TSH levels &lt;0.1",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    compared with levels between 0.1 and 0.44",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    (HRs 1.84 versus 1.24).",
"   </p>",
"   <p>",
"    In a study evaluating only patients with exogenous subclinical hyperthyroidism, there was an increased risk of cardiovascular or overall mortality only in patients with fully suppressed TSH levels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/39\">",
"     39",
"    </a>",
"    ]. In this cohort study of 17,684 patients (mean age 61.6 years) taking T4 replacement therapy, TSH levels were fully suppressed (&lt;0.03",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    or low (0.04 to 0.4",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    in 6 and 21 percent of patients, respectively. Compared to patients with normal TSH, patients with suppressed TSH concentrations (&lt;0.03",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    had increased cardiovascular morbidity and mortality (adjusted HR 1.37, 95% CI 1.17-1.60), whereas those who had serum TSH levels between 0.04 and 0.4",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    had a smaller increase in risk that was not significant (adjusted HR 1.10 [95% CI 0.99-1.23]).",
"   </p>",
"   <p>",
"    Overall, the increased risk of mortality from subclinical hyperthyroidism appears to be small, but increases with age and degree of TSH suppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dementia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are conflicting, subclinical hyperthyroidism may also be associated with an increased risk of dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/29,40-42\">",
"     29,40-42",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective cohort study of 1864 participants (mean age of 71 and TSH of 0.1 to 10",
"      <span class=\"nowrap\">",
"       mU/L),",
"      </span>",
"      followed for a mean of 12.7 years, women (but not men) whose TSH was in the lowest tertile had a 2.39 increased risk of developing Alzheimer disease compared with the middle tertile [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar results were seen in a population-based study of 1171 subjects in which subclinical hyperthyroidism (TSH &lt;0.46",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      was associated with cognitive dysfunction (HR 2.26, 95% CI 1.32-3.91) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a population-based study from Scotland (n = 2004), persistent endogenous subclinical hyperthyroidism (TSH &lt;0.4",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      was associated with an increased risk of dementia (adjusted HR 1.79, 95% CI 1.28-2.51) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, a cross-sectional study of primary care patients in England failed to demonstrate an association of subclinical hyperthyroidism with depression, anxiety, or cognitive function [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with exogenous subclinical hyperthyroidism, disturbances in sleep and decreases in some physical components have been reported without significant effect on mood or mental health [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In hypothyroid patients randomly assigned to the usual dose of T4 (euthyroid group) versus higher dose T4 (subclinical hyperthyroid group), the SF-36 physical component and general healthy subscale were slightly worse in the subclinical hyperthyroid group [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/46\">",
"       46",
"      </a>",
"      ]. In contrast, mental health, mood, and motor learning were improved.",
"     </li>",
"     <li>",
"      In a six-month randomized trial of T4 titrated to establish continuation of TSH suppression versus normalization of TSH in 24 patients with a history of differentiated thyroid carcinoma, there were no significant changes in any SF-36 components in either group [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, in a non-blinded study in which subjects were given a T4 dose that was 50 mcg greater or less than their optimal dose (based on TRH stimulated TSH testing), patients on the higher dose had improved \"well being\" using a visual analog scale compared with baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with endogenous subclinical hyperthyroidism, scores for both the physical and mental health components appear to be lower than in euthyroid control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/48\">",
"     48",
"    </a>",
"    ]. The low scores were due to symptoms related to thyroid hormone excess (palpitations, nervousness, tremor, and sweating).",
"   </p>",
"   <p>",
"    Thus, quality of life may be impaired in some patients with subclinical hyperthyroidism, particularly those with endogenous subclinical hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/24\">",
"     24",
"    </a>",
"    ]. The variability in findings is likely related to differences in patient populations, duration of subclinical hyperthyroidism, and degree of TSH suppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The negative feedback relationship between serum T4 and T3 and TSH concentrations is a log-linear one. Thus, even small increases in serum T4 and T3 concentrations (whether caused by exogenous thyroid hormone therapy or endogenous thyroid hormone secretion) suppress TSH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/47\">",
"     47",
"    </a>",
"    ]. There is general agreement that measurement of serum TSH is the most sensitive indicator of thyroid hormone activity in its target tissues (in the absence of pituitary or hypothalamic disease). In most circumstances, the initial screening test for thyroid disease is the serum TSH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link\">",
"     \"Laboratory assessment of thyroid function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the serum TSH concentration is below normal (&lt;0.5",
"    <span class=\"nowrap\">",
"     mU/mL",
"    </span>",
"    in many laboratories), the TSH measurement should be repeated along with a serum free T4 and T3 to make the diagnosis of subclinical hyperthyroidism. The diagnosis of subclinical hyperthyroidism is based upon the combination of a low serum TSH concentration and normal serum free T4 and T3 concentrations. It may occur in the presence or absence of mild symptoms of hyperthyroidism. Because the serum TSH concentration can be transiently reduced, a serum TSH measurement, along with a free T4 and T3, should be repeated after one to three months to confirm the diagnosis.",
"   </p>",
"   <p>",
"    Other causes of low TSH concentrations should be excluded. There are three causes of the combination of low serum TSH and normal free T4 and T3 concentrations other than subclinical hyperthyroidism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central hypothyroidism &mdash; Some patients with central hypothyroidism have low serum TSH and normal (but usually low or low-normal) free T4 and T3 concentrations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"       \"Diagnosis of and screening for hypothyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=see_link&amp;anchor=H12#H12\">",
"       \"Central hypothyroidism\", section on 'TSH low'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonthyroidal illness &mdash; Euthyroid patients with nonthyroidal illness, especially those receiving high-dose glucocorticoids or dopamine, may have low serum TSH and low-normal free T4 and T3 concentrations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"       \"Thyroid function in nonthyroidal illness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recovery from hyperthyroidism &mdash; Serum TSH concentrations may remain low for up to several months after normalization of serum T4 and T3 concentrations in patients treated for hyperthyroidism or recovering from hyperthyroidism caused by thyroiditis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the diagnosis of subclinical hyperthyroidism is uncertain, measurement of 24-hour thyroid radioiodine uptake or thyroid radionuclide imaging may be helpful. A high or relatively high 24-hour uptake (relative to the low serum TSH value) or a focal area of increased radionuclide uptake supports the diagnosis of subclinical hyperthyroidism. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of true subclinical or overt hyperthyroidism during pregnancy may be difficult because of the changes in thyroid function that occur during normal pregnancy. Transient subclinical hyperthyroidism in the first trimester of pregnancy is considered a normal physiologic finding. True subclinical hyperthyroidism may occur, but it is not typically associated with adverse outcomes during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/49\">",
"     49",
"    </a>",
"    ] and does not require therapy. Furthermore, in pregnant women with overt hyperthyroidism, the goal of therapy is to maintain serum free T4 concentrations in the high-normal range and serum TSH concentrations in the low-normal or suppressed range (ie, to maintain persistent but minimal mild hyperthyroidism). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link&amp;anchor=H994022#H994022\">",
"     \"Overview of thyroid disease in pregnancy\", section on 'hCG and thyroid function'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=see_link\">",
"     \"Hyperthyroidism during pregnancy: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with subclinical hyperthyroidism should be questioned about symptoms of hyperthyroidism (eg, tremor, palpitations, heat intolerance), in addition to a past history of thyroid disease, exposure to iodine containing radiographic contrast media or herbal products containing iodine, and use of medications that may suppress TSH (T4, high dose glucocorticoids). Women of childbearing age should be questioned about the possibility of pregnancy. All patients should be examined for the presence of thyroid gland enlargement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nodularity.",
"   </p>",
"   <p>",
"    In patients not taking T4 who have persistently subnormal TSH values and in whom we are considering treatment, we obtain a radioactive iodine uptake and scan to help determine the etiology of subclinical hyperthyroidism (",
"    <a class=\"graphic graphic_table graphicRef76972 \" href=\"UTD.htm?31/45/32476\">",
"     table 1",
"    </a>",
"    ). Women of childbearing age should have a negative pregnancy test prior to undergoing radioactive iodine scanning.",
"   </p>",
"   <p>",
"    If the scan shows one or more focal areas of increased uptake, this could account for the low serum TSH. If there are focal areas of increased uptake, a thyroid ultrasound would then be useful in delineating the presence of discrete nodules. In patients with low or no uptake on radioiodine scan, the etiology of subclinical hyperthyroidism may be thyroiditis or recent iodine exposure (",
"    <a class=\"graphic graphic_table graphicRef76972 \" href=\"UTD.htm?31/45/32476\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In postmenopausal women or other patients at risk for osteoporosis, a bone densitometry study may be useful in making a decision to treat subclinical hyperthyroidism or to monitor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link\">",
"     \"Osteoporotic fracture risk assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=see_link\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Patients on T4 for the treatment of hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both low bone density and atrial fibrillation can result in substantial morbidity in older patients and, therefore, subclinical hyperthyroidism should be avoided. Patients receiving thyroid replacement therapy who have TSH concentrations below normal should have their dose adjusted to maintain a normal serum TSH concentration (approximately 0.5 to 5.0",
"    <span class=\"nowrap\">",
"     mU/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of hypothyroidism\", section on 'Goals of therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of hypothyroidism\", section on 'Older patients or those with coronary heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Patients on suppressive levothyroxine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subclinical hyperthyroidism is unavoidable when thyroid hormone is given to suppress TSH secretion in an attempt to prevent or reduce goiter growth or prevent recurrence of thyroid cancer, since it is the goal of therapy. However, the adverse effects of suppressive therapy can be minimized by treatment with the lowest dose of T4 necessary to meet the desired goal [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/36,50\">",
"     36,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with thyroid cancer, subclinical hyperthyroidism is the goal of thyroid hormone therapy. In these patients, the benefits of TSH suppression are thought to outweigh the risks of subclinical hyperthyroidism. This topic is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the management of differentiated thyroid cancer\", section on 'Thyroid hormone suppression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Candidates for suppressive therapy and goal TSH levels in patients with benign thyroid disease are also reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22535?source=see_link\">",
"     \"Thyroid hormone suppressive therapy for thyroid nodules and benign goiter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postmenopausal women taking suppressive doses of thyroid hormone should receive calcium and vitamin D supplementation if needed, and consideration should be given to instituting antiresorptive therapy to prevent bone loss. Drug options for prevention of osteoporosis are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17593?source=see_link\">",
"     \"Bone disease with hyperthyroidism and thyroid hormone therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33113?source=see_link\">",
"     \"Prevention of osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Endogenous subclinical hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data to guide clinical decisions regarding the treatment of patients with endogenous subclinical hyperthyroidism. In some patients the values are normal on retesting weeks or months later, so that intervention should not be considered unless persistently low TSH values are documented [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/9,11\">",
"     9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential benefits of treatment include improvement in certain cardiovascular parameters and in bone mineral density. However, there are no studies evaluating the long-term benefits of correcting subclinical hyperthyroidism, particularly studies with clinically important endpoints, such as cardiovascular disease and fracture. As an example, in a prospective but uncontrolled study of patients with subclinical hyperthyroidism, antithyroid drugs reduced heart rate, atrial and ventricular premature beats, left ventricular mass index, interventricular septal thickness, and left ventricular posterior wall thickness [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/51\">",
"     51",
"    </a>",
"    ]. Similar improvements in hemodynamic parameters were seen in another study following radioiodine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two other non-randomized studies, postmenopausal women with nodular goiter and subclinical hyperthyroidism treated with antithyroid drugs or radioiodine for two years had higher bone density than similar women who were not treated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, in some patients with subclinical hyperthyroidism, normalization of TSH results in improvement in surrogate outcomes. Long-term clinical trials are required to determine if correcting subclinical hyperthyroidism improves cardiovascular or skeletal outcomes. In the absence of data to guide selection of patients with endogenous subclinical hyperthyroidism for therapy, we base our decision to treat on clinical risk for complications of subclinical hyperthyroidism and the degree of TSH suppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Patients at high risk for complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients at high risk for skeletal or cardiac complications (eg, elderly patients &gt;65 years of age, patients with risk factors for cardiac arrhythmias, and postmenopausal women with or at risk for osteoporosis), we use the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the serum TSH value is &lt;0.1",
"      <span class=\"nowrap\">",
"       mU/mL,",
"      </span>",
"      we treat the underlying cause of subclinical hyperthyroidism.",
"     </li>",
"     <li>",
"      If the serum TSH is 0.1 to 0.5",
"      <span class=\"nowrap\">",
"       mU/L,",
"      </span>",
"      we suggest treatment if there is underlying cardiovascular disease or if the bone density is low. We are also more likely to consider treatment if a thyroid radionuclide scan shows one or more focal areas of high uptake (ie, evidence of autonomy). Subclinical hyperthyroidism due to autonomous nodule(s) is more likely to progress to overt hyperthyroidism than is subclinical hyperthyroidism due to Graves' disease. We suggest observation if the bone density is normal and the thyroid scan fails to show a focal area of high uptake. We might also consider observation if a patient is on a beta-adrenergic antagonist drug for other reasons. In observed patients, we measure TSH, free T4, and T3 every six months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Patients at low risk for complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients at low risk for complications of hyperthyroidism (young individuals, premenopausal women), we use the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the serum TSH value is &lt;0.1",
"      <span class=\"nowrap\">",
"       mU/mL,",
"      </span>",
"      we treat the underlying cause of subclinical hyperthyroidism if the patient has symptoms suggestive of hyperthyroidism",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      if a thyroid radionuclide scan shows one or more focal areas of increased uptake.",
"     </li>",
"     <li>",
"      If the TSH is between 0.1 to 0.5",
"      <span class=\"nowrap\">",
"       mU/mL,",
"      </span>",
"      observation alone is appropriate. We measure TSH, free T4, and T3 every six months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These recommendations are consistent with those of a clinical consensus group (comprised of representatives from the Endocrine Society, American Thyroid Association, and the American Association of Clinical Endocrinologists) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23913/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Treatment options",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment options for patients with subclinical hyperthyroidism are the same as those for overt hyperthyroidism and depend upon the underlying etiology. Beta-adrenergic antagonist drugs are useful to control symptoms of adrenergic overactivity (eg, palpitations, tremor). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=see_link\">",
"     \"Beta blockers in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with Graves&rsquo; disease or nodular thyroid disease with autonomy, treatment options include thionamides, radioiodine, or surgery. The treatment of these conditions is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=see_link\">",
"     \"Treatment of Graves' hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=see_link\">",
"     \"Treatment of toxic adenoma and toxic multinodular goiter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=see_link\">",
"     \"Radioiodine in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with low or no uptake on radioiodine scan, the etiology of subclinical hyperthyroidism may be thyroiditis or exogenous thyroid hormone intake (",
"    <a class=\"graphic graphic_table graphicRef76972 \" href=\"UTD.htm?31/45/32476\">",
"     table 1",
"    </a>",
"    ). Most patients with thyroiditis require no treatment since thyroid dysfunction is rarely severe and is transient. However, thyroid tests should be monitored, initially every four to eight weeks, until normalization. Symptomatic patients may benefit from beta-adrenergic antagonists. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24694?source=see_link\">",
"     \"Painless thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=see_link\">",
"       \"Patient information: Antithyroid drugs (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subclinical hyperthyroidism is defined biochemically by a low serum TSH concentration but normal serum free T4 and T3 concentrations. Patients with subclinical hyperthyroidism typically have few or no symptoms of hyperthyroidism. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common causes of subclinical hyperthyroidism are treatment with T4 (exogenous) and autonomously functioning thyroid adenomas and multinodular goiters (endogenous) (",
"      <a class=\"graphic graphic_table graphicRef76972 \" href=\"UTD.htm?31/45/32476\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subclinical hyperthyroidism is associated with an increased risk of atrial fibrillation and, primarily in postmenopausal women, a decrease in bone mineral density. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients receiving thyroid replacement therapy for the treatment of hypothyroidism and who have TSH concentrations below normal should have their dose adjusted to maintain a normal serum TSH concentration (approximately 0.5 to 5.0",
"      <span class=\"nowrap\">",
"       mU/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Patients on T4 for the treatment of hypothyroidism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with thyroid cancer and in some patients with benign nodular thyroid disease, subclinical hyperthyroidism is the goal of thyroid hormone therapy. In these patients, the benefits of TSH suppression are thought to outweigh the risks of subclinical hyperthyroidism. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Patients on suppressive levothyroxine therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with endogenous subclinical hyperthyroidism at high risk for cardiac or skeletal complications (ie, the elderly) and who have a TSH concentration less than 0.1",
"      <span class=\"nowrap\">",
"       mU/L,",
"      </span>",
"      we recommend treatment of the underlying cause of subclinical hyperthyroidism (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      For similar patients who have TSH values between 0.1 and 0.5",
"      <span class=\"nowrap\">",
"       mU/mL,",
"      </span>",
"      we suggest treatment if the bone density is low",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      if the radionuclide scan shows one or more focal areas of increased uptake (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If bone density is normal and the thyroid scan fails to show a focal area of high uptake, we typically observe patients. In observed patients, we measure TSH, free T4, and T3 every six months. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Patients at high risk for complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with endogenous subclinical hyperthyroidism at low risk for cardiac or skeletal complications (young individuals, premenopausal women) and TSH values less than 0.1",
"      <span class=\"nowrap\">",
"       mU/mL,",
"      </span>",
"      we suggest treatment if the radionuclide scan shows one or more focal areas of increased uptake (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For low risk patients who have a TSH value between 0.1 and 0.5",
"      <span class=\"nowrap\">",
"       mU/L,",
"      </span>",
"      we suggest observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We measure TSH, free T4, and T3 every six months. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Patients at low risk for complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment options for patients with subclinical hyperthyroidism are the same as those for overt hyperthyroidism and depend upon the underlying etiology. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Treatment options'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/1\">",
"      De Whalley P. Do abnormal thyroid stimulating hormone level values result in treatment changes? A study of patients on thyroxine in one general practice. Br J Gen Pract 1995; 45:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/2\">",
"      Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/3\">",
"      D&iacute;ez JJ. Hyperthyroidism in patients older than 55 years: an analysis of the etiology and management. Gerontology 2003; 49:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/4\">",
"      Rieu M, Bekka S, Sambor B, et al. Prevalence of subclinical hyperthyroidism and relationship between thyroid hormonal status and thyroid ultrasonographic parameters in patients with non-toxic nodular goitre. Clin Endocrinol (Oxf) 1993; 39:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/5\">",
"      Charkes ND. The many causes of subclinical hyperthyroidism. Thyroid 1996; 6:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/6\">",
"      Kasagi K, Hatabu H, Tokuda Y, et al. Studies on thyrotrophin receptor antibodies in patients with euthyroid Graves' disease. Clin Endocrinol (Oxf) 1988; 29:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/7\">",
"      Murakami M, Koizumi Y, Aizawa T, et al. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission. J Clin Endocrinol Metab 1988; 66:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/8\">",
"      Sawin CT, Geller A, Kaplan MM, et al. Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism. Arch Intern Med 1991; 151:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/9\">",
"      Eggertsen R, Petersen K, Lundberg PA, et al. Screening for thyroid disease in a primary care unit with a thyroid stimulating hormone assay with a low detection limit. BMJ 1988; 297:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/10\">",
"      Bagchi N, Brown TR, Parish RF. Thyroid dysfunction in adults over age 55 years. A study in an urban US community. Arch Intern Med 1990; 150:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/11\">",
"      Parle JV, Franklyn JA, Cross KW, et al. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf) 1991; 34:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/12\">",
"      Franklyn JA, Black EG, Betteridge J, Sheppard MC. Comparison of second and third generation methods for measurement of serum thyrotropin in patients with overt hyperthyroidism, patients receiving thyroxine therapy, and those with nonthyroidal illness. J Clin Endocrinol Metab 1994; 78:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/13\">",
"      Sundbeck G, Jagenburg R, Johansson PM, et al. Clinical significance of low serum thyrotropin concentration by chemiluminometric assay in 85-year-old women and men. Arch Intern Med 1991; 151:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/14\">",
"      Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/15\">",
"      Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/16\">",
"      Belin RM, Astor BC, Powe NR, Ladenson PW. Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the third National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2004; 89:6077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/17\">",
"      Meyerovitch J, Rotman-Pikielny P, Sherf M, et al. Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. Arch Intern Med 2007; 167:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/18\">",
"      Schouten BJ, Brownlie BE, Frampton CM, Turner JG. Subclinical thyrotoxicosis in an outpatient population - predictors of outcome. Clin Endocrinol (Oxf) 2011; 74:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/19\">",
"      Rosario PW. The natural history of subclinical hyperthyroidism in patients below the age of 65 years. Clin Endocrinol (Oxf) 2008; 68:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/20\">",
"      Rosario PW. Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU/l: a prospective study. Clin Endocrinol (Oxf) 2010; 72:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/21\">",
"      Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): the natural history of endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab 2011; 96:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/22\">",
"      Das G, Ojewuyi TA, Baglioni P, et al. Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism. Clin Endocrinol (Oxf) 2012; 77:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/23\">",
"      Ross DS. Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 1994; 4:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/24\">",
"      Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008; 29:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/25\">",
"      Cooper DS, Biondi B. Subclinical thyroid disease. Lancet 2012; 379:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/26\">",
"      Collet TH, Gussekloo J, Bauer DC, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012; 172:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/27\">",
"      Heeringa J, Hoogendoorn EH, van der Deure WM, et al. High-normal thyroid function and risk of atrial fibrillation: the Rotterdam study. Arch Intern Med 2008; 168:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/28\">",
"      Gammage MD, Parle JV, Holder RL, et al. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med 2007; 167:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/29\">",
"      Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab 2011; 96:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/30\">",
"      Nanchen D, Gussekloo J, Westendorp RG, et al. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab 2012; 97:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/31\">",
"      Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 2012; 126:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/32\">",
"      Yavuz DG, Yazici D, Toprak A, et al. Exogenous subclinical hyperthyroidism impairs endothelial function in nodular goiter patients. Thyroid 2008; 18:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/33\">",
"      D&ouml;rr M, Robinson DM, Wallaschofski H, et al. Low serum thyrotropin is associated with high plasma fibrinogen. J Clin Endocrinol Metab 2006; 91:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/34\">",
"      Demir T, Akinci B, Comlekci A, et al. Levothyroxine (LT4) suppression treatment for benign thyroid nodules alters coagulation. Clin Endocrinol (Oxf) 2009; 71:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/35\">",
"      Eustatia-Rutten CF, Corssmit EP, Heemstra KA, et al. Autonomic nervous system function in chronic exogenous subclinical thyrotoxicosis and the effect of restoring euthyroidism. J Clin Endocrinol Metab 2008; 93:2835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/36\">",
"      Mercuro G, Panzuto MG, Bina A, et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab 2000; 85:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/37\">",
"      Ochs N, Auer R, Bauer DC, et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008; 148:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/38\">",
"      Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol 2008; 159:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/39\">",
"      Flynn RW, Bonellie SR, Jung RT, et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab 2010; 95:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/40\">",
"      Kalmijn S, Mehta KM, Pols HA, et al. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin Endocrinol (Oxf) 2000; 53:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/41\">",
"      Tan ZS, Beiser A, Vasan RS, et al. Thyroid function and the risk of Alzheimer disease: the Framingham Study. Arch Intern Med 2008; 168:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/42\">",
"      Ceresini G, Lauretani F, Maggio M, et al. Thyroid function abnormalities and cognitive impairment in elderly people: results of the Invecchiare in Chianti study. J Am Geriatr Soc 2009; 57:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/43\">",
"      Roberts LM, Pattison H, Roalfe A, et al. Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction? Ann Intern Med 2006; 145:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/44\">",
"      Schlote B, Schaaf L, Schmidt R, et al. Mental and physical state in subclinical hyperthyroidism: investigations in a normal working population. Biol Psychiatry 1992; 32:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/45\">",
"      Eustatia-Rutten CF, Corssmit EP, Pereira AM, et al. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. Clin Endocrinol (Oxf) 2006; 64:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/46\">",
"      Samuels MH, Schuff KG, Carlson NE, et al. Health status, mood, and cognition in experimentally induced subclinical thyrotoxicosis. J Clin Endocrinol Metab 2008; 93:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/47\">",
"      Carr D, McLeod DT, Parry G, Thornes HM. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol (Oxf) 1988; 28:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/48\">",
"      Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 2000; 85:4701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/49\">",
"      Casey BM, Dashe JS, Wells CE, et al. Subclinical hyperthyroidism and pregnancy outcomes. Obstet Gynecol 2006; 107:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/50\">",
"      Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010; 20:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/51\">",
"      Sgarbi JA, Villa&ccedil;a FG, Garbeline B, et al. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab 2003; 88:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/52\">",
"      Faber J, Wiinberg N, Schifter S, Mehlsen J. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur J Endocrinol 2001; 145:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/53\">",
"      Mudde AH, Houben AJ, Nieuwenhuijzen Kruseman AC. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf) 1994; 41:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/54\">",
"      Faber J, Jensen IW, Petersen L, et al. Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol (Oxf) 1998; 48:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23913/abstract/55\">",
"      Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291:228.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7881 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-A93D27A9D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_22_23913=[""].join("\n");
var outline_f23_22_23913=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Exogenous subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Endogenous subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY AND NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Bone and mineral metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Coronary heart disease events, heart failure, and other cardiac parameters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dementia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Patients on T4 for the treatment of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Patients on suppressive levothyroxine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Endogenous subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Patients at high risk for complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Treatment options",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7881\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7881|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/0/19469\" title=\"figure 1\">",
"      Increased incidence of AF in subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7881|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/45/32476\" title=\"table 1\">",
"      Causes of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/20/38219\" title=\"table 2\">",
"      Clinical manifestations subclinical hyperthyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=related_link\">",
"      Beta blockers in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17593?source=related_link\">",
"      Bone disease with hyperthyroidism and thyroid hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=related_link\">",
"      Cardiovascular effects of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=related_link\">",
"      Central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=related_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=related_link\">",
"      Disorders that cause hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4165?source=related_link\">",
"      Exogenous hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=related_link\">",
"      Hyperthyroidism during pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=related_link\">",
"      Laboratory assessment of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=related_link\">",
"      Overview of the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24694?source=related_link\">",
"      Painless thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=related_link\">",
"      Patient information: Antithyroid drugs (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33113?source=related_link\">",
"      Prevention of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=related_link\">",
"      Radioiodine in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=related_link\">",
"      Thyroid function in nonthyroidal illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22535?source=related_link\">",
"      Thyroid hormone suppressive therapy for thyroid nodules and benign goiter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=related_link\">",
"      Treatment of Graves' hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=related_link\">",
"      Treatment of toxic adenoma and toxic multinodular goiter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_22_23914="Hematologic consequences of malignancy: Anemia and bleeding";
var content_f23_22_23914=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hematologic consequences of malignancy: Anemia and bleeding",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/22/23914/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/22/23914/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/22/23914/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/22/23914/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/22/23914/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/22/23914/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/22/23914/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia frequently complicates the course of cancer. While anemia may be a presenting sign of malignancy, more often it is a consequence of a patient's antineoplastic therapy or progressive disease. Since anemia is a frequent cause of fatigue and fatigue ranks as the most common symptom plaguing cancer patients and limiting their daily routines, recognizing anemia and its causes is important for identifying appropriate interventions that may improve the cancer patient's quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=see_link\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=see_link\">",
"     \"Cancer-related fatigue: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple factors may contribute to the development of anemia. In determining which factors may be responsible, it is important to correlate patients' clinical histories and physical exam findings with laboratory observations, realizing that more than one contributor may underlie the development of anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link&amp;anchor=H50#H50\">",
"     \"Approach to the adult patient with anemia\", section on 'Multiple causes of anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with anemias in general, three broad categories should be considered when assessing causes of anemia in patients with malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link&amp;anchor=H15#H15\">",
"     \"Approach to the adult patient with anemia\", section on 'Causes of anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Red blood cell (RBC) losses from the body (blood loss anemia)",
"     </li>",
"     <li>",
"      Increased RBC destruction (hemolytic anemia)",
"     </li>",
"     <li>",
"      Decreased red blood cell production (hypoproliferative anemia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While one or more of these three mechanisms must be responsible when anemia is present, some causes are relatively specific for patients with malignancy. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Direct effects of the neoplasm",
"     </li>",
"     <li>",
"      An effect of a product of the neoplasm",
"     </li>",
"     <li>",
"      Effects of treatment directed against the neoplasm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This review will discuss those causes of anemia that are of specific relevance in patients with neoplastic disease. A general discussion of anemia and treatment of anemia in patients with malignancy is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38213?source=see_link\">",
"     \"Anemias due to decreased red cell production\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the",
"    <span class=\"nowrap\">",
"     WHO/National",
"    </span>",
"    Cancer Institute, normal values for hemoglobin (Hgb) are 12 to 16",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in women and 14 to 18",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in men [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/6\">",
"     6",
"    </a>",
"    ]. Anemia is defined, as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mild (Grade 1) &mdash; Hgb from 10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      to the lower limit of normal",
"     </li>",
"     <li>",
"      Moderate (Grade 2) &mdash; Hgb 8.0 to 9.9",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Severe (Grade 3) &mdash; Hgb 6.5 to 7.9",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Life-threatening (Grade 4) &mdash; Hgb &lt;6.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6778603\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with malignancy may have bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anemia due to a wide number of causes, which will be discussed in depth in the following sections. Causes for bleeding in the patient with malignancy that should be kept in mind include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bleeding from the tumor itself. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'External bleeding'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H6\">",
"       'Internal bleeding'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Thrombocytopenia from treatment-associated bone marrow suppression. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Anemia from effects of cancer treatment'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Tumor-associated immune thrombocytopenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link&amp;anchor=H19#H19\">",
"       \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\", section on 'Clinically apparent associated conditions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=see_link&amp;anchor=H10#H10\">",
"       \"Pathogenesis and etiology of disseminated intravascular coagulation\", section on 'Malignancy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acquired inhibitors of coagulation (eg, acquired VWD, acquired factor VIII deficiency). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link&amp;anchor=H13#H13\">",
"       \"Classification and pathophysiology of von Willebrand disease\", section on 'Acquired von Willebrand disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link&amp;anchor=H3#H3\">",
"       \"Acquired inhibitors of coagulation\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Use of therapeutic or prophylactic anticoagulation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19367?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of venous thromboembolism in patients with malignancy\", section on 'LMW heparin versus warfarin'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link&amp;anchor=H10#H10\">",
"       \"Hypercoagulable disorders associated with malignancy\", section on 'Prevention of VTE'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pre-existing coagulation or bleeding disorders (eg, von Willebrand disease, peptic ulcer disease). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"       \"Approach to the adult patient with a bleeding diathesis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANEMIA FROM DIRECT EFFECTS OF NEOPLASMS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     External bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraluminal neoplasms (ie, malignancies arising from or metastatic to the gastrointestinal or genitourinary tract) may bleed, producing blood loss anemia. When evaluating cancer patients who have anemia, stool and urine samples should be examined for evidence of blood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11336?source=see_link\">",
"     \"Evaluation of occult gastrointestinal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the patient's hemoglobin, hematocrit, and red blood cell indices may be normal in the early stages of blood loss, persistent bleeding will result in the laboratory findings of iron deficiency when the patient's iron stores become depleted. This is usually reached in men when total blood loss exceeds 1200 mL and in women at about 600 mL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link&amp;anchor=H17#H17\">",
"     \"Approach to the adult patient with anemia\", section on 'Decreased RBC production'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Decreased concentrations of serum ferritin, reflecting deficient stores of iron, may be present. In addition, microcytic, hypochromic red blood cells may be evident on review of peripheral blood smears (",
"    <a class=\"graphic graphic_picture graphicRef64267 \" href=\"UTD.htm?21/45/22232\">",
"     picture 1",
"    </a>",
"    ). A progressive decrease over time in RBC mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mean corpuscular hemoglobin concentration (MCHC) is another clue that iron deficiency may be developing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link&amp;anchor=H23#H23\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Estimation of iron stores'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Impaired iron absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;While iron deficiency most commonly arises from bleeding, it may occasionally result from impaired iron absorption. Iron malabsorption should be considered in patients whose malignancies involve the mucosa of the duodenum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    upper jejunum, the sites of maximal iron absorption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H21#H21\">",
"     \"Regulation of iron balance\", section on 'Intestinal iron absorption'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This effect can be direct, as in gastrointestinal lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/9\">",
"     9",
"    </a>",
"    ], or indirect, as in amyloidosis from multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/10\">",
"     10",
"    </a>",
"    ]. Iron malabsorption may also arise in patients who have had certain surgical operations, for example, partial or total gastrectomy resulting in achlorhydria, gastric dumping, or afferent (blind) loop syndromes with or without bacterial overgrowth [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. If iron deficiency anemia is present and bleeding as a source of iron loss is not evident, disorders of impaired iron absorption should be considered. In such cases, an oral iron absorption test may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/9,14\">",
"     9,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Internal bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, there may be significant bleeding into the body of the tumor, resulting in acute anemia. Most patients suffering this complication have hepatocellular carcinoma, and spontaneous liver rupture can arise with catastrophic consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Other malignancies associated with hemorrhage into the tumor, with risk of massive internal bleeding include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Malignant hepatic epithelioid hemangioendothelioma [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Peliosis hepatis and liver cell adenomas [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/15,17\">",
"       15,17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Liver metastases, especially from cutaneous or ocular melanomas [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Splenic hemangiosarcomas [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Stromal ovarian tumors or cancers metastatic to the ovary [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Retroperitoneal tumors with retroperitoneal hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/22-25\">",
"       22-25",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cavernous hemangioma is the most common benign tumor involving the liver. While the vast majority of these are small and asymptomatic, some can result in spontaneous fatal hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/26\">",
"     26",
"    </a>",
"    ]. Surgery and angiography with embolization are preferred approaches to management of patients with intratumor bleeding and rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/15,26,27\">",
"     15,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other causes of bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all bleeding episodes will be related to direct effects of the patient's malignancy, and other causes (for example, peptic ulcer disease and mucosal erosive disease) should be considered. Additionally, coagulopathies can enhance bleeding risk, and correlation of patients' hemorrhagic tendencies should be made with laboratory tests assessing the patient's hemostatic competencies (platelet count, prothrombin time, activated partial thromboplastin time, thrombin time and fibrinogen). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hemophagocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemophagocytosis is characterized by ingestion of RBCs by macrophages or cancer cells. While the hemophagocytic syndrome is most commonly seen in association with infection, particularly Epstein Barr virus (EBV) infection, this disorder can complicate certain malignancies, producing anemia in the absence of documented infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link\">",
"     \"Hemophagocytic lymphohistiocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\", section on 'Hemophagocytic lymphohistiocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cancer types most commonly associated with this syndrome are the leukemias and the lymphomas. The latter are usually of T-cell lineage, although NK-cell, B-cell, and myeloid proliferations causing hemophagocytosis have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35126?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T-cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4249?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interferon-gamma and monocyte-colony stimulating factor (M-CSF) levels may be elevated, and levels of such cytokines and growth factors which stimulate macrophage activation may correlate significantly with the degree of clinical manifestations and laboratory data [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/30\">",
"     30",
"    </a>",
"    ]. Rarely, solid tumors demonstrate hemophagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Detection of hemophagocytosis is often made by bone marrow biopsy, which reveals macrophages or cancer cells with ingested whole RBCs. Therapy is treatment of the underlying malignancy, but prognosis is poor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bone marrow replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukemias, lymphomas, and plasma cell dyscrasias are hematopoietic malignancies that commonly involve bone marrow, supplanting normal hematopoiesis and resulting in myelophthisis with anemia and other cytopenias. Solid tumors can also produce anemia by involving the bone marrow space through metastasis.",
"   </p>",
"   <p>",
"    Disruption of the bone marrow microenvironment produces a leukoerythroblastic blood picture. This process is defined by the appearance of immature granulocytes, tear drop RBCs, and nucleated red blood cells in peripheral blood (",
"    <a class=\"graphic graphic_picture graphicRef55274 graphicRef68110 \" href=\"UTD.htm?18/43/19130\">",
"     picture 2A-B",
"    </a>",
"    ). Detection of this finding on review of a patient's peripheral blood smear should alert the clinician to the possibility of myelophthisic disease.",
"   </p>",
"   <p>",
"    While leukoerythroblastosis can arise from hematopoietic malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/34\">",
"     34",
"    </a>",
"    ], it is more commonly seen in patients with tumors metastatic to bone marrow (",
"    <a class=\"graphic graphic_picture graphicRef70576 \" href=\"UTD.htm?2/11/2228\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/35\">",
"     35",
"    </a>",
"    ]. In this instance, myelofibrosis and hepatosplenic extramedullary hematopoiesis appear to be important to the pathogenesis of the leukoerythroblastosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Solid tumor types most commonly resulting in this disorder are prostatic and gastric carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/36,38\">",
"     36,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical manifestations and diagnosis of primary myelofibrosis\", section on 'Secondary forms of myelofibrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ANEMIA FROM PRODUCTS OF NEOPLASMS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Amyloid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloid, either primary (AL) or secondary (AA), may deposit in a variety of organs including bone. While large bone deposits of amyloid (amyloidomas) may be seen, producing osteolytic lesions and pathologic fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/39\">",
"     39",
"    </a>",
"    ], extensive replacement of bone marrow by amyloid is not common. Hence, anemia and other cytopenias are not a prominent feature of amyloidosis unless renal failure (from renal amyloid) or bleeding (from intestinal amyloid, amyloid angiopathy, or coagulopathy) is present.",
"   </p>",
"   <p>",
"    In AL amyloid, fibrils consist of the N-terminal amino acid residues of the variable portions of a monoclonal immunoglobulin light chain, and multiple myeloma may or may not be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    .) In AA amyloid, fibrils consist of fragments of the serum amyloid A precursor (SAA), a non-immunoglobulin protein product of hepatocytes, induced by interleukin-1, interleukin-6, and tumor necrosis factor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30086?source=see_link\">",
"     \"Pathogenesis of secondary (AA) amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While disorders causing secondary (AA) amyloid are chiefly chronic inflammatory and infectious diseases, malignant diseases giving rise to AA amyloid have been reported, including Hodgkin lymphoma, non-Hodgkin lymphoma, macroglobulinemia, renal cell carcinoma, and hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/41-47\">",
"     41-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolysis, defined here as a shortening of RBC survival to less than 100 days, may occur in various malignancies. Two different mechanisms may be involved:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Production of autoantibodies that recognize red cell membrane antigens and cause an autoimmune hemolytic anemia",
"     </li>",
"     <li>",
"      Microangiopathic changes, which cause fragmentation hemolysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Autoimmune hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune hemolytic anemia (AIHA) is usually associated with the presence of immunoglobulin (IgG) or complement (C3d) on the surface of circulating RBCs, as detected by the direct Coombs' test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\", section on 'Antibody detection: the direct Coombs' test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of spherocytic RBCs on the peripheral smear, along with increased serum concentrations of indirect bilirubin and lactate dehydrogenase (LDH) and reduced concentrations of haptoglobin are the hallmark findings (",
"    <a class=\"graphic graphic_picture graphicRef70611 \" href=\"UTD.htm?27/1/27670\">",
"     picture 4",
"    </a>",
"    ). While cancer-associated AIHA is most frequently noted in patients with chronic lymphocytic leukemia, other associated tumors include non-Hodgkin lymphoma, Hodgkin lymphoma, carcinomas, multiple myeloma, Waldenstrom macroglobulinemia, acute myeloid leukemia, angioimmunoblastic lymphadenopathy with dysproteinemia, acute lymphoblastic leukemia, and myelodysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the majority of AIHAs are due to warm-reacting antibodies, certain malignancies may be associated with cold-reacting antibodies. These include chronic lymphocytic leukemia, Waldenstrom macroglobulinemia and the lymphomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16422?source=see_link&amp;anchor=H2#H2\">",
"     \"Paroxysmal cold hemoglobinuria\", section on 'Pathophysiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33672?source=see_link\">",
"     \"Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of cancer-associated AIHA is directed at the underlying malignancy. Of note, AIHA may be exacerbated by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    and other purine nucleoside analogs used in the treatment of certain indolent lymphoproliferative disorders, such as CLL and follicular lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. The mechanism is unclear, but may be related to altered T-cell immunity and dysregulation of B-cells, since fludarabine induces a decline in CD4 cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\", section on 'Genesis of antibody production'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8665?source=see_link&amp;anchor=H3#H3\">",
"     \"Autoimmune complications following purine analog therapy\", section on 'Autoimmune hemolytic anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Microangiopathic hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In microangiopathic hemolytic anemia (MAHA), Coombs' testing is negative, and schistocytes (RBC fragments) are the hallmark peripheral blood smear finding (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"     picture 5",
"    </a>",
"    ). MAHA in malignancy may be a consequence of disseminated intravascular coagulation (DIC) or thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=see_link\">",
"     \"Pathogenesis and etiology of disseminated intravascular coagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with TTP-HUS present with thrombocytopenia and a microangiopathic blood smear but, since there is primary platelet consumption, levels of the coagulation components are usually normal and there is little or no prolongation of the PT or aPTT. Measurement of fibrinogen and D-dimer also helps to clarify the situation, since these tests are generally normal in TTP-HUS and abnormal in DIC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'DIC versus TTP-HUS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In DIC, peripheral blood schistocytes are generally few in number, whereas in TTP-HUS they are often plentiful and readily detectable on review of peripheral blood smears. Accordingly, serum LDH levels due to hemolysis and tissue ischemia are generally more strikingly elevated in TTP-HUS than in DIC, often reaching levels higher than 1000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/54\">",
"     54",
"    </a>",
"    ]. Similarly, peripheral blood nucleated RBCs due to stress erythropoiesis are more common with TTP-HUS than with DIC, unless leukoerythroblastosis from myelophthisis is present as a confounding factor.",
"   </p>",
"   <p>",
"    Most patients with cancer-related MAHA have already been diagnosed with cancer, although it can occasionally be a presenting sign of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/55\">",
"     55",
"    </a>",
"    ]. However, many disorders other than cancer may trigger MAHA, particularly DIC [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/56\">",
"     56",
"    </a>",
"    ]. Hence, implicating cancer as the cause of MAHA requires exclusion of these other causes.",
"   </p>",
"   <p>",
"    Both solid tumors and hematologic malignancies may give rise to MAHA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/57\">",
"     57",
"    </a>",
"    ]. However, in contrast to leukemia-associated MAHA, which is generally DIC with risk of hemorrhage from consumptive coagulopathy (as in acute promyelocytic leukemia), solid tumor-associated MAHA is generally thrombotic, with an increased risk for thrombotic complications and renal failure. The solid tumors most commonly associated with MAHA are mucinous adenocarcinomas (eg, gastric, breast, pancreas, prostate, lung) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link&amp;anchor=H3#H3\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Mucin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MAHA may also arise as a consequence of antineoplastic therapy. This primarily occurs with one of three regimens: \"standard-dose\"",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/58\">",
"     58",
"    </a>",
"    ]; the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ; or the use of radiation and high dose chemotherapy prior to bone marrow transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/61-63\">",
"     61-63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology of TTP-HUS as a late complication of high-dose alkylator therapies accompanying autologous or allogeneic hematopoietic cell transplantation (HCT) is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/64-68\">",
"     64-68",
"    </a>",
"    ]. The clinical manifestations in these patients can often be attributed to acute graft-versus-host disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disseminated fungal, bacterial,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    viral infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1609?source=see_link\">",
"     \"Kidney disease following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of interest, while von Willebrand factor proteolysis is deficient in classic TTP-HUS, this does not appear to be the case in HCT-associated TTP-HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mechanisms responsible for cancer-triggered MAHA are uncertain. However, investigations have yielded several insights, particularly in cancer-associated DIC. For example, tissue factor, the activator of factor VII, has been shown to be expressed on the surface of certain tumor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/70\">",
"     70",
"    </a>",
"    ] as well as on circulating procoagulant microparticles in patients with malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. In addition, tumor necrosis factor and interleukin-6, proinflammatory cytokines associated with the malignant state, may dysregulate anticoagulant and antifibrinolytic mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cancer procoagulant (CP) is a calcium-dependent cysteine protease, which has been found in malignant and fetal tissue, but not normally differentiated tissue. It activates factor X directly, independent of the tissue",
"    <span class=\"nowrap\">",
"     factor/factor",
"    </span>",
"    VIIa complex. CP is present in extracts of cells obtained from patients with acute promyelocytic leukemia (APL), malignant melanoma, and cancers of the colon, breast, lung, and kidney. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1224?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis of the hypercoagulable state associated with malignancy\", section on 'Cancer procoagulant'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism by which APL leads to DIC, which is often accompanied by secondary fibrinolysis, is incompletely understood. Three tumor cell procoagulants may be of primary importance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1224?source=see_link\">",
"     \"Pathogenesis of the hypercoagulable state associated with malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\", section on 'Disseminated intravascular coagulation'",
"    </a>",
"    .) These are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tissue factor, which forms a complex with factor VII to activate factors X and IX",
"     </li>",
"     <li>",
"      Cancer procoagulant, which activates factor X independent of factor VII",
"     </li>",
"     <li>",
"      Increased annexin II receptor expression on the surface of the leukemic promyelocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/75\">",
"       75",
"      </a>",
"      ]. Annexin II receptor binds plasminogen and its activator, tissue plasminogen activator, increasing plasmin formation by a factor of 60.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The induction of tumor cell differentiation with retinoic acid can lead to rapid improvement in the coagulopathy. As an example, all-trans-retinoic acid (ATRA), used to treat APL, blocks transcription of the annexin II gene in leukemic promyelocytes, and reduces the incidence of severe DIC in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=see_link\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mechanisms in cancer-associated TTP-HUS are less certain. It is presumed that direct endothelial injury is the initiating event in these settings [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/62,76\">",
"     62,76",
"    </a>",
"    ]. However, the onset of clinically evident disease is often delayed, frequently occurring months after chemotherapy has been discontinued or hematopoietic cell transplantation has been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/63,66,68\">",
"     63,66,68",
"    </a>",
"    ]. Affected patients typically present with slowly progressive renal failure, hypertension, and a relatively bland urine sediment, often occurring in the absence of clinically apparent tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H19#H19\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of MAHA requires identifying and focusing on treatment of the underlying cause [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/56\">",
"     56",
"    </a>",
"    ]. In patients with DIC,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    administration remains controversial and of no proven benefit based on controlled clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/77\">",
"     77",
"    </a>",
"    ]. Nevertheless, patients with clinically overt thromboembolic complications from DIC may benefit from heparin administration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link&amp;anchor=H28#H28\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients receiving antineoplastic agents commonly associated with TTP-HUS (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    ), careful monitoring for the early appearance of schistocytes and other manifestations of MAHA is essential, since early discontinuation of the offending agent can be beneficial in curtailing MAHA progression [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/78\">",
"     78",
"    </a>",
"    ]. In patients with cancer-induced TTP-HUS or TTP-HUS occurring after hematopoietic cell transplantation, plasmapheresis may improve the MAHA in some patients. However, treatment of these ominous complications is generally unsatisfactory, with death arising shortly after its detection in the majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/57,58,66,78\">",
"     57,58,66,78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anemia of inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain cytokines (eg, interferon-alpha, interferon-beta, interferon-gamma, TNF-alpha, TGF-beta, IL-1, IL-6), produced in response to malignancy, may result in anemia by mediating a block in iron utilization, inhibiting erythropoietin mRNA synthesis, and exerting other ill-defined suppressive effects on erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/79-83\">",
"     79-83",
"    </a>",
"    ]. IL-1, IL-6, and TNF-alpha induce increased levels of the iron-regulatory hormone hepcidin, which sequesters iron in macrophages, shunting iron away from erythropoiesis. Variously known as the \"anemia of chronic disease (ACD)\" or \"anemia of (chronic) inflammation\", anemia due to inflammatory cytokines should be diagnosed after excluding other causes of anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H2#H2\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the anemia in ACD is most often normocytic and normochromic, careful review of peripheral blood smears will often reveal a small population of hypochromic microcytic RBCs. Other findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abundant iron stores in bone marrow macrophages (unless concomitant blood loss has occurred) with decreased, if not absent, numbers of sideroblasts",
"     </li>",
"     <li>",
"      Serum erythropoietin levels that are inappropriately low given the degree of anemia and intact renal function",
"     </li>",
"     <li>",
"      Low plasma concentrations of iron and total iron binding capacity in the presence of normal or increased plasma ferritin concentrations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management involves treating the underlying disorder, although recombinant erythropoietin (EPO) administration may be of some benefit in certain patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/84\">",
"     84",
"    </a>",
"    ]. In this setting, measurement of the plasma EPO concentration may be helpful. Patients with ACD due to cancer, rheumatoid arthritis, or AIDS who have EPO levels below 500",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    (although some authors suggest a cutoff of 100",
"    <span class=\"nowrap\">",
"     mU/mL)",
"    </span>",
"    will frequently respond to the administration of recombinant human EPO. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H17#H17\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Treatment issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pure red cell aplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;While a variety of drugs, chemicals and non-malignant conditions may be responsible for the development of acquired pure red cell aplasia (PRCA), this profound hypoproliferative anemia, characterized by markedly decreased or absent erythroid progenitors in the bone marrow, marked reticulocytopenia, and normal leukocyte and platelet counts, can be a consequence of malignancy.",
"   </p>",
"   <p>",
"    In older series, thymomas accounted for as many as 50 percent of PRCA cases, with the incidence of PRCA in patients with thymomas ranging from 1 percent to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/85-87\">",
"     85-87",
"    </a>",
"    ]. Subsequent series, however, implicate thymomas less frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/88\">",
"     88",
"    </a>",
"    ]. Of the hematologic malignancies reported in association with PRCA, chronic lymphocytic leukemia (CLL) is one of the most frequently cited, with as many as 6 percent of CLL patients developing PRCA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/89\">",
"     89",
"    </a>",
"    ]. Of these, two-thirds have B-cell CLL and one-third have T-cell CLL. However, in a Mayo Clinic series of 47 adults with acquired pure red blood cell aplasia, LGL leukemia was the most common underlying cause [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2793?source=see_link\">",
"     \"Treatment of large granular lymphocyte leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17433?source=see_link\">",
"     \"Acquired pure red cell aplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other hematologic malignancies reported in association with PRCA include non-Hodgkin lymphomas, Hodgkin lymphoma, acute lymphoblastic leukemia, chronic myeloid leukemia, multiple myeloma, and primary myelofibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. While non-hematologic solid tumors have also been reported in association with PRCA, a cause-and-effect relationship between the patient's solid tumor and their PRCA has not necessarily been established in all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mechanisms causing cancer-associated PRCA include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/87,93-97\">",
"     87,93-97",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immunoglobulin inhibitors of erythropoietin responsive cells",
"     </li>",
"     <li>",
"      Immunoglobulin-mediated cytotoxicity of erythroblasts",
"     </li>",
"     <li>",
"      T-cell inhibition of erythropoietin-responsive cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immunoglobulin inhibitors of erythropoietin have also been described; however, this mechanism as a cause of cancer-associated PRCA is much less common than mechanisms involving immunoglobulins directed against marrow erythroid cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/98\">",
"     98",
"    </a>",
"    ]. In PRCA associated with CLL, serum inhibitors of erythropoiesis have not been typically found. Rather, T lymphocytes appear to suppress erythroid growth in these patients, including those with B-cell as well as T-cell CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/99,100\">",
"     99,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients receiving human recombinant erythropoietin, PRCA may rarely develop as a consequence of antierythropoietin antibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17433?source=see_link&amp;anchor=H26#H26\">",
"     \"Acquired pure red cell aplasia\", section on 'Anti-EPO antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Parvovirus B19 infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Now widely recognized as a cause of acquired PRCA, parvovirus B19, which selectively invades erythroid progenitors, can cause profound erythroid hypoplasia with erythroid maturation arrest, particularly with protracted infections arising in patients with altered immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/101\">",
"     101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=see_link\">",
"     \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since patients with cancer are often immunosuppressed, either primarily by their malignancy or secondarily by therapy for their disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/102\">",
"     102",
"    </a>",
"    ], parvovirus B19 infection must be considered as a possible cause of hypoproliferative anemia in such patients. In addition to profound erythroid hypoplasia with erythroid maturation arrest, a characteristic bone marrow finding in patients infected with parvovirus B19 is the presence of giant pronormoblasts with prominent eosinophilic intranuclear viral inclusions. Bone marrow biopsy can be highly informative in evaluating these patients (",
"    <a class=\"graphic graphic_picture graphicRef51435 \" href=\"UTD.htm?26/42/27304\">",
"     picture 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17433?source=see_link&amp;anchor=H17#H17\">",
"     \"Acquired pure red cell aplasia\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with thymoma-associated PRCA, resection of the thymoma has reversed the PRCA in 29 percent of cases and has improved the response rate to corticosteroids in others [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/86\">",
"     86",
"    </a>",
"    ]. In patients whose thymomas are unresectable, radiotherapy may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/103\">",
"     103",
"    </a>",
"    ]. In patients with PRCA associated with other tumors, resection of the primary tumor may reverse the PRCA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/104\">",
"     104",
"    </a>",
"    ]. In patients whose PRCA does not remit in response to treatment of their malignancy, immunosuppressive therapies may be required, including corticosteroids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , antithymocyte globulin, and cyclosporin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/88,97,105-108\">",
"     88,97,105-108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While high-dose immunoglobulin infusions are the treatment of choice in patients with protracted parvovirus B19 infection in the setting of altered immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/109,110\">",
"     109,110",
"    </a>",
"    ], high-dose immunoglobulin infusions may also be beneficial in patients with antibody-mediated PRCA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/111\">",
"     111",
"    </a>",
"    ], including cases associated with hematologic malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/112\">",
"     112",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17433?source=see_link&amp;anchor=H20#H20\">",
"     \"Acquired pure red cell aplasia\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ANEMIA FROM EFFECTS OF CANCER TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most commonly, anemia in patients with cancer is the consequence of cancer therapy. Ionizing radiation, encompassing sites of marrow hematopoiesis, results in depletion of hematopoietic stem cells. However, systemic antineoplastic therapy contributes more to anemia development than radiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stem cell death with long-term myelosuppression can occur following chemotherapy with non-cell-cycle-dependent drugs such as alkylators, often in a dose-dependent fashion.",
"     </li>",
"     <li>",
"      Long-term myelodysplasia may be a consequence of alkylating agents and inhibitors of topoisomerase II [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/114-116\">",
"       114-116",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use of non-myeloablative doses of chemotherapy agents (ie, myelotoxic doses that do not require stem cell rescue) acting against actively proliferating cells (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , anthracyclines,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      ) leads to death of committed progenitor cells, invariably yielding early short-term myelosuppression. Although usually short term, treatment-related myelosuppression may worsen both in duration and severity as the number of treatment courses increases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other mechanisms by which chemotherapy causes anemia include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suppression of hematopoietic growth factor synthesis, especially erythropoietin [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/117\">",
"       117",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Oxidant damage to mature hematopoietic cells [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/118\">",
"       118",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Induction of immune-mediated hematopoietic cell destruction (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/55/4983?source=see_link\">",
"       teniposide",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/118-121\">",
"       118-121",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Exacerbation of an underlying AIHA associated with the patient's malignancy, as in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      treatment of CLL [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/50\">",
"       50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Induction of microangiopathic hemolytic anemia, as in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      -induced hemolytic uremic syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?23/22/23914/abstract/78\">",
"       78",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Acute bone marrow stromal damage with intramedullary serofibrinous exudate and hemorrhage, particularly from high dose chemotherapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anemia may be \"apparent\" rather than real in patients with a normal RBC mass but an expanded plasma volume. This may be the result of fluid retention or volume expansion from other causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to the adult patient with anemia\", section on 'Volume status'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of symptomatic anemia from chemotherapy-induced myelosuppression includes transfusion of packed red blood cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the administration of recombinant erythropoietin or darbepoetin. Issues surrounding the use of ESAs versus transfusion are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link\">",
"     \"Use of red blood cells for transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics link (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/15/20721?source=see_link\">",
"       \"Patient information: Anemia of chronic disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors may contribute to anemia in the cancer patient. It is important to correlate patients' clinical histories and physical exam findings with laboratory observations, since more than one contributor may be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link&amp;anchor=H50#H50\">",
"     \"Approach to the adult patient with anemia\", section on 'Multiple causes of anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Mechanisms of anemia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     General mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three general mechanisms for the development of anemia in any patient. One or more of these may be present in the anemic cancer patient:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blood loss",
"     </li>",
"     <li>",
"      Increased red blood cell destruction (hemolysis)",
"     </li>",
"     <li>",
"      Decreased red blood cell production",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Mechanisms specific to the cancer patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following general mechanisms for development of anemia in the cancer patient include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct effects of the neoplasm (eg, bleeding from the tumor, bone marrow replacement). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anemia from direct effects of neoplasms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors produced by the cancer cells (eg, autoantibodies, microangiopathy, amyloid production, cytokine inhibition of erythropoiesis). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Anemia from products of neoplasms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Effects of cancer treatment (eg, suppression of erythropoiesis by radiation therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemotherapeutic agents). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Anemia from effects of cancer treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/1\">",
"      Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997; 34:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/2\">",
"      Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/3\">",
"      Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19:2865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/4\">",
"      Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19:2875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/5\">",
"      Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001; 93:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/6\">",
"      Rodgers GM 3rd, Becker PS, Bennett CL, et al. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2008; 6:536.",
"     </a>",
"    </li>",
"    <li>",
"     United States FDA toxicity criteria, search under \"hemoglobim\" at: www.fda.gov/cder/cancer/toxicityframe.htm (Accessed on July 21, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/8\">",
"      Escobar MA. Bleeding in the patient with a malignancy: is it an acquired factor VIII inhibitor? Cancer 2012; 118:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/9\">",
"      Reid TJ 3rd, Stamm CP, Dunning DM, Redmond J 3rd. Iron malabsorption in a patient with large cell lymphoma involving the duodenum. Am J Gastroenterol 1992; 87:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/10\">",
"      Dauth J, de Coning JP, Politzer WM, et al. Unusual presentation of multiple myeloma. A report of 2 cases. S Afr Med J 1984; 65:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/11\">",
"      Sutton DR, Baird IM, Stewart JS, et al. Gastrointestinal iron losses in atrophic gastritis, postgastrectomy states and adult coeliac disease. Gut 1971; 12:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/12\">",
"      Kimber C, Patterson JF, Weintraub LR. The pathogenesis of iron deficiency anemia following partial gastrectomy. A study of iron balance. JAMA 1967; 202:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/13\">",
"      Schade SG, Cohen RJ, Conrad ME. Effect of hydrochloric acid on iron absorption. N Engl J Med 1968; 279:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/14\">",
"      Ekenved G. Iron absorption studies. Studies on oral iron preparations using serum iron and different radioiron isotope techniques. Scand J Haematol Suppl 1976; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/15\">",
"      Dewar GA, Griffin SM, Ku KW, et al. Management of bleeding liver tumours in Hong Kong. Br J Surg 1991; 78:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/16\">",
"      Srivastava DN, Gandhi D, Julka PK, Tandon RK. Gastrointestinal hemorrhage in hepatocellular carcinoma: management with transheptic arterioembolization. Abdom Imaging 2000; 25:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/17\">",
"      Hayward SR, Lucas CE, Ledgerwood AM. Recurrent spontaneous intrahepatic hemorrhage from peliosis hepatis. Arch Surg 1991; 126:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/18\">",
"      Cooperman AM, Weiland LH, Welch JS. Massive bleeding from a ruptured metastatic hepatic melanoma treated by hepatic lobectomy. Case report and review of the literature. Mayo Clin Proc 1976; 51:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/19\">",
"      Autry JR, Weitzner S. Hemangiosarcoma of spleen with spontaneous rupture. Cancer 1975; 35:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/20\">",
"      Margolin KA, Pak HY, Esensten ML, Doroshow JH. Hepatic metastasis in granulosa cell tumor of the ovary. Cancer 1985; 56:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/21\">",
"      LITTON MA, LITTON EW, FOX TC. HEMORRHAGE FROM A GRANULOSA-THECA CELL TUMOR OF THE OVARY; (AN UNUSUAL CAUSE OF ACUTE ABDOMINAL PAIN IN A CHILD). Wis Med J 1965; 64:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/22\">",
"      Witz M, Bernheim J, Dinbar A, Griffel B. Kidney fibroxanthoma (malignant fibrous xanthoma): a rare tumor and an unusual cause of retroperitoneal hemorrhage. J Surg Oncol 1984; 26:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/23\">",
"      Witz M, Shpitz B, Dinbar A. Massive intraabdominal bleeding due to a retroperitoneal leiomyosarcoma. J Surg Oncol 1983; 24:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/24\">",
"      Nguyen HT, Wolf JS Jr, Nash PA, et al. Acute retroperitoneal hemorrhage due to transitional cell carcinoma of the renal pelvis. J Urol 1995; 153:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/25\">",
"      Swift DL, Lingeman JE, Baum WC. Spontaneous retroperitoneal hemorrhage: a diagnostic challenge. J Urol 1980; 123:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/26\">",
"      Graham E, Cohen AW, Soulen M, Faye R. Symptomatic liver hemangioma with intra-tumor hemorrhage treated by angiography and embolization during pregnancy. Obstet Gynecol 1993; 81:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/27\">",
"      Okazaki M, Higashihara H, Koganemaru F, et al. Intraperitoneal hemorrhage from hepatocellular carcinoma: emergency chemoembolization or embolization. Radiology 1991; 180:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/28\">",
"      Gaffey MJ, Frierson HF Jr, Medeiros LJ, Weiss LM. The relationship of Epstein-Barr virus to infection-related (sporadic) and familial hemophagocytic syndrome and secondary (lymphoma-related) hemophagocytosis: an in situ hybridization study. Hum Pathol 1993; 24:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/29\">",
"      Aung W, Koslosky W, Chin NW, Pincus MR. Diffuse large cell lymphoma of B-cell type associated with reactive hemophagocytosis. Ann Clin Lab Sci 1996; 26:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/30\">",
"      Kobayashi Y, Uehara S, Inamori K, et al. Hemophagocytosis as a para-neoplastic syndrome in NK cell leukemia. Int J Hematol 1996; 64:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/31\">",
"      Imashuku S, Hibi S, Sako M, et al. Hemophagocytosis by leukemic blasts in 7 acute myeloid leukemia cases with t(16;21)(p11;q22): common morphologic characteristics for this type of leukemia. Cancer 2000; 88:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/32\">",
"      Tsoi WC, Feng CS. Hemophagocytosis by rhabdomyosarcoma cells in bone marrow. Am J Hematol 1997; 54:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/33\">",
"      Molad Y, Stark P, Prokocimer M, et al. Hemophagocytosis by small cell lung carcinoma. Am J Hematol 1991; 36:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/34\">",
"      Conlan MG, Armitage JO, Bast M, Weisenburger DD. Clinical significance of hematologic parameters in non-Hodgkin's lymphoma at diagnosis. Cancer 1991; 67:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/35\">",
"      Rubins JM. The role of myelofibrosis in malignant leukoerythroblastosis. Cancer 1983; 51:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/36\">",
"      Delsol G, Guiu-Godfrin B, Guiu M, et al. Leukoerythroblastosis and cancer frequency, prognosis, and physiopathologic significance. Cancer 1979; 44:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/37\">",
"      O'Keane JC, Wolf BC, Neiman RS. The pathogenesis of splenic extramedullary hematopoiesis in metastatic carcinoma. Cancer 1989; 63:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/38\">",
"      Shamdas GJ, Ahmann FR, Matzner MB, Ritchie JM. Leukoerythroblastic anemia in metastatic prostate cancer. Clinical and prognostic significance in patients with hormone-refractory disease. Cancer 1993; 71:3594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/39\">",
"      Kavanaugh JH. Multiple myeloma, amyloid arthropathy, and pathological fracture of the femur: a case report. J Bone Joint Surg Am 1978; 60:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/40\">",
"      Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/41\">",
"      Lanjewar DN, Raghuwanshi SR, Gupta D, et al. Systemic amyloidosis in Hodgkin's disease. Indian J Pathol Microbiol 1998; 41:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/42\">",
"      P&eacute;rez Equiza E, Argui&ntilde;ano JM, Gastearena J. Successful treatment of AA amyloidosis secondary to Hodgkin's disease with 4'-iodo-4'-deoxydoxorubicin. Haematologica 1999; 84:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/43\">",
"      Simmonds PD, Cottrell BJ, Mead GM, et al. Lymphadenopathy due to amyloid deposition in non-Hodgkin's lymphoma. Ann Oncol 1997; 8:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/44\">",
"      Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstr&ouml;m's macroglobulinemia. J Clin Oncol 1993; 11:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/45\">",
"      Coakley FV, Hricak H, Presti JC Jr, Small EJ. Diffuse retroperitoneal amyloidosis due to renal cell carcinoma. Br J Radiol 1999; 72:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/46\">",
"      Delgado MA, Liu JY, Meleg-Smith S. Systemic amyloidosis associated with hepatocellular carcinoma. Case report and literature review. J La State Med Soc 1999; 151:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/47\">",
"      Terrier B, Jaccard A, Harousseau JL, et al. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients. Medicine (Baltimore) 2008; 87:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/48\">",
"      Spira MA, Lynch EC. Autoimmune hemolytic anemia and carcinoma: an unusual association. Am J Med 1979; 67:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/49\">",
"      Engelfriet CP, Overbeeke MA, von dem Borne AE. Autoimmune hemolytic anemia. Semin Hematol 1992; 29:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/50\">",
"      Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/51\">",
"      Gonzalez H, Leblond V, Azar N, et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol Cell Ther 1998; 40:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/52\">",
"      Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998; 16:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/53\">",
"      Juliusson G. Complications in the treatment of CLL with purine analogues. Hematol Cell Ther 1997; 39 Suppl 1:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/54\">",
"      Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher 1998; 13:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/55\">",
"      Lin YC, Chang HK, Sun CF, Shih LY. Microangiopathic hemolytic anemia as an initial presentation of metastatic cancer of unknown primary origin. South Med J 1995; 88:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/56\">",
"      Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/57\">",
"      Rytting M, Worth L, Jaffe N. Hemolytic disorders associated with cancer. Hematol Oncol Clin North Am 1996; 10:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/58\">",
"      Sheldon R, Slaughter D. A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer 1986; 58:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/59\">",
"      Laffay DL, Tubbs RR, Valenzuela R, et al. Chronic glomerular microangiopathy and metastatic carcinoma. Hum Pathol 1979; 10:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/60\">",
"      Lockhart AC. Microangiopathic haemolytic anaemia in metastatic malignancy. Hosp Med 2001; 62:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/61\">",
"      Lesesne JB, Rothschild N, Erickson B, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989; 7:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/62\">",
"      Groff JA, Kozak M, Boehmer JP, et al. Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy. Am J Kidney Dis 1997; 29:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/63\">",
"      Jackson AM, Rose BD, Graff LG, et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984; 101:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/64\">",
"      Wassmann B, Martin H, Elsner S, et al. Microangiopathic hemolytic anemia and renal impairment following autologous bone marrow transplantation: a case of hemolytic uremic syndrome? Bone Marrow Transplant 1994; 14:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/65\">",
"      Anthony MT, Zeigler ZR, Lister J, et al. Plasminogen activator inhibitor (PAI-1) antigen levels in primary TTP and secondary TTP post-bone marrow transplantation. Am J Hematol 1998; 59:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/66\">",
"      Fuge R, Bird JM, Fraser A, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 2001; 113:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/67\">",
"      Zeigler Z, Kelton J, Moore J, et al. Calpain activity in bone marrow transplant-associated thrombotic thrombocytopenic purpura. Bone Marrow Transplant 1999; 24:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/68\">",
"      van der Lelie H, Baars JW, Rodenhuis S, et al. Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support. Cancer 1995; 76:2338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/69\">",
"      van der Plas RM, Schiphorst ME, Huizinga EG, et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 1999; 93:3798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/70\">",
"      Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/71\">",
"      Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol 2007; 62:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/72\">",
"      Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009; 27:4834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/73\">",
"      Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988; 8:5588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/74\">",
"      van der Poll T, B&uuml;ller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/75\">",
"      Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/76\">",
"      Porta C, Danova M, Riccardi A, et al. Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production. Mayo Clin Proc 1999; 74:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/77\">",
"      Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood 1982; 60:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/78\">",
"      Bruntsch U, Groos G, Tigges FJ, Gallmeier WM. Microangiopathic hemolytic anemia, a frequent complication of mitomycin therapy in cancer patients. Eur J Cancer Clin Oncol 1984; 20:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/79\">",
"      Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/80\">",
"      Means RT Jr. Advances in the anemia of chronic disease. Int J Hematol 1999; 70:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/81\">",
"      Sharma S, Nemeth E, Chen YH, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 2008; 14:3262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/82\">",
"      Hohaus S, Massini G, Giachelia M, et al. Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol 2010; 28:2538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/83\">",
"      Falkensammer CE, Thurnher M, Leonhartsberger N, Ramoner R. C-reactive protein is a strong predictor for anaemia in renal cell carcinoma: role of IL-6 in overall survival. BJU Int 2011; 107:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/84\">",
"      Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998; 16:3412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/85\">",
"      JACOBS EM, HUTTER RV, POOL JL, LEY AB. Benign thymoma and selective erythroid aplasia of the bone marrow. Cancer 1959; 12:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/86\">",
"      Hirst E, Robertson TI. The syndrome of thymoma and erythroblastopenic anemia. A review of 56 cases including 3 case reports. Medicine (Baltimore) 1967; 46:225.",
"     </a>",
"    </li>",
"    <li>",
"     Dessypris EN. Pure Red Cell Aplasia, Johns Hopkins University Press, Baltimore 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/88\">",
"      Charles RJ, Sabo KM, Kidd PG, Abkowitz JL. The pathophysiology of pure red cell aplasia: implications for therapy. Blood 1996; 87:4831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/89\">",
"      Chikkappa G, Zarrabi MH, Tsan MF. Pure red-cell aplasia in patients with chronic lymphocytic leukemia. Medicine (Baltimore) 1986; 65:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/90\">",
"      Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood 1996; 87:3000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/91\">",
"      Carloss HW, Saab GA, Tavassoli M. Pure red cell aplasia and lymphoma. JAMA 1979; 242:67.",
"     </a>",
"    </li>",
"    <li>",
"     Krantz SB. Acquired pure red cell aplasia. In: Hematology: Basic Principles and Practice, 2nd ed, Hoffman R, Benz EJ, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 1995. p.350.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/93\">",
"      Krantz SB. Pure red-cell aplasia. N Engl J Med 1974; 291:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/94\">",
"      Abkowitz JL, Kadin ME, Powell JS, Adamson JW. Pure red cell aplasia: lymphocyte inhibition of erythropoiesis. Br J Haematol 1986; 63:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/95\">",
"      Taniguchi S, Shibuya T, Morioka E, et al. Demonstration of three distinct immunological disorders on erythropoiesis in a patient with pure red cell aplasia and autoimmune haemolytic anaemia associated with thymoma. Br J Haematol 1988; 68:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/96\">",
"      Masuda M, Arai Y, Okamura T, Mizoguchi H. Pure red cell aplasia with thymona: evidence of T-cell clonal disorder. Am J Hematol 1997; 54:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/97\">",
"      Yamada O, Yun-Hua W, Motoji T, Mizoguchi H. Clonal T-cell proliferation causing pure red cell aplasia in chronic B-cell lymphocytic leukaemia: successful treatment with cyclosporine following in vitro abrogation of erythroid colony-suppressing activity. Br J Haematol 1998; 101:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/98\">",
"      Peschle C, Marmont AM, Marone G, et al. Pure red cell aplasia: studies on an IgG serum inhibitor neutralizing erythropoietin. Br J Haematol 1975; 30:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/99\">",
"      Mangan KF, Chikkappa G, Scharfman WB, Desforges JF. Evidence for reduced erythroid burst (BFUE) promoting function of T lymphocytes in the pure red cell aplasia of chronic lymphocytic leukemia. Exp Hematol 1981; 9:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/100\">",
"      Fujisao S, Tsuda H. Th1/Th2 balance alteration in the clinical course of a patient with pure red cell aplasia and thymoma. Br J Haematol 1998; 103:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/101\">",
"      Frickhofen N, Chen ZJ, Young NS, et al. Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br J Haematol 1994; 87:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/102\">",
"      Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000; 96:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/103\">",
"      Penn CR, Hope-Stone HF. The role of radiotherapy in the management of malignant thymoma. Br J Surg 1972; 59:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/104\">",
"      Gajwani B, Zinner EN. Pure red-cell aplasia. Associated with adenocarcinoma of stomach. N Y State J Med 1976; 76:2177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/105\">",
"      Zaentz SD, Krantz SB, Brown EB. Studies on pure red cell aplasia. Maintenance therapy with immunosuppressive drugs. Br J Haematol 1976; 32:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/106\">",
"      Firkin FC, Maher D. Cytotoxic immunosuppressive drug treatment strategy in pure red cell aplasia. Eur J Haematol 1988; 41:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/107\">",
"      Abkowitz JL, Powell JS, Nakamura JM, et al. Pure red cell aplasia: response to therapy with anti-thymocyte globulin. Am J Hematol 1986; 23:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/108\">",
"      Kwong YL, Wong KF. Association of pure red cell aplasia with T large granular lymphocyte leukaemia. J Clin Pathol 1998; 51:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/109\">",
"      Kurtzman G, Frickhofen N, Kimball J, et al. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989; 321:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/110\">",
"      Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med 1990; 113:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/111\">",
"      McGuire WA, Yang HH, Bruno E, et al. Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin. N Engl J Med 1987; 317:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/112\">",
"      Clauvel JP, Vainchenker W, Herrera A, et al. Treatment of pure red cell aplasia by high dose intravenous immunoglobulins. Br J Haematol 1983; 55:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/113\">",
"      Asbell SO, Leon SA, Tester WJ, et al. Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate 1996; 29:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/114\">",
"      Pedersen-Bjergaard J. Radiotherapy- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review. Leuk Res 1992; 16:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/115\">",
"      Cremin P, Flattery M, McCann SR, Daly PA. Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin. Ann Oncol 1996; 7:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/116\">",
"      Sobecks RM, Le Beau MM, Anastasi J, Williams SF. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/117\">",
"      Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995; 95:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/118\">",
"      Doll DC, Weiss RB. Hemolytic anemia associated with antineoplastic agents. Cancer Treat Rep 1985; 69:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/119\">",
"      Marani TM, Trich MB, Armstrong KS, et al. Carboplatin-induced immune hemolytic anemia. Transfusion 1996; 36:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/120\">",
"      Habibi B. Drug induced red blood cell autoantibodies co-developed with drug specific antibodies causing haemolytic anaemias. Br J Haematol 1985; 61:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/22/23914/abstract/121\">",
"      Noronha V, Burtness B, Murren J, Duffy TP. Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature. Clin Colorectal Cancer 2005; 5:283.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7140 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.181.191-2D925142A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_22_23914=[""].join("\n");
var outline_f23_22_23914=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6778603\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANEMIA FROM DIRECT EFFECTS OF NEOPLASMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      External bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Impaired iron absorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Internal bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other causes of bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hemophagocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bone marrow replacement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ANEMIA FROM PRODUCTS OF NEOPLASMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Amyloid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hemolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Autoimmune hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Microangiopathic hemolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anemia of inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pure red cell aplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ANEMIA FROM EFFECTS OF CANCER TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Mechanisms of anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - General mechanisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Mechanisms specific to the cancer patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7140\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7140|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/45/22232\" title=\"picture 1\">",
"      Microcytic hypochromic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/37/43606\" title=\"picture 2A\">",
"      Tear drop cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/43/30390\" title=\"picture 2B\">",
"      Leukoerythroblastic blood smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/11/2228\" title=\"picture 3\">",
"      Metastatic cancer marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/1/27670\" title=\"picture 4\">",
"      Spherocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/50/38694\" title=\"picture 5\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/42/27304\" title=\"picture 6\">",
"      Giant proerythroblast in PRCA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=related_link\">",
"      Acquired inhibitors of coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17433?source=related_link\">",
"      Acquired pure red cell aplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38213?source=related_link\">",
"      Anemias due to decreased red cell production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8665?source=related_link\">",
"      Autoimmune complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=related_link\">",
"      Cancer-related fatigue: Prevalence, screening and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=related_link\">",
"      Cancer-related fatigue: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=related_link\">",
"      Classification and pathophysiology of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33672?source=related_link\">",
"      Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=related_link\">",
"      Clinical manifestations and diagnosis of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4249?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35126?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T-cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11336?source=related_link\">",
"      Evaluation of occult gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1609?source=related_link\">",
"      Kidney disease following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16422?source=related_link\">",
"      Paroxysmal cold hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=related_link\">",
"      Pathogenesis and etiology of disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30086?source=related_link\">",
"      Pathogenesis of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1224?source=related_link\">",
"      Pathogenesis of the hypercoagulable state associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/15/20721?source=related_link\">",
"      Patient information: Anemia of chronic disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=related_link\">",
"      Regulation of iron balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=related_link\">",
"      Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2793?source=related_link\">",
"      Treatment of large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19367?source=related_link\">",
"      Treatment of venous thromboembolism in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_22_23915="Treatment for moderate pediatric lead poisoning";
var content_f23_22_23915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patients (asymptomatic) with venous lead level 45 mcg/dL (2.17 micromol/L) to 69 mcg/dL (3.33 micromol/L)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Report to appropriate health authorities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Perform history, physical examination and laboratory examinations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Hospitalize patient.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. In cooperative patients, treat with DMSA (succimer). In other patients treat with CaNa",
"        <sub>",
"         2",
"        </sub>",
"        EDTA 1000-1500 mg/M2/day as a continuous infusion in 0.9 percent saline, daily for&nbsp;five days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. If day 21 lead level &gt;45 mcg/dL (2.17 micromol/L), may be retreated with succimer or CaNa",
"        <sub>",
"         2",
"        </sub>",
"        EDTA as above.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Provide parents with educational and nutritional counseling.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Do not discharge until environmental investigation is completed and recommendations on care at home are made. Patients must be discharged to a lead-safe environment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Monitor lead level every&nbsp;two weeks x 3, then repeat every&nbsp;one month x 3-4, then every&nbsp;three to four&nbsp;months for one year. Continue to check lead levels until &lt;30 mcg/dL.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_22_23915=[""].join("\n");
var outline_f23_22_23915=null;
var title_f23_22_23916="Classification prostatitis";
var content_f23_22_23916=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of prostatitis with prostatic localization studies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"25%\">",
"     </colgroup>",
"     <colgroup span=\"4\" width=\"12%\">",
"     </colgroup>",
"     <colgroup width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Mid-stream urine",
"        <br/>",
"        (VB2)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Expressed prostatic secretion",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Organism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        White cells",
"       </td>",
"       <td class=\"subtitle2\">",
"        Culture",
"       </td>",
"       <td class=\"subtitle2\">",
"        White cells",
"       </td>",
"       <td class=\"subtitle2\">",
"        Culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ABP",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td>",
"        Enterobacteriaciae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CBP",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td>",
"        Enterobacteriaciae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CP/CPPS, inflammatory",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CP/CPPS, noninflammatory",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asymptomatic inflammatory prostatitis*",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ABP: acute bacterial prostatitis; CBP: chronic bacterial prostatitis; CP/CPPS: chronic prostatitis/chronic pelvic pain syndrome; VB2: clean-catch mid-stream urine specimen.",
"     <br/>",
"     * Asymptomatic inflammatory prostatitis is generally detected incidentally, for example, on a biopsy performed for a different purpose.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Doble A. Br J Urol 1994; 74:537 and Krieger JN, et al. JAMA 1999; 282:236.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_22_23916=[""].join("\n");
var outline_f23_22_23916=null;
var title_f23_22_23917="Imaging guidelines from COG for Ewing family of tumors";
var content_f23_22_23917=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for imaging for Ewing sarcoma family of tumors from the Children's Oncology Group (all imaging studies are required unless otherwise noted)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        At presentation and prior to local control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Site",
"       </td>",
"       <td class=\"subtitle2_single\">",
"        Testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Primary and bone metastases",
"       </td>",
"       <td class=\"indent1\">",
"        AP and lateral radiographs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Primary tumor",
"       </td>",
"       <td class=\"indent1\">",
"        MRI with gadolinium (presurgery exam should be performed within four weeks of local control procedure)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bone metastases",
"       </td>",
"       <td class=\"indent1\">",
"        MRI with gadolinium or CT scan with contrast (recommended for possible bone metastases if diagnosis uncertain)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Chest",
"       </td>",
"       <td class=\"indent1\">",
"        CT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        AP and lateral radiographs (recommended at presentation only)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Whole body",
"       </td>",
"       <td class=\"indent1\">",
"        Technetium bone scintigraphy and/or FDG-PET (recommended at presentation, particularly if primary bone tumor negative on bone scintigraphy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Baseline after local treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Site",
"       </td>",
"       <td class=\"subtitle2_single\">",
"        Testing and timing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Primary and bone metastases",
"       </td>",
"       <td class=\"indent1\">",
"        AP and lateral radiographs within two weeks of surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Primary tumor",
"       </td>",
"       <td class=\"indent1\">",
"        MRI with gadolinium or CT scan with IV contrast (in patients without significant metallic artifact at primary tumor site) three to four months after local control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bone metastases",
"       </td>",
"       <td class=\"indent1\">",
"        MRI with gadolinium or CT scan with contrast (recommended for possible bone metastases if diagnosis uncertain)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Surveillance on chemotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Site",
"       </td>",
"       <td class=\"subtitle2_single\">",
"        Testing and timing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Primary and bone metastases",
"       </td>",
"       <td class=\"indent1\">",
"        AP and lateral radiographs after 10 cycles (approximately halfway through postoperative chemotherapy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MRI with gadolinium or CT scan with IV contrast recommended if symptoms or abnormal imaging (and surgical intervention or radiation therapy contemplated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chest",
"       </td>",
"       <td class=\"indent1\">",
"        CT after 10 cycles (approximately halfway through postoperative chemotherapy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Whole body",
"       </td>",
"       <td class=\"indent1\">",
"        Technetium bone scintigraphy (if disease positive on prior bone scintigraphy) or FDG-PET (if disease positive on prior FDG-PET and bone scan-negative) recommended",
"        <br/>",
"        <ul>",
"         <li>",
"          At end of cytotoxic chemotherapy",
"         </li>",
"         <li>",
"          Sooner if symptoms or abnormal imaging (and surgical or other intervention contemplated)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Surveillance postchemotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Site",
"       </td>",
"       <td class=\"subtitle2_single\">",
"        Testing and timing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Primary and bone metastases",
"       </td>",
"       <td class=\"indent1\">",
"        AP and lateral radiographs every three months x 8, then every six months x 6, then every 12 months x 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MRI with gadolinium or CT scan with IV contrast recommended if symptoms or abnormal imaging (and surgical or other intervention contemplated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Chest",
"       </td>",
"       <td class=\"indent1\">",
"        AP and lateral radiographs every three months x 8, then every six months x 6, then every 12 months x 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CT recommended if abnormal radiographs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Whole body",
"       </td>",
"       <td class=\"indent1\">",
"        Technetium bone scintigraphy (if positive on prior scans) or FDG-PET (if positive on prior scans and bone scan-negative) if symptoms or abnormal imaging AND surgical or other intervention contemplated",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AP: anterior-posterior; CT: computed tomography scan; FDG-PET: fluorodeoxyglucose positron emission tomography; MRI: magnetic resonance imaging.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Meter JS, Nadel HR, Marina N, et al. Pediatr Blood Cancer 2008; 51:63.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_22_23917=[""].join("\n");
var outline_f23_22_23917=null;
var title_f23_22_23918="Cerebral autoregulation";
var content_f23_22_23918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F66923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F66923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Normal cerebral autoregulation and its disturbance during acute ischemic stroke",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 400px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Mounzer Kassab.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_22_23918=[""].join("\n");
var outline_f23_22_23918=null;
var title_f23_22_23919="Variation in causes of maternal mortality worldwide";
var content_f23_22_23919=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F86824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F86824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Variation in causes of maternal mortality worldwide",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 549px; background-image: url(data:image/gif;base64,R0lGODlhOgIlAsQAAP///wAAAFe23QCZZv8AAP+ZM93d3SIiIu7u7pmZmWZmZoiIiBEREURERDMzM7u7u8zMzFVVVXd3d6qqqn9/fwQICgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAA6AiUCAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOknQGnqKmqq6ytrq+wsbKztLW2t7i2pbuAAbxmvr/CecHDYcXGyXHIylzMzdBpz9FX09TXx9ha1trd2ySwLQmnCSQNDd4x3OnsU8gBBfHy8tMNAQ8jDOXtNev8/0zezRv4zEAABxJEIAhgAOAMfw4jFhE4kJ6JBQ0mMBBh75RBCAcOKFAAAEFHdB0D/+xrB1GiSyAUKxZ45mABAAYTABhsaFABAgAjAZzT6YBEgo38Wr5cuiNmRWYQAvxUEEEnQ6sNgZK8R2KBA1T/lDIda8MpwRISUjFAsBOriKBcRUS1+UBsMrtk88IwO4/ZgZV/27bVKhSdAQcaGyrAO4yx3scq+Foc8WDtCAkNBF8lfPgUSs+Of4WGTBocOJnxRkNWXZr0u1etZbCOrXc27RO2bzPNrXsE794Sf/cWDhwg8dvHi7NUniM5c2/OW0d/jm26a+rKra/GXlz7Y+/c74Z/OF73a1cyFoAftb48r3cD4suXXy8u8PbuS8GfP7/gwYTd5RfbfvzF9wxGGinUkf8DCCRwAAB1ncLgbgJKB06B9JlQ0005LfCgSQY4WMIBNi2FX4WhEFggVFIBVVVdI/0kogGLnVLiSyei+ImK/DGTFiqWITBSABCIGIEDDTVwo0s56mjKhRgO4BdgCShgEwI4iYgQACAtGZyT30GJITKV/SQCZg6eUpWIlR1EIoVg5sVjf/k1GWcm57VS551k2fkln3AC6pugJhI6qKF/GuonopAs6pCjjDYCaViRPsropJUmgulymSZ1aaee+gZbDUMhURc+QWCUgohBnDqYCK82ByqnIgRAwK244sqMqir8JYM9qG7B6whBAcDqCzUGEAEELsQaKw6bzjrIO7lWuyv/Or2u1Ox/XQz7FknGPvhCA0jqFIG2Kji7mQ7RShsItdXqWoK36p1CUr0BLBCUAg4cEMABWXWVEVIGfRUAv6eg+qMDzP4VAUNXHRUAAw9EeJCZov7L7FEGo/rwxNiKYHEDHCd8poTMUrauyKhMOJJ64xhQsI1WGVziwsymVI5BHXnZrrt/wBsvAdee8BEAvhLGb8MAkrAhTlYlpJ5N/ALAK2ZIN8DsTqdaveSbJ1BlrD5AFeVhQ1iTUOxR5VR9dchWF5XCm/zuzJBBNk1wd74A6G3A20ZtZFBC42AMwM9A9yF0vEVTlhI+Se8LbrEjRDVVVW3VJYKIKf2L9D47eUsj/ypeSsCAZ+Fu/qCSInhLWOqpdy5u63KTMDrNxe40WGCb/SV73GBpFvDhiWuzuLXzws1AVYdDvo/k36KlFltXaR570yIkHTrcRya5pIf4qMoq5yW6vra4nGNPQl3DA9C9UFSDq/tmOA2GUwPYzwWhL8KbVvw1x8tV40oSgJyMAx8bUtrkwDWCpH0uc8EQ0QIYsDGSaI8hXVuAVxLSJRJIoCgIcAA6xvegDyIghHADQNpIaDUKGouBInAAw8yVgC11MHd729hajnYUBEywgokBCv+uEivE/Y8Y4BjarXaVCiWBBh/jyBf0Xicyy5wpM9WLoLhqxACbXLAh9aJYm/q1pP/OMECEsBNRCCWUQgicjmTo2+IpulgCIaFiWWOkm/z2djqKWaWPqOKiTU4yRJ6sDFINmN1JjmiHAMrLPY4ynbg8dEKwMVIOeWLFnp7gIQ+JIALlY94ll/EpJ1QmROJKWg1HiclSMsEAfmSVKmuXMVWwcgxGrI4pV2EAUJ5JlJG5pRhyCUApsIqSCLBkMIUJBmJSA1LHWmQLnMnMQylKGtX8AjWhsc1lZtMZrgTGN7vQTWWUEwXnvGUmVxEEytmAdUdQTyOxOc4tvEMA+MxnPpl4CmXKwJ2k8pIOjsWHdJrAoKO8pz712TgHqQ8GAKUBPHtA0D0g1H/1zIJCF4rPAbb/RWL6OJr7SALStpGkMwfLnjRLSpQ5egkCNrNaPzcWx7F17HCo+EhIWIUzFc6Unme4KCM3ytEBfu4BAOvbWiJAkoVAAKkN0YiQSDIUWJbjAIbRB1SVahJsJVAhdHyAAromgQexkG1lg11PZPSgt0UFbegig1BrldFv+Iaj+0weCf6CL49I1SsyTQWNtqKwqkTOSqowCKomuj+BKYRIZ60pqwbDuVQcAEsNUEDK0DBX4tUVC0RdqEcZAtgROagcpSUWYX/5uU9KILW1WuySrNc6bDk1sqpT62bSdxEF0JGzQP1sFULLUL2GKyF1KQdMW8cAyySXS0UJylDceFWbuLFi/yqBLgAcQJIOjgBLdBkrVxTwoMSYxKw1lapbUvfDFyYgAj/BX3DL0NniETevXQHSjSZoL1gFoGn8TWlQUAquA5yOby3sL0j+5U+k0qxeB0jZSdCb2zVCLCusEiRMJdQ+uc5XuFK4b0eX4MBmdLa+iVunLZVQYnN+GMRQQLEoTgzj4YaTvjWmgoxT9OIcB+TGHvZxFHYMChoLOca5SLKSl8zkJjv5ybfoMRvCceRIPcBg5bJYAFKITjoEAK8jrjKjFpCQECIXL0Q+KJgFkGYxh8IAB8gJbV3QZnCsuc5u7oS/mGexcrEAz7W6c54jFcIlhRCYtdLkHL4MZkAPehOuc/9dlxct6EcDypdwpppNDiNQ3Hi50pa+U4CZJzFl0fnTjQ41Mx3NaLw6WtXioXSqYc1KVoOa1kNFtatxnVBdF5XXl7T1rIH9P2Hvmth+oLIjjP1rZCsONTNplK9F6+xno+bVTZl2cattUWhjm13axi+3ieFtacv62OPGAzyubW5M3jrddVi3TL4tq3M3G96NLPcjmE1tfOeb3fsOd5j97WV9L1vgbCZ4vA0uKYTTG97yfkq7l/Fuhb8h4mcJuL37bfFlMJwR/N52x+GA8b5MnOQVH/kaSj6Zg29c5CpvA8tTc/KLpzzmnP34IkIubpyvXOeK4PnAfa6GmUdb4+4eNtH/pQF0TTl86T8HuMuTjm6oB7XpbrgyhzmCumk+3eo5v/ao1EDmkmwJmf6cNNXvDXb6ejtKUnoDnHPiS6shWu0UV3rbcfn2KBF5z9nbxyr//PW9y7XvY3pDoVtrLFommp0v77nhj4H4FcFBVXWXwN09HfmhT76Zle8RGzD9JrR3+qCF/zzorw13GY96BNIkfOcTrnrKs97vhhA67WuvzdDTqRC6f3i6jR6A1uc+9bx3hu8zBHzkJ38byzfQ8Wcv/HET3/jNp/7zvXB93Gd/7RzfPvRvn/jv573q4gdt9ONufpTrPf1W6H75CRF8+I9/3tinv/Pt7471V38F9cd/1eB//9MHfjAngP1HfpbXfjb3fggYYwTIgG7Qamz3gEMWgfqnfRaYgPjnfRlogJK3gU4gfwv4gedXgSLYBCQoehIoczeXgkmwgr9ngu6HfjC4BDLIfDTYgDZ4gzGIgdOyfz54BDkofS04ZS84hERQhOy3gxOYhEooBEz4f950guEXhUQIhIIQgFiIBFNYgFZ4gF24hFr4LkI4hjBRhr1whmjoA1+4BmmyZT+hZVzGeSDoeW0IDmP3Am+oBlaiE2GFZmyIhraiRIzRh21AMo21F4M4hoU4NIeohmgAASXSZx1mh2EYgnlYK0pENLIhiWZAIyZwaAelaHe4e5uYRIb4iQrIgv9r8AB1aDWxWAJcmIq+0YmR2IozmAaUpDab9lVVWIMomIqPyDis2IHzlwa/U2qbh4nCeIW2WIzIow6gqDiN2IXSKEDH+BT5F4QaaIu3uIrUqIs66I2nSIXjlI2PtBfVWFDXiIXquETbSBDduIXvGIXx6InjiIwlaI6ZiIfEiIvz2Bf1aIbfCI6HI5D7yI0e6I/PKIYBKY7sSI5G6IQu6ICbmI+5yI+u6JA8OIwZqZATyZG7aI8HCY4aOZD0UJBreJLRKJJ82I4WdY9KmJILSY8NaZLniJDhCIkqmRos2QT6chkPNRE0OYQ2OZIMmYxPgAAmdEJVowS1iJIwSWcyaQT/erMKsyiFR+mDSRmTFNmET5CVlrVZXtiVN/iVVhmWk+JDPnFCKoiWMKiW03SVSXBCcImDcpmCdPlndmkEC4YKRbmEeymCfQmAf1kEnfNfeumSEemTN0mQOfkEiWQAePljjhmSEgmWJFmOUDABl3WZjbmTPJmQm7mWnVmRUfAjgjma/4iKVHmadcmWVMCapzCYQzCVLymbfkmbVICXeSmVhbmBhxkZiVkECUAuMBVXRpmZeVicKYCIUBBFUtEAzZibw2mB0IlOxzkEMqQeTul4LBCHDWAmsQeA2fmA24kb/reHRoAQeoMARxIDfwhLNmF6XuecbbieB+V/VVkEvmUP/w9zei2giHW3ANeJUa+Jjt/En7Ton7w5BBZ2MTRAiYG3OeLpjEPmnnQGhY74n72ZmlICokTgQ69lODAgihfaeKUIeTqGdZHhodhIosbJljQaBAgwAQ2RoyjaArBIApmXoNbEgRInGzIKjzfKnTYaoUKwGPiAJTDUAr04Avgpey8qdXtxpPiYpOy5pJCJBDI0AmEKA78jFF1npUSaceqgpTXJpf3ppcaYBP3SQBlKmMMFo9HJpkjppg8Kp9OIBOqBP/ZAoFx5p1jKh3rqlXx6Gn6qjXdpMBQqnIY6bw+RqGm5qL4BoV96BAYwAWS2AD1qBNFCfJWKkc+JqbWiqXEKqP8tMoLxh6foZKlziaqHo6p/yqkMYJnBGYOveqgdaqr7SatTSKs4YJuMKalXSqlGCqyEKKy26qhIYKy4WajJWqRryqwfyqTR+azriATAGarNWa1qmqXYOqPaqqQi6qAUpZwOwJx2Kq4mt6w9qJmbippLuSLEegPUaRJCChO9qqzXOq+neq5dmq75agPfKRUf5JohBqu4Iat86ayN2q3vKQHxOZ/ImqbxGrAgObD1OpsGS7A+EKDKgmC8OqnWSq4CG6wi26ch+7ElCqkTkrEN66vTBLGGKbEvu6re+qng+q4a23Iq27EsC7OIObHyOJMoO66IWq5I2rKMurO3WgQmapb/DHuBNvtnOEucOnuvPXKwM4AlqOCuovqvKdu0K9usUJupSKuPRqAeTHVGrrq0Gzu00PiYPGuvODkmYCsDaaEYrXq1EJi1ALi12tm1e4uva1usUuGUjYuZ8Cq0aEu0amu0NSq10FoExnqbgvsEpCqvlJutlrutbbsem3usJxu5NAe6d0uveQuyXtsffSsD37qrZ0m3kvuraSu6rxuisUsfsxtkqnt0HNu6Htu7R4u5FHsHo+qwaua0W2qIHJqqpeuOuLu6xQuRrmstNzesi7tyZsu0uhu6Kji9j6aR3cutSasHzUu4MQq9Uum8Qoa+GOm9o6sFabM/qLCVQ1qzAGu3/9qLtf+ravQ7r/aLvFpgEFumMuoQvnU7ucY7uAMcagUMkgc8tV8wLHOWn8PrGBQYwZ4rvz5Wwa17wZkLBhrcMpeIetdLvACsif57thSMi+lbvWMgaaRIi6YYtNj7wgAZw+JraSSsvSa8vF4gabLIwTzswhAcwBIsw0JMw/Wrvm4bBsNSn8AYnQ6cuzcLvz/ovttgvrUhxQZMxeekwDTDjKfWwh5suEHwucPkxtBBxhZsxtbbwaW6uyoowjomx90wxDBcxOuLRGycx+QbEHzsDn5sPHRcwnastHjMuk4cwmCsUYtcHY1MxI/MvlucGmL8wZM8gokcYpcMQJkcyJtMyP8dHJSHU8pNMcpD5srRAMg/LMhVrG6dPBOsDMowLMBQTE6yzE2nXMupjMtsvMvBDC2wHGPJbE7DDJtsq7yDbMyrPJl35cVeuMye28x38czWYMv/177pmqfYnIWVDFrcHINiPIHejK6/ayC4uM7AdczWHGjlLKraPILp7IXBy33tXLDvPKKGuM+Qu8TFV8+tfM8Tkc8qSNCi2s/k9M9vKs1E49A068uJ25G0aNFKGcTArNCgBdHOINEuG9C0DM1TlssHzZR2BtK5ydABwdG5KdL2RNJRa9I2LXMqjczYrGzNAdM4KNNSSNPbkNPUS9G8/MNFt9MIndQoDYCs/BBALZX/Qv3GRK1RRl2rpVvV4WrQPK3HtBjVP8nE2sTVP6CunJXV4GzW2EnPLH3NYC0m/ajM51wNbN0DaB1Uam3Gd/3GTP3W9hzXviHWkcnFHy3YEf299LXXW+3S9vTXc93SiH04hN3RD1zWjj1cVx3SAz3FjT3ZzQTZGi3ZhyzXo10WUx2Dfd0Um92iejIRjI3Uq33Wol2SpA3CuFHZnPnLzjDbzdHatAjcqgiJNSzbma1RzSHPAJ3Rtg3XpT3YCC3VdR1/vg0twt2TCIzXsY3TnQ3a2vTb3yudtx3KB6XbetsXyq3Px+0O182Jiv0Q283cwNvdzz1M4H2/yy2ZgJ3Qk73S/5GN2r6JzusdYu1tmvjNLvGt34pL3AMef/ed3e4s36q50T1t3rAr4WJJ3Q0eYwWe1/2Q4Cvpd1m91NYd3qDo1Ido4b6L4UaE4jLX4TBO34782fWdDSV+4CXN4uTc3yqevCa9DdV9Ax5OA0MO3zKuyTSO2+J04xCe3yG+3y6uDj1+uT9uyRvuuTGO40zOvZ5t3N7NfQ+OwSuu4Kcd2DXu32VO5N3phUFeFlne5Ah+5Kic5OTdBPlrpgusxB9u4gH+vDwe3WON5s2tyFc+gm8u5mcN4kAp4nKu1E+gwCFTpei55Sd84WQ+6Px95lNOuuNs5V/O2Vou5IcuQMXN3Qz+6f9EMCwH2q+eJep83ukPW+GAXtiLvt+xXOgqOOpGnOiN/tRrjes5MCyzpOdEjriX7pnj3cvRuekRfuwTPlxtvueh7ubvLRuKrsuMfuo1DqghM+w67KLUPu1aDet+rumzbtlP/t+Ejurxp+vTbNW9/s18Dew4oOo3w+q24eHi7dxKHtbnvts67unbXtTVrg7uXtFdbuqME+1J3DqhmXYaauTivu9m3u+mjenSTe4azu6aXfB7cfBRPtEKz+Uc/wNojGDnGYzF/upVHut/buuBzuwTwfASD+dhXukwce2CPt/abvG4dPO7TuUB7/LmDvO0ju1Gr94lr86uAPIPHe/Nnu7/Xwv1pETpQc/pLV/uPl8rMi/yQ2/X9A4Tref0sE31Xu/sAt3zdS684W7zN/31FP7y6q7mfb7xA++5Y+/xfCisuaDzea/2yj7Prj7xJ56oO//sAK7x0B72Z/33bj/4j3/UI0/qCc/iIy5lH8/ycJ/sjo5OXZ/jaN/iNO/52R750m76v17GdB74QQX07z7mUo/pIc+Hn//2oQ/kjO+Gjo/obmjssc/zC1/5oX/5gt/2vI/1m8/vaw/dSQ/wty/wWx9iu4/zvE74q0/M1//UJA75xx/1tT73s09ntR/NWW/30T9k03/1PKDv8676Xn735OT6t2zpv4/4Fb/8XP/v513//xkOAoA4kqV5oikaCK3rBqo80/UZDLmuB4T//2K2oakHBAqHgQKz2cTtdsajj/V6JUtLpxMazU2p1msrSzyj0yRzOnxkz7ZcpvcLF43Jd1U9ukfLzfVJqRXa5F39GS7yffFQBTHSuCEFWF5irsw9OYJBVpHBaG4WDD5+ImJJrrICKNZQRhIFcpmCpaSKznYOvCqRlvL6tiqFlhEjFwl/EgwvxoIa39F2LaMaC0wD2/Yy5x4nhysxQjefUXN27n1nnwuzotO9ixuyO9Pvqnvj43lja5PiVs7eqE0C/Unjp/AGuX2zts278c+dOngQKy48NzGjpIOoFA7cWOSio5AJb/+QtIMw1D2O5Bp+fBgwYhGRh2g+S+kHE8+WyAi6fGYNks82K/UUFDRUjM01OqUcTRR0YdEiDn/NxCjxpBKc9Z6eIjp1TdOx+UpepWeSZdJaS9+UxQPW0zWuZsNV1ZIW1txeuOLKEGgxK9qYZoHepVhYLL+1SFESVlmXLWSDb5EATtwRJmOslrXWtAvLa6F4wfQZHotY803UndVGVVVZqWumokeY9kg0M+t6nMWc67uO9wrSanJflnWYeG8tyauAjK1rZGQ/0sFR/7zYNuXm8H6/CV6d0ArmykDnHB8W+N3V3hvVDt/4ervZbuNjvi1XPd3d+t8fBx4S4mlnx1//wVf/0mAFWpfaVO4BeMNz5sw32WPZ0bYdXP8hh18Q5kU4iYDKHSLcgd21puAqHWo4YHsgeqcbe/g4JpV91XgYDYpO8deNhTaG6Nsze00iXE+YwIibcW0IR6RLEAapZI4U0kgfQAxC9aNsGN7X4ocIRgnLiNDJhOV6G+44yZKANOlgUFCGKaN8VWo5nRZt+pfmfmb2x92FYQIyJpUl9ljjlikauCKeM6qWZG9yukhnnn/yyKePkwJ5Z6FWAhrgkG7GsSialKqJ3lebgsoRnFFCSqI4htpZaYaSYXqorF3S6memnY4Dy5GXOBmYqPnpGdiaBM7a4GsPOspaq2RKqqutuA37/2WxLOY66q68ijnalD5hq6y0sZaqYkfVQtsomCE+O+irnN6Yjpc6krpnslnWSi63cSAq7pyEWgordv2Sdy6qy77ZrGbt5jULvFziOG8zgIWL77gD7yuitxKDi+7E60poamkeN9yRwokxHF2dGFN78MX1QSxvtsTWG+EDmDSgcbkzu1qky9pOG8exZd57ZqTqFsvqhCVr8aslD2saMNS3RswzvduGePMsBBvdc6g/04y1sSIfRzLKJ7e3NDxLU0xy22BbWzOAWve6s79H8wX31UGPbS45Zr8IMoApr8g2h24frvfHSb93syUOGKAzHk4T7lnRfQKtb9+JGix1qhmtGv9k5eQYfi3ipiseeoQIOBBBEUdGffmljObteb4sC002k6mfLfh7owv17du2v3yl7ALDzO0COfNLtcx3ey1s6s0KpijvgTPOrtqFC5848Znj7srpcr+nwAIAGODA+c23/D3ePrsft9gJcv739cv5/gzlilntbj2l16xiXdub5gSIubDxDUAJYIAlXCc58aVuf/GSR/eyFzK/pSd+6WJW/upBve11BIBiM+DswJc851GQY2gDlBlIiDzj4Qp6BAwf/fywoOMFC3QrLEYH8QBC0lUwgOMb4RATmDGGoPA0KvQeDld2QrsVzH4a9N+TdniID35rbUEk4vSYGEOLmZBpoov/3RcHuDghdtGC58HgqaYoRg/28DgUo9wPg7dE1LlxeE283ROPiAsyVk2GZ+RiHuNYvc7tkXYJi2Mb9FjGA0avDSLkmwun1r5EhtGP3brkI0uIwAIWUXM1jGIGMfm+KjISEI4MJBhPGRg6bpGSoQxfJZ34xgi1cJZ9hGAh1egc3bHpfkgjHzxW+bxWRhIXuoQhK80Ip1ry8ZaDA+QxnWnMFPbvmbBk48iEyUFfPuOaSswmsjr5wrY0E5Iz3CU0i6fJB7YzkxMcpyCfaSLrubF34IQjHk2ZTHRWU52DlGUa0dhLYr7TFdTEZj3FyTCHDs1y5swhVawIC4hmkWgTtSVA/xmKzHUyM6CelJ8RE6rQJD7Ui+kcKUg7Sk9SttGfG1zkPkuDUY6Vc6XnnGdK+7nRaJqUDwt9qTVVKtKdxsyjPLjhTxWJyprK0ahKFWjHCkpImQ4UlFYtaUJzuVWtHvSq5mSqTikKEotO4qbk1GhZOcrTSYIVq6rr6lB7alC5qtWG+JSrPhFqMqkSlao5Paol7dVUeSY1sCzNKg2D6tWwEhSycR3rXg/rSh2mUiOABR788LpZuNJymUH9I0pBy07RvhWYg53qYqXZyMzOIq8fpaL0JBvar97Wtrsc7WM969O2AjW13CybN2nqV3LI1pmrVSxS62rakLK2uaNdg3NjOf9Z4LpTuPUrpWX/2Ri0xiG5gmUrYd2aWLuKFbuInS51S2vd3Pr2rpRFZHerIEEagTcw4m3tctEb2fimt7zBZW97OaneT8K3vow9baHIKuDsvs5pqoQtD3/74H/VDsD/VbA9cbtbx1b3jvI9MEmve1QHR7ewvBTEhKH6Wgun+HPK9DB0mavieCL4wybtLYf3K10Dn7iyJG4pT1t83HB+NqMSHfKCa+xfE8d4wATGQ4iz6eMb35O+TO6wQYw8v1Zwma/kjTKEq9zQJIv4yzs282zD3GM0bzemb4ZxKbzM1b/SmbNf062Tn+vSJzd2ze5N84a37GMU29i8dbWzKMF8ZRn//9nP2j1zniU9ZSoP2spwpvSIg6zlC+fYyYwO9IoejbA9axjKiZZypjmtZrq2us2mLnOslypkUJc4wV0YtY5Lvek299fSbC5qpd/b63fy2NC/Jnano4toQDO4y5p1Ma/7rGSApVrXuCbyeYU95WRvu8mRNra1h7s7Pv+52mdd9niXHG43K7vYhG60oIFM5vXWmqqHvvW9Q53uaR+Zn81etVNrm+1oH7zcmqb2VBpgCeaxz7DxHji0Fa7XT/c71wivBS4ol18+zBrDnZ0zxb1tb4LjO0gLOAACEHCA9QVm2Ppmd2v3jXGU+5unlLvxfSP8q5BfdsbonrSsaf7jEEVg/30LcGDM811zo2O5wfzGucYtXvQ84yLq+Rwz1bkt86fLe+EBv8sBEiCCBDgAnqjtNrnHbe5gDp3t89Y2HbKuaKcPJNhtJzqzA5xxr0ep7GdPe9MoZ/jDIz7xil884xvv+MdDPvKSnzzlK295S1Tg8prfPOc7r3gKvCfpIpAA02mEstO3B/WHUf2DFsb6S6+85S+nyuvfVPsn3V5Vqc896C5dAocHAOKN4T3td79646sG+clXvu9tz3zcP1/30e/98adf/OYvv/rZ337rrQ8S738f/Nh/FfHDr/3un9/53Ef/+sd//fZLP/3Ql3/82Q9/6rs///rfP//77///A2AACv/gABJgARrgASJgAirgAjJgAzrgA0JgBErgBFJgBVrgBWJgBmrgBnJgB3rgBw4BApBAy4FgCZrgCaKBCKJPAqigOCiA2YnAAhCeCRhADRpAC7KXCk7AA6SADe4fBCTGAsDcWNhgDQaFChoAC04FAkQOAOCgBiIAA9QgAxzADCaDAZiPDUrAAdCgA2ACF9IDBCjAGI7hExKDBCgAACgAAzAADI4AAqzcJRyAAjRhOIghGSqAGeJDFSrhVKDhXUQAT9ShQkThFFZhUCwAAyUABDCAHlpgArjO8gBAA0xAOCRAT7ShCUhAA0CADTriKkRhICpAA7AcPRwABEThAzyAFT7/AAOoTycmYQMwwBC2AiNGAB5+YjjA4QHM4iAuBAScoidyxAQwwAMUoUtAIgBIIiVyBCNOgOAJHgcmYwNIgBq6ITIYgAQkgDBqYhouRAIcgAEEwA2GoylCQCsyIRiKgANc4wgAoy+uAjj2BjgygALwYEYoAE9440I8411MYzW+IEfIIzS2Iwa63Bo+QCrSwwPA3ALcowgw4QMEYw3mIiMMpNlFYzgsTwPkjCSOADx+pC5KYWLAoQPU4xrSIj0wYRFWJDIcwAQcI0ccZDEqZEagY9kZAAMAYQeKodlNQDXSQwM0pPAdwJGoYzIwIgIowAFEwEjSwwJIQORIwEOaxRoe/8BVliJHJOLLIWElcsQDJABVLoQ4CqJL9CQA/GRQRIBJymLpcWARgmQrZKQ8vmENwiJF4kMTLoAC7KRKsuQI0qEILOU+hkMrLkACIGZBNgbMRaVLpA8VumJcigNcSqYuZqVZTMAYeqUHBiImVCYjNMA+jqIJJMA+JmU4RA5l4kMrYgJh0uXKQaJbEkM/mkVNTmJK4oMCRIAIIkBoHiFitiQyFCIK3gUxGqMPhiEDhKYs9qUIGMBe2uAEjOMVBoDjeCY9OAAdcqNgOpADVONpisNLxmRGiGMdjqFLzOVRKsRW8iJu4kMERCVyZoTLYeVVNoBYXiBtkudeLoAvkiUmMP8AUF4h+sAlPrBjCpxnFJpdeU5mT3wmMSjoCKiPS1DjCIwmeTKAVxLjg7bCf14Ch7JCTiZmBFBjI2bgSoqnfNLDDTohDSZAfLIoPtwhGQZnISRAA/zlCMggANxM5BBjjaqBarpEIt6iA1zmLyrnKOqkQB5lRo7lXTanQtAlACSlk1ZgPh4JiAapw3EhfCaGLeIiPWDpJRAmABhpPYoAR+IDEvahSzwAGi4AkNbiAgRAf7qpU+YkfuJDIgbAIpqoTTolBIyjlVLgSt6lEdJDBCQdF67cCZQmGbpnPKrnmsKlGSbAZi6iSkphTh7iEY4noF5lZLpEU44hA8imjGYoQY7/6kmaqstpKQMaQJNuZjKUnTxO6QgQoywqQOto6qtKAljqKY9GQBVGKisk4zLO6noy0CUoJnYCJQKQaFBkpgIkq5Ryoaoio2Z6IAK8o11mojgIpTzqpgnopjyuYm5SIVbKKRo8Ji9CTgks0Asuz6m2wj9ao0y24acuxIGe3aROJoHqKz/c5DYuaTPiYR5yYFHyRAOs6xkwIlsWLAmMYXkyaGHOYmI2KyvoJm/65ht+6zoWKyPMZEIWI776aog+J47W4F6OZXU66KhCLL2KQygGwCgeqUFCgMoi6lMKYRaewI46AEdaITLop0KkJwn8KAnsaBgGZFq6hALA6MkWgoe2/yZ5UmmBSqu2ImM4jqOrEic9/KEMiGA2NqYpwqSKJkOFCqbw3SoAtG2HAizaGi1PZCw2UmaMjqWs+t9FAgChYuCMlmEYTiTelgATOmHDEgHVTqc4MOJyRqzbhmMRNip1WueHusRKyq37cWvkGgAj1m0rrFx9qmszNuJSNqXUKiDN2iziDsGYWkKZCiYDPefQ2m3AYiN/+uIl9oS/rkJqYu3/7SUZfq5c9gTD/mICJGJixp5jxiBfeiA4lqfXzmylmsDK9aigom4INiHr1kDLYS5eksDdcu8MfK/t5iUakmGU8sMWOkB2zuJ85qz50sOtHkCwrqj8ViDf+q0keC/1lv/AxI5jxWqkIoInMpChPlblr2SvGgRtkpYsR7zcebLsfN7sVzplhHJEZ1ouByal6TqlAY8hApfA8pTn29ZiqmLk8KpB/9ogKiKt8KElDLMC5kIAYnaiYwYAMJpdA6iwXCImF5rwzH7wVJDqrlYwPRgn/lbgDT6n8+piy/nvCB6AwzVlyC6C/vawGgRkDFrhAonuVe5pur4vR5TneZ5nBkelqc7hqEbtVExrnLpE0YIgn/rp+ILiXk7lajYiTj4uMWBhf9bgFpIAOGLsi/Ju72aoCGwoek5AvH7sQpCgGFqxH78sBdvxCtdgiu7sBjojtkLoF1/lEJLiF8swMaylcpr/qjjoLoBeowEk63POb5NmMSie3RaPpfg65u9C8hDjowJ3IBZb4o1GQGJOKK6+KDsipqLyw7RWqx9r43aewJt2qsU2YZ56auai5q/ALj8gAHAScRtD8t0uMAIObE6qrw/rqAyfMZX+6WQqMSMwpI7iJwTIYAA4wARc8gwUcSoP6bJawiwvgjjnMxGw5xiTZyVD8hFz4Cm3JT6orTJOqkfy6OKGgwZbwjjPgFCmMwlAAFsGLz9qLb5uIzaPX05qKC/zQ+faMEafwXCeIDMLbJJWMQ1WYanKrCQkMUmvwtGOwCXaoxpuM1J68+WidP/RL0AzQkFPsimD89dOJh4HKxyG/3Q4yLFDiyYMT0BT1rRCaHV7BgXUvvOltWI1P/BYJjJaFnWDlqUGhu4XD7QKfO9bF4Ims7QMNK6SnnM3y2IxU7VTGid60u3/7fNNJ8NR53JYP2ANJy9iLq84sCaZJobi1rUKNPECnPMITjBVy/Ll6nL/0WkANLMek7X9JoPLybUB0i9pM0J25uhdCOlkcikAeGlPX3Zpd64ml+P+0ecXLzUrdLVBZ8RgE/VkH+BYQ+QjIwO/nsAE1PYvvueiQjQJOJz6nDYKuO51csQoYyVf4wNiNsAwIyZ3L7Nfl3VGwLRaNvVCn6SRVje86izhvtwE9DYr0LNJtjcJ1CoQq2d9K/9nmwqnOAfFyzH2y5210bqhRCtE0e7vzDqnfyuEZH/gG9+3xIrwOkoAdEKzcC5PAMzihI9AuHLhuEbzFppqaE+XAL/kOvPDQ08uN9/22cYqcdNAIXIq7aZ0DS+ijDt14UYxj/qzHOriXgvhIZ8wxDY3WjalgCID4CLsfBZ42am4HofmTCvEdW/wN0ZizjCjVorxfO+4DbBwhndz1E64ON5zNxO5JGwj+uBuCRBuXdqhqYYplxcpy/EwGeOxif/33SKj61SoLT/4WS/yl2tsCFftCdQwPi8kiRvpiubwAph4rsKxtWrGA4SmZQeFAcT2bI/FkQvnHNJkefODYRM6KEL/cWuTwG+r9q9qtZK3QhRmJiCDrzuuXIl7+HHrOBGsYs32rZ4ng6I2aos3owy28y82ravH9GiX+tY2oQTYeGln9YTzaYWXgDQHKLrW562fQASn4S2i5w9DrkxueIeTcdxu8kII9wa2tehq+wysswAHFQI8c4ZjNhg79sUmJg5jYRpG+YofZogT9gwLubA/uMuu9TBOdQYqdhsOeLvLgEQvkMPPJ6pD5PK4op2KQ1Xj6wOcp3jzw8Oisqf3rj3jcxCvqLnn+rIPcpOu+prWNJWz12O/bvi2ushLAl0joiu2r0KvaJvbJKOn+fgxucRjn3E7IXIvIVRfGmtD80+2fIgi//TPmw/Rv+EIUr0IPECrZ8S6Zzvp3iKNcuZ687wh7LboevloKbcJTABWl3KHdrZCbPlY2PLSHmG0H+9iI+/YI4PJc+DaT70qCzMxn31Q3Siqe/EX6yLCYrpSXn3aO2YWBnLQT1lqm+wJ0nEB0+qBt/34Xbdr1mpiCjJ1Ro7gwft6vrdAYiJSm5TRYzA+putVXv2ldXIKB6WAErxzYr2v+1H54qAru7nuB+l0kj5FL4TCMisZq48NOqRgiz3VGybGPu+10v69TzlwK3LaeXFQfyCDDn/Kw/Xb+/tG/5+Ex7HkW2A59/HtQq2ems9tmvZ0CeEID2ESFvKlZnMnvlznEv8/JNswCADiSJbmiaJHMiZHCsfyTNf2jZfHZPRGDgwKh7iIg9FgRIgzhM+AMCkWCMYEcPgxt0MF4wAGMxSkSTgQbnBNhoD77dauZYvvQTmnNcgihToPGCgo0wYXIDeYqFgzoaBwpfjAAMdH8nAQwYAgGbW46JcQGrp30oYo+PTkSVIFaXCwsDoCgeTHACGbq3tjAOGDuxuMCpB6Cuig8NRZkqCAuxArnAcBPFtNYiqdWyXnuGuwMGWsLesksixbF5BAi07+jtP2YHiY6MAiY47gDr+Y3a9IXI8GC6CUS8UPoCB17DTlomWGxQqFFGVAiFVMUYIGyk54ObTAQcVEPSD/BPBlcOSaA/QCVPpk6KXKORAnTpTlAotEfDN7KoiA4M8qBTFNLDgwr1e9nmsStHzBlIiTYgkFTR3IM+qWnDazLuK0wsAtrSolNICQRVWiqz34OTL1jyyRYinl2kWRQOTdIWATiL3myQgSPHsBGnDQclyuBRwP5SwMObLUJwr0Si5yJMmSXY0eXe4HgaPaROEcKfAKAMGBBgEyRfsMOzYKom8YPJBtozMk3Lxp/MiYSMIBB8gYvGYVTsLt3syJLNgtQfEgtlWbz5ImKjtq64Hk0ZO+BZa3cKVEPNjNvTyA8+lT2x5BUBe09jDaNEC/SrWYMAeq02fyWyqKrJDTY2WI/5TAFzLRNwGCCqYXlze5SLDgf7MIB4t/g9xkoSKdGJCAhkxEEJ0SByw4BQAEqSYibymu2B93VfDkwHGeoIVSXR2KYIZDunC4YyDciDWch1FAkKIUVFiBBXjMTdFKk+nVEUFlMeZC2xsVtodASGMEA2SQeSSwBGMq4rfLJZls4qOFamrCSXsPUEjFLmxB0CJuCGRSY55r+ACLD2KOuUQDEgBw2jvNPGPjf4sCMN+gsiQqQkg77rmcLoV8JykXqnnxQBWZSoPQoPr4WVgUbDkJiAECGSBchwGO5gldrHZqA5IsTHDoWqzw4xQcUO34ETiWMbcCS3BsJ0iwcDDALHPeGf9yK65afRhiQDxZyoYPFAZ5VFImVZtqahCE4oumEvjV1o6zCmrtZ0N+cWyrr8ZaX5v/vXVIXM3VIcZmunQywagWYotqvCqRCaka9zVLD7Sl+JBgwp8xZoqBzUVJDCy6fOuFxB3OW6TCkjFsKKLRAriuDwk5G4BxQarGmmvpcTOChLIcgKdtD9TbHsNmPmwyZJ/aJmoiD7y2gMEidCRmlwooR9+rBOk4IAScvLIjyodSWnRhugLAqyLxVSoUCc2Y1mjYsSlb1CqMNaCGmSOfiPR7bu+FpGkKWHwDhxrzOFhlAtPXAH9pcEkX4EIsEB0AVO84dtl731VFBC4l7ngNpPT/kXYfEeT0c4cTJCDBPaFEcLh1CJwOWDmnO22hgJfb5YIpqpELBC17JBE7vz0sZaHO7aQnScBp2sGAA7zHpjkcz9+uDVc7KQLOFLFDKpIDdAPdnt3rEd9cjU+LLIsDve4ZensT2EYr9Uy1owAmDEzPC2svkHhCFLBG7q7hOIIw1onQlgZxjxYM6z9mkB9ktBCO7c2BdUeB1AKf1iuytY1LpUFTbzgGAPOtogcYI+EBrbOD+DmwIquC14ZC8YLBNWwEcXIX1LhDJSt1Lh4tcYm7OLVClWSJWokgSE5+IoVK+Is+MEMDl+YEpVzYaocPzJEEgwiPFvZAEbTIzFhKwC0A/1QsSE/4VnqyMAL+beN0E6BiZBhyPCzOBICw8kc4CtI/AdqsU2Jx40ycwDMffE5udrjDBrlTk+vJcSQ1TNogIgUDqU2OjBTTl4vo4YArAiJBPOFk117QlUWORGNhyoMZqQczmbnOAGdx4SpSRgKz7KgvfxFlRSShBbHQbg04ctnlbohD6OAvCGGSYXsEoxlbjiQTA2wdIIbow6Jp0Y89caSKDnkMG4XxYLoZpjIVoZtFrIqasoGbsCBEPJ0t4ihyeAU2pbXAHXyTIrYT0j5KJc0eRMAHkNwY+kS4ikxUSaCXQssv0DfPd0TvDd6UgWniFjbx1dA6OXTAlWQBxUlayP+cbmgAORM6hPc9QIVr2Mc496azJTIHinUC6Q0QEBqSupQzF5ypcywzxn/hIhSV0qRNS8Cin/Yjha6cg34U5zG3qQYZe2zORCRUSqH2735SJcemGNqsjYwuFAANmyR3WU4WQHVlVRUBiWRaVpLUUxAcEp/bgNmbp/Ihqml9GhDrir21DgKWFtzbYc6JwoK85RVkLStw8EoSTIKVC5LYQ1OLZpYcfbQiHHVDYctqjtQg1h+pkIAlW5WcxXbqlIw77GZJAMfPnjYRdF2tCHrZLtcOKpE6ka0nWuvaJtbUtkwEpSJ5y4VieHay38QncN2kibB88bhzUawi+rk3/8GVuen/QSYBqTsE0w6CtG5zgW6xa6EFuMGD4NUKbLEWL+n6srzVZd472VsRaJ5QTNJpKHxn8j4tiPS+ZDlp0RJoAoPyFzcNHAFuB6wQgxD3M5KoEUo2okoEv40HPYCfhGfCSieqUZpHecOJ7Hthw/TwsiHWBQVfUMFfbrHEsrEViylCoBju9sU05kWNZ2LEFyDxxjy2gVgaINoe66KLg/GpkI8MACQ1r6VIJtUdQdxkCSPAs8aBcpRzQJ0ra3kE4GCAcZJA3i0DQhKUEHOU99S8bK3HyGZmAjKm2+YaYyrOugAwnZGsHVHceRAkFE1s9/zioxbyooAObg/nW+gBHzjRQijJ/xPwxOgaLzrSQQDbNil94Uljmhf3mvGmwQuogqz400JoYsxITGrXXlV6qW50y/7cava6ONZBeF0C2kjrXNMZYGJ4r65//WJPikDYwC52j/kqAlkae9mS9ooxmQ1t/naVe9GutoTZyeWkWnvb8BXoT67L7XBjN6NBFre5z43udKt73exut7vfDe94y3ve9K63ve+N73zre9/8ZgNiApAQCbQGCBOIWb8PfgPIvYEjWArAIQXuzBQgwA24KDgDEI7xGbBkOVPLBWLCDPEaTPwkZDN4xk9+gnlccOQd3QfFATCJK7jgDc94gzPF64ZDCdwNrdv5JJawpzfEouBvONQk3P/gAIvTxtcov7d42wcfl4wcFzE3SZvEGwvNHSfkRDkUYrQZADWEnDW32fgIVLOOqZdcExZvOsrFe3O4AeXlMS8EA9aFBUMcjiW7cuLXS4AYFkB81Q6fMhyo8PK2mwTgbs+4ysEYAAcYfu4kjznZPGtZvqtgHSV/wd9JEHjJtaYQiKhZCAufeIMvfsGN3zZr+CCB2IddRQPnexUCgB6+C1zykMqg6JfQ9dPbiOsDR8xmItCgwrMkFpO4jeLdwPrWW3vnYe/Bv40vRp7HnOhuiIY60IAfnAegV58/O2siP3AEZIkj70PD8iGF9OczXvr0r7/974///Ot///zvv///D4AjASiAA0iABWiAB4iACaiAC8iADeiADwiBESiBE0iBFQhsIQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Khan KS, Wojdyla D, Say L, G&uuml;lmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet 2006; 367:1066.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_22_23919=[""].join("\n");
var outline_f23_22_23919=null;
